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Background: Lewy body dementia, comprising both dementia with Lewy bodies and Parkinson’s
disease dementia, is the second commonest cause of neurodegenerative dementia. Existing evidence
suggests that it is underdiagnosed and without a consistent approach to management.
Objectives: To improve the diagnosis and management of Lewy body dementia by (1) understanding
current diagnostic practice for dementia with Lewy bodies and Parkinson’s disease dementia; (2) identifying
barriers to and facilitators of diagnosis and management; (3) developing evidence-based assessment toolkits
to improve diagnosis of dementia with Lewy bodies and Parkinson’s disease dementia; (4) producing a
management toolkit to facilitate management; and (5) undertaking a pilot cluster randomised clinical trial.
Design: Work package 1 assessed clinical diagnostic rates from case notes for dementia with Lewy
bodies and Parkinson’s disease dementia before and after (work package 1 repeated) introduction of
an assessment toolkit. In work package 2, we developed a management toolkit for Lewy body dementia.
In work package 3, we developed assessment toolkits for dementia with Lewy bodies and Parkinson’s
disease dementia and piloted these and the management toolkit in a clinical service. In work package 4,
we undertook a pilot study of 23 services in nine NHS trusts that were cluster randomised to receiving
and using the management toolkit or standard care. Work package 5 comprised a series of qualitative
studies, examining barriers to and facilitators of diagnosis and management.
Setting: Secondary care memory assessment and movement disorder services in England.
Interventions: Assessment toolkits for Lewy body dementia consisted of questions for diagnostic
symptoms, and management toolkits comprised 161 guidance statements grouped under five
symptom domains.
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Review methods: The systematic reviews of pharmacological and non-pharmacological management
were based on published literature, with meta-analysis when possible, following a search of several
electronic databases and the grey literature using terms related to Lewy body dementia, without
restriction on time or language.
Participants: Participants aged ≥ 50 years diagnosed with dementia with Lewy bodies or Parkinson’s
disease dementia and, for work package 1 and work package 1 repeated, non-dementia with Lewy
bodies and non-Parkinson’s disease dementia controls. The qualitative studies included people with
Lewy body dementia, carers and professionals.
Main outcome measures: For work packages 1 and 1 repeated, diagnostic rates for dementia
with Lewy bodies and Parkinson’s disease dementia as a proportion of all dementia or Parkinson’s
disease. For work packages 2 and 3, the production of diagnostic and management toolkits. For work
package 4, feasibility of undertaking a cluster randomised trial of the toolkits, measured by number
of participants recruited and use of the toolkits, assessed qualitatively.
Results: Work package 1 – 4.6% of dementia cases in secondary care received a dementia with
Lewy bodies diagnosis (with significant differences in diagnostic rates between services) and 9.7% of
those with Parkinson’s disease had a diagnosis of Parkinson’s disease dementia. There was evidence of
delays in diagnosis for both dementia with Lewy bodies and Parkinson’s disease dementia compared
with control patients, and the costs of dementia with Lewy bodies and Parkinson’s disease dementia
were also greater than those for matched controls (p < 0.01 for both). Work package 2 – we produced
252 statements regarding Lewy body dementia management and, following a Delphi process, 161 statements
were included in a management toolkit.Work package 3 – piloting indicated that separate assessment
toolkits for use in memory clinic and movement disorder services were preferred, but a single toolkit
for Lewy body dementia management was suitable.Work package 4 – we were able to recruit Lewy body
dementia patients to target and recruited 131 patients within 6 months (target n = 120), of whom > 80%
were retained in the study at 6 months.Work package 5 – barriers to diagnosis and management of Lewy
body dementia were complex. Managing Lewy body dementia often requires input from a range of
specialties and, therefore, care pathways may be fragmented. Positive attitudes to diagnosing Lewy body
dementia, working with a team with expertise in Lewy body dementia and opportunities for cross-
specialty discussion of patients with complex needs facilitated diagnosis and management.The toolkits
were generally well received, particularly the management toolkit. Implementation, however, varied,
reflecting differences in attitudes, skills, time and local leadership.Work package 1 repeated – following
introduction of the assessment toolkit, we found that 9.7% of dementia cases had dementia with Lewy
bodies (a significant increase from baseline; p = 0.0019), but Parkinson’s disease dementia rates were
similar (8.2%) to baseline.
Limitations: We included only two geographical regions and evidence informing the management
toolkit was limited. Work package 4 was a pilot study and, therefore, we did not set out to assess
the extent to which use of the management toolkit altered outcomes at the individual patient level.
We noted implementation of the toolkits was variable. The increase in diagnostic rates in dementia
with Lewy bodies following introduction of the assessment toolkits cannot be necessarily causally
attributed to them.
Conclusions: Dementia with Lewy bodies and Parkinson’s disease dementia were diagnosed in
secondary care NHS services, with a lower frequency (around half) than that expected from known
prevalence rates. The introduction of assessment toolkits for dementia with Lewy bodies and Parkinson’s
disease dementia was associated with increased diagnostic rates of dementia with Lewy bodies, but not
Parkinson’s disease dementia. Qualitative studies indicated inherent complexities of the disease itself,
with treatment requiring input from different specialties and the potential for fragmented services, a
workforce with variable training and confidence in Lewy body dementia, and negative attitudes towards
diagnosis. The cluster randomised pilot trial demonstrated that patients could be successfully recruited,
and provided preliminary evidence that the toolkits could be implemented in clinical services.
ABSTRACT
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Future work: The evidence base informing the management of Lewy body dementia is limited,
especially for non-pharmacological interventions. More well-designed randomised controlled trials for
both cognitive and non-cognitive symptoms are needed.
Trial registration: Current Controlled Trials ISRCTN11083027.
Funding: This project was funded by the National Institute for Health Research (NIHR) Programme
Grants for Applied Research programme and will be published in full in Programme Grants for Applied
Research; Vol. 9, No. 7. See the NIHR Journals Library website for further project information.
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Lewy body dementia includes dementia with Lewy bodies and Parkinson’s disease dementia. It is thesecond most common cause of neurodegenerative dementia in older people, but is underdiagnosed.
There is no consistent approach to management.
We aimed to improve the diagnosis and management of Lewy body dementia by:
l understanding current practice
l identifying barriers to diagnosis and management
l developing evidence-based assessment toolkits
l producing and piloting a management toolkit.
We focused on hospital-based specialist services. Participants included people aged ≥ 50 years
diagnosed with Lewy body dementia, carers and health-care professionals. Current diagnostic rates
for dementia with Lewy bodies and Parkinson’s disease dementia were lower than expected (4.6% and
9.7%, respectively). There was evidence of delays in diagnosis for both dementia with Lewy bodies
and Parkinson’s disease dementia. The use of services and the overall costs of care for patients with
dementia with Lewy bodies and Parkinson’s disease dementia were greater than for patients who had
other dementias. We found many barriers to the diagnosis and management of Lewy body dementia
and these indicated the need to upskill staff, challenge negative attitudes towards diagnosis and
improve management pathways.
Using published evidence and clinical opinion, we produced assessment and management toolkits for
dementia with Lewy bodies and Parkinson’s disease dementia. We used these in a pilot clinical study
and showed that we were able to recruit people with dementia with Lewy bodies and Parkinson’s
disease dementia to the study. The toolkits were well received, but their use by clinical staff was
variable. Following introduction of the assessment toolkits, there was an increase in diagnostic rates
for dementia with Lewy bodies, but not Parkinson’s disease dementia. Our findings indicate that a
further larger study of the management toolkit is both feasible and merited.
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Lewy body dementia includes two closely related conditions: dementia with Lewy bodies and Parkinson’s
disease dementia. Lewy body dementia is the second most common cause of neurodegenerative dementia
in later life, although there remains a large discrepancy between rates from clinical studies and those
based on autopsy (4–7% and 15–20% for dementia with Lewy bodies, respectively). Both dementia with
Lewy bodies and Parkinson’s disease dementia present with a range of clinical features, including cognitive
impairment, motor symptoms, autonomic symptoms, sleep problems and neuropsychiatric features.
Both dementia with Lewy bodies and Parkinson’s disease dementia are associated with lower quality
of life and higher carer stress, and have poorer outcomes, including increased mortality and higher rates of
functional dependence. Accurate recognition is key for appropriate management, but currently many cases
are not correctly recognised at initial assessment.
Little is known regarding prevalence or diagnostic practice in the UK and there are no systematic
approaches to management or recognised care pathways.
DIAMOND-Lewy (Improving the DIAgnosis and Management of Neurodegenerative Dementia of Lewy
body type) was a comprehensive 5-year programme of work seeking to investigate and implement
ways to improve both the diagnosis and management of Lewy body dementia (i.e. both dementia with
Lewy bodies and Parkinson’s disease dementia) within the NHS.
Objectives
l To undertake a baseline study of current practice in secondary care NHS services regarding the
diagnosis and management of Lewy body dementia.
l To develop evidence-based practical toolkits for the assessment and management of Lewy
body dementia.
l To implement the assessment toolkit and undertake a study to determine whether or not introduction
of the toolkit resulted in an increase in diagnostic rates of dementia with Lewy bodies and Parkinson’s
disease dementia.
l To implement and undertake a pilot cluster randomised study of the management toolkit in NHS
secondary care services to assess the feasibility of patient recruitment and retention, outcome
measures and implementation of the toolkits in routine practice.
l To undertake qualitative studies to explore the barriers to and facilitators of making a diagnosis and
improving management of Lewy body dementia.
Methods
These objectives were met through five closely inter-related work packages, with a patient and public
involvement group providing regular input throughout. We used mixed methods, including case note
screening, systematic reviews, consensus methods, qualitative studies and a pilot cluster randomised trial.
Work package 1
This provided a baseline measure of the proportion of cases diagnosed as having Lewy body dementia
within NHS services and investigated diagnostic practice. Work package 1A focused on dementia with
Lewy bodies and work package 1B focused on Parkinson’s disease dementia. Our hypotheses were that
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dementia with Lewy bodies would be diagnosed in ≤ 5% of dementia cases and Parkinson’s disease
dementia in ≤ 10% of Parkinson’s disease cases.
We included services in two geographical parts of the UK, the north-east of England and East Anglia,
and examined case notes of consecutive referrals to nine memory assessment services across four
NHS trusts over an 18-month period. We identified all patients with a diagnosis of dementia, and of
those patients who had been given a diagnosis of dementia with Lewy bodies.
We examined the notes of consecutive referrals to five movement disorders services, each in a
separate NHS trust, comprising two geriatric medicine services and three neurology/geriatric medicine
services. We identified all patients diagnosed with Parkinson’s disease and Parkinson’s disease dementia.
Work package 2
We undertook systematic reviews of pharmacological and non-pharmacological management of Lewy
body dementia, taking account of PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) reporting standards. For the pharmacological review, studies were identified through
bibliographic databases, trials registers and grey literature. Reference lists of relevant studies and
previous systematic reviews were also examined and input was sought from experts on Lewy body
dementia. We used the keywords ‘Lewy or parkinson’ and ‘dementia’ and conducted searches until March
2015, without restrictions on publication date or language, but opinion papers were excluded. Studies
were grouped and analysed according to pharmacological strategy. Methodological quality was assessed
using the QATQS (Quality Assessment Tool for Quantitative Studies) [URL: www.ephpp.ca/tools.html
(accessed April 2021)].
The strategy for the non-pharmacological review was similar. We used the search terms [(Lewy OR Park*)
and Dementia]. Interventions were any non-pharmacological treatment identified using a wide range
of terms that covered individual non-pharmacological therapies. Searches were conducted on
30 October 2016.
Work package 3
Work package 3 identified, from the existing literature, validated questions designed to elicit key
diagnostic features for dementia with Lewy bodies and, separately, for Parkinson’s disease dementia.
Toolkits were then produced for dementia with Lewy bodies and Parkinson’s disease dementia and
implemented, along with the management toolkit developed in work package 2, in a single NHS trust.
Work package 4
In this work package, the assessment toolkit was introduced to 23 memory or movement disorder
services, with half the services randomised to receive and use the management toolkit and the other
half continuing with standard care (control arm). From these services, patients with dementia with
Lewy bodies and Parkinson’s disease dementia were recruited and assessed on a number of clinical
and cognitive outcome measures at baseline, 3 months and 6 months. Our aim was to determine the
feasibility of undertaking such a study and we aimed to recruit 120 subjects with dementia with Lewy
bodies or Parkinson’s disease dementia.
Work package 5
This work package had three components: first, an investigation of the barriers to and facilitators of
making a diagnosis and managing Lewy body dementia; second, and linked with work packages 3 and 4,
exploration of views on the assessment and management toolkits; and third, exploration of implementation
of the assessment and management toolkits in clinical practice. Methods included qualitative interviews
with clinicians, patients and carers, observation of routine practice and clinician questionnaires.
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Work package 1 repeated
Finally, we undertook a repeat assessment over 18 months of dementia with Lewy bodies and Parkinson’s
disease dementia diagnostic rates following introduction of the assessment toolkits in some of the same
services that had participated in work package 1.
Results
Work package 1
We identified 4504 patients with dementia, of whom 207 (4.6%) had a diagnosis of dementia with
Lewy bodies. Prevalence in individual services ranged from 2.4% to 5.9% and was significantly higher
among services in the north-east of England than in East Anglia (5.6% vs. 3.3%, χ2 = 13.6; p < 0.01).
From these patients, we recruited 74 patients with dementia with Lewy bodies and 72 non-dementia
with Lewy bodies control patients (defined as the next diagnosed dementia case seen by that service,
matched for age, sex and Mini Mental State Examination score), all of whom consented to an in-depth
case note examination. Patients with dementia with Lewy bodies had a significantly longer time from
referral to diagnosis and more frequently received an incorrect prior diagnosis (in 30% of cases) than
patients with non-dementia with Lewy bodies dementia. There were significantly higher health-care
costs for patients with dementia with Lewy bodies than for patients with non-dementia with Lewy
bodies dementia (p < 0.01).
We examined the notes of 2263 referral patients to five movement disorders services, each in a
separate NHS trust, comprising two geriatric medicine services and three neurology/geriatric medicine
services. Of these patients, 1563 were diagnosed with Parkinson’s disease, of whom 151 (9.7%) had
a diagnosis of Parkinson’s disease dementia. There was no significant variation between regions or
services. We recruited 38 patients with Parkinson’s disease dementia and 35 Parkinson’s disease
control patients (defined as the next patient with diagnosed Parkinson’s disease seen by that service,
matched for age and sex), all of whom consented to an in-depth case note examination to determine
pathways to diagnosis and management. Those with Parkinson’s disease dementia had evidence of
delayed diagnosis, with 46% having impaired activities of daily living and 39% receiving a dementia
treatment before a dementia diagnosis. There were significantly higher health-care costs for patients
with Parkinson’s disease dementia than for Parkinson’s disease control patients (p < 0.01).
Work package 2
The reviews of pharmacological and non-pharmacological management of Lewy body dementia found
a limited number of randomised controlled trials and very few non-pharmacological studies. High-level
evidence was rare, with only 17 randomised controlled trials. Methodological quality was rated as weak
for 41% of included studies, moderate for 39% and strong for 20%. Meta-analysis indicated beneficial
effects of donepezil and rivastigmine for cognitive and psychiatric symptoms. Rivastigmine, but not
donepezil, was associated with greater risk of adverse events. Meta-analysis of memantine suggested
that it is well tolerated, but with few benefits. Descriptive summaries provided some evidence of
benefits for galantamine, modafinil, levodopa, rotigotine, clozapine, duloxetine, clonazepam, ramelteon,
gabapentin, zonisamide and yokukansan. Piracetam, amantadine, selegiline, olanzapine, quetiapine,
risperidone and citalopram did not appear to be effective. This review concluded that high-level
evidence related to pharmacological strategies for managing Lewy body dementia was rare. There were
very few non-pharmacological studies and most were of poor quality with potential bias, with only one
randomised trial. The review concluded that no definite recommendations could be offered regarding
non-pharmacological management.
This existing evidence base, supplemented by two public and patient workshops, was used to produce
252 statements regarding Lewy body management. Following assessment by 26 experts using a Delphi
approach, 161 statements were included in a final management toolkit that comprised three components:
(1) a single summary page, (2) more detailed pages outlining management approaches to different
symptom domains and (3) a detailed reference guideline.
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Work package 3
Following piloting, the main feedback on the assessment toolkits was that there should be separate
assessment toolkits for use in memory/dementia services and general/movement disorder services,
rather than separate assessment toolkits for dementia with Lewy bodies and Parkinson’s disease
dementia. A single management toolkit covering both dementia with Lewy bodies and Parkinson’s
disease dementia worked well. The assessment toolkits were redesigned and so the final toolkits
comprised (1) an assessment toolkit for the diagnosis of dementia with Lewy bodies for use in memory
services, (2) an assessment toolkit for the diagnosis of Lewy body dementia (covering both dementia
with Lewy bodies and Parkinson’s disease dementia) for use in movement disorder services and
(3) a management toolkit for Lewy body dementia (covering both dementia with Lewy bodies and
Parkinson’s disease dementia).
Work package 4
All but one service was able to take part in the study and recruit subjects. A total of 131 patients
were recruited and assessed at baseline, 3 months and 6 months on a number of clinical and cognitive
outcome measures. One hundred and twenty-seven participants (control arm, n = 52; intervention
arm, n = 75) underwent baseline assessments and 109 participants completed the 6-month follow-up.
For both dementia with Lewy bodies and Parkinson’s disease dementia, and taking account of the
cost of implementing the management toolkits, total costs increased over the course of the study
in the control arms and decreased in the intervention arms, although these differences were
not significant.
Work package 5
Key barriers to the diagnosis and management of Lewy body dementia included clinician skills, training
and knowledge (particularly in nurse-led memory services), service organisation, complexity of Lewy
body dementia, and clinician attitudes and beliefs regarding the value of diagnosing Parkinson’s disease
dementia. The toolkits were generally acceptable, but implementation varied. In memory services, the
assessment toolkit was primarily seen as relevant when a diagnosis of dementia with Lewy bodies was
already suspected. In movement disorder services, implementation was hindered by time constraints
and, for some, negative attitudes to diagnosis. Clinicians valued the management toolkit and found it
easier to integrate into practice. Key benefits for clinicians were ease of access to trustworthy, up-to-date
knowledge and increased awareness of the range of symptom areas affected by Lewy body dementia.
Work package 1 repeated
We screened 2058 notes from memory services, identifying 1279 patients with dementia, of whom
6.2% had dementia with Lewy bodies (a significant increase from the baseline of 4.6%; p = 0.0019).
We screened 3405 case notes from movement disorders services and identified 1968 patients with
Parkinson’s disease. Of these patients, 8.2% had Parkinson’s disease dementia (a non-significant change
from the 9.7% identified at baseline).
Public and patient involvement
Public and patient involvement was fundamentally important to the quality and relevance of our
research. We established a public and patient involvement group that met regularly throughout the
programme. The group reviewed the patient information sheet and consent forms, advised on toolkit
structure and administration, advised on consent procedures and data capture for work package 5,
contributed to the design and content of study newsletters, the website and public and patient
involvement workshops, made recommendations about future public and patient involvement in
research and wrote sections of this report, including the Plain English summary. In addition, separate
public and patient involvement workshops in work package 2 highlighted patient and carer
management priorities.
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Conclusions
Dementia with Lewy bodies and Parkinson’s disease dementia were diagnosed in secondary care NHS services
with a lower frequency (around half) than that expected from known prevalence rates.The introduction of
assessment toolkits for dementia with Lewy bodies and Parkinson’s disease dementia significantly increased
the rates of dementia with Lewy bodies diagnosis (from 4.6% to 6.2%), but not of Parkinson’s disease
dementia. Qualitative approaches showed that clinician barriers to improving diagnosis and management
included uncertainty around making the diagnosis and perceptions that it may not alter management. The
systematic reviews indicated a limited evidence base to inform the content of the management toolkit,
highlighted the lack of non-pharmacological studies and indicated a clear need for trials to be undertaken
in dementia with Lewy bodies and Parkinson’s disease dementia. A comprehensive management toolkit
was introduced in a pilot cluster randomised trial, indicating that such trials are feasible.
Implications for practice
The main implications of our findings for clinical practice are as follows:
l In the regions we studied, dementia with Lewy bodies and Parkinson’s disease dementia appeared
to be underdiagnosed compared with expected rates, with variability in diagnostic rates between
services. This suggests that improvements may be needed in the way in which clinicians assess
people for symptoms and make diagnoses.
l We found that the reluctance of some clinicians to make a formal diagnosis of dementia could be a
significant factor contributing to the underdiagnosis of Lewy body dementia (particularly Parkinson’s
disease dementia). This implies that negative attitudes to disclosure may need to be challenged,
possibly through supervision, appraisal or local audits to examine the diagnostic rate of Parkinson’s
disease dementia.
l Using a structured method, such as the assessment toolkit for diagnosis, may help increase
diagnostic rates.
Recommendations for research
Findings from the programme have a number of important implications for future research:
l The evidence base informing the management of Lewy body dementia is limited, especially for
non-pharmacological interventions. More therapeutic studies are needed, especially well-designed
randomised controlled trials for both cognitive and non-cognitive symptoms.
l Further study of effective ways of addressing the barriers to implementation of the assessment and
management toolkits is merited, particularly as many barriers were outside the scope of our programme.
l Research into how best to co-ordinate multispecialty input to patients with Lewy body dementia is
needed to streamline management and facilitate a holistic approach.
l Further work is needed to better understand how assessment toolkits for Parkinson’s disease
dementia can be integrated into practice to improve diagnostic rates. Qualitative studies indicate
that there remain important barriers and negative attitudes to diagnosis and management, and
further work is needed to see how these are best addressed.
l Our successful pilot demonstrates that a larger, more comprehensive trial of introducing the
management toolkit could be undertaken, but this would need to include a minimum of 410 (and up
to 908) patients, depending on the primary outcome.
l In such a study, it would be important to adopt a clear implementation strategy to ensure that it
is appropriately resourced. An alternative approach to a larger trial would be to introduce and
evaluate the toolkits through service quality improvement initiatives, working with services using
principles from implementation science.
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Lewy body dementia (LBD) is a term used to describe two closely related conditions: dementia with
Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). They form the second most common
neurodegenerative dementia (after Alzheimer’s disease), but it is recognised that they are underdiagnosed.
Diagnosis has important implications for management, as those with LBD present with a range of variable
clinical features, including cognitive impairment, motor symptoms, autonomic symptoms, sleep problems
and neuropsychiatric features.
We undertook this programme because little is known regarding the prevalence or diagnostic practice
of LBD in the UK and, although national management guidelines [e.g. National Institute for Health
and Care Excellence (NICE) 20181] do recognise the importance of both DLB and PDD and make
some limited management recommendations, there are no systematic approaches to management
or recognised care pathways. DIAMOND-Lewy (Improving the DIAgnosis and Management of
Neurodegenerative Dementia of Lewy body type) was a comprehensive, multidisciplinary 5-year
programme of work seeking to investigate and implement ways to improve both the diagnosis and
management of LBD (i.e. both DLB and PDD) within the NHS.
We achieved this through a number of interlinked work packages (WPs), with a very strong patient
and public involvement (PPI) core running throughout the programme. In this synopsis, we first describe
our approach to PPI and how this influenced the design of the programme. In WP1, we undertook a
retrospective case note study to investigate current practice in secondary care NHS services with regard
to the diagnosis and management of LBD. In WP2, we undertook systematic reviews of pharmacological
and non-pharmacological management of LBD and used this evidence, supplemented by a Delphi study
of expert clinicians, to produce an evidence-based management toolkit. In WP3, we developed assessment
toolkits for the diagnosis of LBD and, incorporating the management toolkit from WP2, piloted these
assessment and management toolkits in routine NHS memory assessment and movement disorder
services. In WP4, we introduced the assessment and management toolkits more broadly within a pilot
cluster randomised trial. WP5 was a series of qualitative studies with three components: (1) an investigation
of the barriers to and facilitators of making a diagnosis and managing LBD, (2) exploration of views on
the assessment and management toolkits and (3) exploration of implementation of the assessment and
management toolkits in clinical practice. Finally, in WP1 repeated (WP1R), we undertook a repeat
assessment of DLB and PDD diagnostic rates following introduction of the assessment toolkits in some
of the same services that had participated in WP1.
A research pathway diagram showing how these WPs linked together is provided (Figure 1). Each WP
will now be discussed in turn after a description of the PPI core running throughout the programme.
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Year 1 Year 2 Year 3 Year 4 Year 5
WP1. Baseline study of 4504 dementia notes
and 1563 PD notes found prevalence of
diagnosed DLB (4.6%) and PDD (9.7%) to be
less than half that expected. Informed need 
for development of assessment toolkits to
improve diagnosis
WP5. Qualitative study investigating barriers
to and facilitators of making a diagnosis of DLB
and PDD. Identif ied several issues, including a
reluctance to make diagnosis in absence of clear
management strategies, emphasising the need
for parallel management toolkit development
WP2. Systematic reviews of pharmacological
and non-pharmacological evidence for
management of DLB and PDD, development of
evidence-based management statements
through a Delphi process of 26 experts, used 
as basis for development of DLB/PDD
management toolkit
Qualitative study within WP5 investigated barriers
to and facilitators of using the toolkits. The toolkits
were well received but implementation varied
WP3. Development of assessment
toolkits for DLB and PDD diagnosis,
and piloting of these and management
toolkit in memory and movement
disorder services; following which
f inal versions created
WP4. Cluster randomised RCT. Assessment toolkits
for diagnosis were introduced into 23 services,
services were randomised to receive the newly
developed management toolkits or ‘usual care’
A total of 131 subjects with DLB or PDD were
recruited and assessed at baseline, 3 months and
6 months (109 subjects completed the study)
Subjects in services randomised to receive the
management toolkit had evidence of less
deterioration in global outcome measures (rated by
clinician and carer), and improvements for carers in
carer burden and depressive symptoms
There was no evidence that introduction of the
management toolkit increased health or social 
care costs
WP1R. Repeat study of 1279 dementia notes
and 1928 PD notes found prevalence of
diagnosed DLB (9.7%), but not PDD (8.2%), was
signif icantly increased over baseline following






















FIGURE 1 Research pathway diagram. PD, Parkinson’s disease; RCT, randomised controlled trial.
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Patient and public involvement throughout
the DIAMOND-Lewy programme
Introduction
Patient and public involvement is seen as fundamentally important to the quality and relevance
of research. In the light of calls for greater transparency and consistency in reporting PPI, we have
followed the GRIPP2-SF (Guidance for Reporting Involvement of Patients and the Public 2–short form)
reporting guidelines, highlighting the impacts of PPI and critically reviewing our approach to PPI.2–4
Much of this section of the report was drafted collaboratively with members of the PPI group.
Aim
The aim was to use PPI to inform all phases of the study from patient and carer perspectives.
Methods
Patient and public involvement in this programme started very early, during the development of the
proposal, with one PPI member (Derek Forster) being a co-applicant. Once the programme started,
we established a PPI group that met regularly throughout the programme. Potential volunteers were
sought through a public meeting organised by the North East Dementias and Neurodegenerative
Research Network (DeNDRoN) in July 2013 and through the existing networks of Derek Forster and
the DeNDRoN PPI co-ordinator. Three PPI representatives agreed to join the group with Derek Forster,
and all four members contributed throughout the programme. All members’ lives have been touched by
neurodegenerative diseases, either as a patient or as a carer. In addition, members were motivated by
their desire to ‘give something back’, interest in medical research and enthusiasm to help progress
research into LBD. Experience of PPI varied. One member had been involved in PPI for > 10 years;
however, for another this was their first PPI experience. All members received training on research
through DeNDRoN. This was supplemented by an introductory session on LBD by Ian McKeith. One of
the co-applicants (CB) facilitated the group and meetings were held on university premises. We followed
the INVOLVE guidance on reimbursing group members for their time and expenses.5
The first PPI meeting focused on how to achieve the desired aim. This led to agreement that the
group would:
l share personal knowledge and experience of DLB, Parkinson’s disease (PD) and PDD
l comment on the practicalities and pressures that participating in the research could create for
patients and carers (safeguarding)
l ensure that information was user-friendly and did not alarm potential participants
l ensure that a patient/carer focus was included in developing the management toolkit
l contribute to study newsletters.
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Members agreed that the timing and duration of PPI meetings should reflect the needs of the
programme. Although the group thought it was unnecessary to link individual PPI members to specific
WPs, they were keen to embed PPI into the programme management structures. To achieve this,
Derek Forster attended both the PPI group and the Programme Management Group (PMG) and
Valerie Argent joined the Programme Steering Committee (PSC) as a lay member.
In addition to the PPI group, two PPI workshops were convened to inform the development of the
management toolkit (see Work package 2: development of management toolkits for Lewy body dementia).
Potential participants were identified by team members through patient and carer interviews
conducted during WP5 and local contacts. One member of the PPI group (Anne Lister) also attended
the PPI workshops for WP2. The content of the workshops is described in Work package 2: development
of management toolkits for Lewy body dementia.
Outcomes of patient and public involvement
The PPI group met 20 times, with full attendance at nearly all meetings. The number of meetings
ranged from one to five per year. Members often prepared for meetings by reading documents, and
commented on documents by e-mail between meetings. The initial expectation of group members and
the research team was that the group would adopt a consultation approach, with an emphasis on
ensuring that documents would make sense to patients and carers, including advising on the feasibility
and acceptability of the study procedures. Over time, however, the group grew in confidence and were
proactive in developing and expanding their role, adopting collaborative and user-controlled approaches
at different times.6 For example, rather than commenting on the public version of the study newsletter
(which was initially drafted by the research team), members took ownership of the newsletter by
redesigning the layout, introducing a new structure and writing much of the content themselves.
A user-controlled approach was adopted to obtain feedback on participants’ experiences of taking
part in the pilot trial. Rather than inviting a single participant to describe their experience at the PPI
dissemination event in the North East, members were keen to present a broader range of experiences.
This led to the development and inclusion of some open questions about study participation with the
letter inviting participants to the PPI event. Overall, 28 detailed responses were received. Two members
of the group (VA and AL) reviewed and collated the information and presented their findings at the PPI
dissemination event. Key themes were the interpersonal skills of the interviewers and having an opportunity
to talk about their situation. Everybody found the home visits convenient and > 70% of respondents said that
they would be willing to take part in a similar study.These comments provided useful feedback for the
researchers and highlight aspects of study design, which may maximise recruitment and retention in future
studies. Furthermore, the comments highlighted the lack of support available after diagnosis, suggesting new
avenues for research and intervention.
Key activities undertaken by both the PPI group and the PPI workshops in WP2 are related to the
research cycle7 and are summarised in Table 1.
Having highlighted some of the successful contributions made by PPI during the programme, we also
acknowledge that its impact in some areas was limited. Owing to uncertainty about which outcome
measures would prove sensitive to changes resulting from the introduction of the management toolkit,
the team proposed a range of measures. Reconciling the perspectives of PPI members and those of the
research team was sometimes challenging, for example in relation to the number of outcome measures
and the perceived burden of these on participants, and in relation to the wording of questions in the
assessment toolkit, some of which were considered to be inaccessible to patients and carers. However,
there was limited scope to make changes because they were validated measures.
PATIENT AND PUBLIC INVOLVEMENT THROUGHOUT THE DIAMOND-LEWY PROGRAMME
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TABLE 1 Summary of key PPI outcomes
Stage of the research cycle7 Example outcomes
Identifying and prioritising the research agenda Future research priorities were highlighted by the PPI
workshops for WP2 and the feedback collected for the
PPI event
Study design Advised on consent procedures for clinic observation
(WP5) and for notes review (WP1)
Reviewed outcome measures to ensure that they were
appropriate and relevant (WP4)
Development of the grant proposal Reviewed draft proposal
Contributed to lay summary
Included as a co-applicant (DF)
Undertaking/managing research Reviewed PIS and consent forms (WPs 1, 2, 4 and 5)
Advised on most appropriate order of questions in
assessment toolkit (WP3) and outcome measures (WP4)
Shared experiences of PD and LBD with a new researcher
to raise awareness and understanding prior to data
collection (WP5)
Advised on eliciting feedback on the toolkits (WP5)
Identified key principles to underpin the management
toolkit (WP2)
Advised on appropriate ways of thanking study
participants (WP4)
Wrote a thank-you letter for study participants (WP4)
Member of PMG (DF)
Member of PSC (VA)
Analysing and interpreting Reviewed qualitative interview data (WP5)
Collected and analysed data on participants’ experiences
of the pilot trial (WP4)
Dissemination and implementation Produced biannual programme newsletters
Produced lay summaries of published papers for the
programme website
Drafted annual progress reports and this section of
the report
Contributed to the organisation of PPI events
Presented at the North East PPI event
Monitoring and evaluation Reflected on their role
Made recommendations for PPI in future research
PIS, patient information sheet.
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Discussion and conclusions
Using more than one approach to PPI in the programme proved effective. While the PPI group
provided continuity throughout the programme, the workshops enabled the inclusion of a broader
range of perspectives, including those of people with dementia. By combining a ‘fully intertwined’
approach to PPI and the ‘one-off’ approach for the workshops, we were able to include patients and
carers who did not wish to commit to ongoing input.8 The inclusion of PPI members on the PMG and
PSC ensured opportunities for communicating with the full team. The detailed understanding of the
programme developed through the PPI group, facilitated the ability of the PPI members to contribute
confidently and effectively to meetings.
All members of the PPI group continued to be involved throughout the programme. This continuity
helped the group to develop in confidence and expertise. Although we have benefited from stable
group membership throughout the programme, members recognise that this may be unusual, as the
health or circumstances of PPI members may deteriorate over a 5-year period, particularly if they are
directly affected by the condition.
A limitation of the PPI group was the homogeneity of members in terms of ethnicity and class,
and the lack of ability to alter some validated questions that members thought contained complex
and inaccessible terms. Previous studies have emphasised the challenges of ensuring diversity in PPI,
in particular the inclusion of people with dementia.9 None of the members of the PPI group had dementia
(although two had PD). Although caring for a spouse with LBD clearly provides significant insight into
living with the condition, this is not the same as first-hand experience.9 Despite the efforts of the
DeNDRoN PPI co-ordinator, no people with dementia were identified for the PPI group. This partly
reflects the low diagnostic rates and delays in diagnosing LBD (see Work package 1: baseline study of the
diagnosis and management of Lewy body dementia). The situation was exacerbated by the high demand for
PPI members in Newcastle upon Tyne, a Centre of Excellence in LBD research.
Reflections
Recent publications on PPI have emphasised the need for increased understanding of effective
approaches to PPI.4,8,10 Unfortunately, we did not obtain formal feedback from workshop participants,
although the attendance of several participants at the subsequent PPI dissemination event suggested
an ongoing interest in the programme. The perception of the PPI group was that although not
everyone in the research team initially recognised the potential value of PPI, their contributions were
increasingly valued as the programme progressed. Although no formal evaluation or opportunities for
reflection were planned at the outset, the process of drafting newsletters, giving presentations at the
PPI event and drafting this section for the final report prompted the group to recognise their wide-
ranging contributions and reflect on their experiences of this approach to PPI. Key factors thought to
contribute to the success of the PPI group were as follows:
l having a simple two-page overview of the programme to help members understand the different
WPs and how they were interlinked
l having regular meetings to maintain interest and understanding of the programme
l working together in a group and sharing ideas
l having a facilitator
l attending to practical issues, for example ease of access, free parking, timely reimbursement of
expenses and flexibility over the timing of meetings
l having access to a computer and large screen to enable the group to produce or edit documents
collaboratively during meetings
l having stability of group membership
l ensuring that meetings were business-like, but enjoyable.
PATIENT AND PUBLIC INVOLVEMENT THROUGHOUT THE DIAMOND-LEWY PROGRAMME
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Several of these factors are consistent with those identified in previous studies.8 Three suggestions
were made for facilitating PPI contributions to future projects. The first concerned the importance
of all team members recognising and valuing the different perspectives offered by PPI members,
even when these challenged their own views. The second related to greater clarity over the
responsibilities and remit of the PPI member within the PSC and finally the group emphasised the
need for the chairperson of the PSC to explicitly invite comments from the PPI member.
After 5 years, members of the PPI group are surprised at their continuing levels of enthusiasm and
commitment. Reflecting on this, members attribute their loyalty to the relevance of the programme
to their lives, compatibility of members and the appreciative facilitation. In terms of personal benefit,
members have valued the opportunity to keep up with research, maintain mental agility and develop
new skills. Although the programme has now ended, the PPI group is planning to share their
experiences to wider audiences through a conference presentation and an article for lay audiences.
In summary, the inclusion of PPI throughout the programme was extremely valuable and added
very positively to the design of the DIAMOND-Lewy programme, its conduct and outcome, with PPI
members making key contributions that affected the design and administration of the assessment
and management toolkits. PPI also played a key role in dissemination and feedback of the study to
participants, with members taking ownership of content for regular study newsletters, designing
suitable methods for thanking participants and playing key roles in the co-design and delivery of the
programme dissemination events.
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Work package 1: baseline study of
the diagnosis and management of Lewy
body dementia
The aim of this WP was to undertake a baseline study of diagnosis and management of LBD in NHSsecondary care services.
Introduction
The accurate recognition of dementia and the diagnosis of dementia subtype helps ensure appropriate
management, and are central to improving patient care. LBD, comprising both DLB and PDD, is the
second most common cause of neurodegenerative dementia in older people, accounting for between 15%
and 20% of all cases of dementia, according to autopsy studies.11 However, clinical and epidemiological
studies suggest rates of only 5–7%.12 This suggests that a considerable number of people with LBD go
undiagnosed and so are not offered potentially beneficial management strategies. More worryingly,
incorrect diagnosis risks inappropriate management with drugs such as antipsychotics, which, even at a
low dose, can have serious side effects and cause mortality in those with LBD.11
Currently, the proportion of cases of dementia diagnosed with DLB and PDD in NHS secondary care
services is not known, nor has there been any systematic study of diagnostic practice or management
in secondary care, although a US-based retrospective survey indicated frequent erroneous diagnosis
and delays to a final correct diagnosis.13 This is an essential first step to improving care. Therefore, this WP
sought to establish the baseline for current diagnostic rates for DLB and PDD, providing a foundation for
the other WPs. The WP was split into two parts: (1) WP1A examined diagnostic and management practice
for DLB and took place in old age psychiatry and memory services, and (2) WP1B examined diagnostic and
management practice for PDD. This latter element was undertaken in movement disorders services run by
neurologists and geriatricians.
Initially, the plan had been to undertake WP1 solely in services in one geographic region of the UK
(the north-east of England). However, there arose an opportunity to undertake a much more
informative two-region study, whereby diagnostic rates for DLB and PDD could be ascertained in
both the North East and East Anglia, two representative but clearly separate UK regions. This change
also allowed some comparison of whether or not any variation in diagnostic rates and practice existed
between regions.
Work package 1A: baseline study of the diagnosis and management of
dementia with Lewy bodies
Methods
This WP took place over the first 2 years of the programme, with the aim of comparing rates of
current clinical diagnosis of DLB with expected prevalence figures, confirming the accuracy of DLB
diagnosis and comparing diagnostic and management pathways of those with DLB with those with
non-DLB dementia. The hypothesis was that the actual rate of diagnosis of DLB would be ≤ 5% and
that pathways to diagnosis of DLB would be longer and more complex than for non-DLB dementia.
The study had two phases: (1) a case note-screening phase to obtain information on consecutive
referrals to services and (2) a phase involving detailed case note examination by clinical members
of the research team (specialty registrars). Ethics approval was obtained for both phases from
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National Research Ethics Service Committee North East – Newcastle and North Tyneside 1 (reference
13/NE/0268). In addition, we obtained approval from the Confidentiality and Advisory Group to allow
the extraction of some information during phase 1 without the explicit consent of the person with
dementia [reference CAG 8.03(PR8)/2013].
We included nine old age psychiatry/memory services across four NHS trusts (two in East Anglia and
two in the North East). Approvals were obtained from all trust research and development departments.
Referral lists were obtained over an 18-month period and consecutive case notes screened by the
research team, with key data extracted, including age, sex, diagnosis and Mini Mental State Examination
(MMSE) score. Those with a DLB diagnosis who were alive and felt to be well enough by the clinical team
(105/207 cases identified) were approached for their consent to be included in a more detailed study of
their notes, with the extraction of information regarding diagnostic and management pathways collected
using a standardised case report form. To describe the management pathway for each participant, data
were collected on the use of services, spanning several years of clinical records before and after final
diagnosis. Data collected included the number of appointments before and after diagnosis, and the
number and type of diagnostic investigations undertaken before and after diagnosis.
For each DLB participant who consented, a non-DLB control participant was recruited by selecting the
next participant seen in the respective service who was diagnosed with non-DLB dementia, matched
for age (± 5 years), sex and MMSE score (in three bands: 0–10, 11–20 and 21–30) and who consented
to participate. To assess the accuracy of the clinical diagnosis of DLB, a panel of three expert clinicians
(not involved in the original diagnoses) independently reviewed clinical documentation and applied
the 2005 international DLB consensus criteria to each case,14 with a primary diagnosis of probable or
possible DLB taken as agreement with a clinician diagnosis of DLB. The expert panel agreed with the
clinical diagnosis in 99% of cases of DLB (74/75) and 97% of cases with non-DLB dementia (72/74).
One DLB case was excluded because the panel felt that there was insufficient evidence to assign any
dementia subtype. Two non-DLB cases were excluded: one because the panel felt that the case had a
diagnosis of mild cognitive impairment (MCI) and the other because the diagnosis was thought most
likely to be PDD.
The data on use of services were combined with unit cost data taken from routine sources, including
NHS reference costs15 and Personal Social Services Research Unit costs.16 This enabled the cost of
service use to be estimated and comparison between the cost of pathways to diagnosis and post-
diagnosis care for DLB participants compared with control participants. Full details of the methods for
this are included in Appendix 1. This study (and WP1B) were approved by the North East – Newcastle
& North Tyneside 1 Research Ethics Committee (reference 13/NE/0268) and the Confidentiality and
Advisory Group [reference 8.03(PR8)/2013].
Statistical analysis
Continuous data were assessed using t-tests, with chi-squared tests used for categorical data. Differences
in costs between DLB and non-DLB participants were explored using independent-samples t-tests with
unequal variance for normally distributed variables, Wilcoxon rank-sum tests for continuous non-normally
distributed variables and chi-squared tests were used to explore differences in proportions. Differences
in average cost between those with DLB and controls in the costs of diagnosis and of post-diagnosis
treatment were estimated using marginal effects from a generalised linear model of costs. The generalised
linear model was specified with a gamma distribution and a log-link function to account for skewness in
the distribution of costs.
Results
We identified 9449 consecutive referrals, of whom 4504 received a diagnosis of dementia. Of those
patients receiving a diagnosis of dementia, 207 (4.6%) received a diagnosis of DLB and of these,
74 DLB patients and 72 non-DLB dementia control patients consented for more detailed study of
their notes (see Appendix 1, Table 8, for details of cohort characteristics).
WORK PACKAGE 1: BASELINE STUDY
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Dementia with Lewy bodies was diagnosed in 4.6% of all those with dementia and there was evidence
of a difference in diagnostic rates between the two regions, with the rate in the North East being
higher (5.6%) than in East Anglia (3.3%) (χ2 = 13.6; p < 0.01). There were differences in the number of
core diagnostic features for DLB between the North East and East Anglia, with more clinical features
being present in DLB cases diagnosed in East Anglia, suggesting a higher ‘threshold’ for diagnosis,
which would be consistent with the lower rates of diagnosis. Use of biomarkers, such as dopaminergic
imaging, was also significantly different between the two areas, with the use of biomarkers being much
less common in East Anglia. Overall, there was evidence of an impact of age, with younger participants
taking longer to receive an accurate DLB diagnosis than older patients. Those with DLB were more
likely to have received another diagnosis before DLB (mean alternative diagnoses before final dementia
diagnosis 1.1 vs. 0.6; p = 0.003). DLB participants also had significantly more clinical assessments and
imaging tests prior to their diagnosis than those with non-DLB dementia (Table 2). Data on costs were
estimated over a time of 6.4 years for DLB participants compared with 5.1 years for non-DLB participants.
Overall, the average cost of care for DLB participants was £6557, compared with £3425 for non-DLB
participants [mean difference £2868, 95% confidence interval (CI) –£68 to £4013; p = 0.055] (see
Appendix 1, Table 9). After controlling for sex, time since diagnosis, total resource use time and other
patient characteristics, having a DLB diagnosis resulted in an increase of £3600 in total costs compared
with non-DLB participants (p< 0.001). For DLB participants, medical history costs represented the largest
contribution, with an average across participants of 40% of total costs compared with 27% for non-DLB
participants (p= 0.042) (see further details in Appendix 1, Tables 10 and 11).
Work package 1B: baseline study of the diagnosis and management of
Parkinson’s disease dementia
This study, also undertaken over the first 2 years of the programme, looked at diagnostic and management
practice in those with PDD, with the aim of establishing baseline diagnostic rates for PDD and comparing
investigations, assessment and management of those with PDD with control participants (i.e. patients with
PD without dementia).
Methods
We included five PD or movement disorder services, each from a separate trust, comprising two
geriatric medicine services and three services that combined geriatric medicine and neurology
expertise. The research team reviewed notes of all referrals to services over an 18-month period.
Those patients identified with PDD who were alive and felt to be well enough by the clinical team
(44/151 identified) were approached for consent for a more detailed study of their notes, with the
TABLE 2 A comparison between regions of factors relevant to diagnosis




Anglia, n Statistic p-value
Core features of DLB at time of diagnosis (mean) 1.5 2.1 –2.78 (Student’s t-test) 0.007
Suggestive features of DLB at time of diagnosis,
including DaT scans (mean)
0.8 0.4 2.63 (Student’s t-test) 0.0011
Abnormal DaT scans prior to diagnosis 24 1 12.9 (chi-squared test) 0.001
DaT scans prior to diagnosis (including normal) 31 1 20.6 (chi-squared test) < 0.001
Total diagnostic features (core and suggestive) of DLB
at time of diagnosis
2.4 2.6 0.80 (Student’s t-test) 0.42
Time between first secondary care appointment and
final diagnosis (years)
1.4 0.9 1.03 (Student’s t-test) 0.31
DaT, dopamine transporter.
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extraction of information with regard to diagnostic and management pathways collected using a case
report form. For each PDD participant who consented, a person with PD but without dementia
(control) was recruited by selecting the next case seen in the respective service who was diagnosed
with PD, matched for age (± 5 years) and sex, and who consented to participate.
Similar methods of analysis as those described for WP1A (see Work package 1A: baseline study of the
diagnosis and management of dementia with Lewy bodies) were used to collect and analyse data, and ethics,
Confidentiality Advisory Group and research and development approvals were sought and obtained.
Results
The research team identified 2263 referral patients, of whom 1563 had a diagnosis of PD. Of these
patients, 151 (9.7%) had received a diagnosis of PDD and of these, 38 PDD patients and 35 PD control
patients were approached and consented for detailed review of their notes (see Appendix 1, Table 8,
for details of cohort characteristics). For PDD, unlike DLB, there was no evidence of a difference in
diagnostic rates between the two regions (p = 0.2), although mean MMSE scores at time of diagnosis
were lower in East Anglia than in the North East (p = 0.008).
Examining the management pathways, there was evidence that dementia was probably present well
before the diagnosis of PDD was made. For example, 46% of those with PDD had impaired activities of
daily living due to cognitive impairment, with a mean intervening time of 1.5 years prior to diagnosis.
Cognitive impairment in multiple domains was present in 57% of patients at a mean period of 2 years
before diagnosis and 39% of patients had received an antidementia drug at an average of 1.75 years
before a dementia diagnosis.
Data on costs were available for an average of 9.3 and 7.8 years of management for PDD patients and
PD control patients, respectively. There was no evidence of a difference in average total costs between
PDD and PD controls (average difference £2024, 95% CI –£3598 to £5548; p = 0.462) (see Appendix 1,
Table 9). After controlling for sex, time since diagnosis, total resource use time and other patient
characteristics, PDD participants had an average total cost of care of £7655 more than PD controls
(95% CI £3676 to £11,634; p < 0.001). PDD participants had higher average costs of investigations
(£250 more, on average, 95% CI £237 to £306; p = 0.001) and higher post-diagnosis management costs
(£570 more, 95% CI £281 to £808; p = 0.001) (see Appendix 1, Tables 10 and 11).
Discussion
Our results showed, in keeping with our expectations, that DLB and PDD were diagnosed at around
half (or less) the rates that one would expect them to be, based on prior epidemiological and pathological
studies.12 There was clear evidence of differences in diagnostic practice between different services and
different regions, with a higher threshold for diagnosing DLB being, unsurprisingly, associated with lower
diagnostic rates. For PDD, there was evidence that the diagnosis was delayed, with those diagnosed by
services in one region having a significantly lower MMSE score at point of diagnosis than the other, and
those diagnosed with PDD had evidence of dementia being present up to 2 years before the actual
diagnosis was made. Our study had limitations, including the use of retrospective data and sampling of
only some services in two geographical regions. Services were not randomly selected, but selected on
the basis of geography. For the detailed case note assessment of subjects, we were able to obtain only a
modest number of cases and there may have been selection bias, as we could consent only people who
were alive and not deemed too unwell by their clinical teams to approach. The diagnostic rate findings
have been fully published17 and the differences in pathways to diagnosis and management are currently
in preparation. In terms of costs for both DLB and PDD groups, there was evidence that after controlling
for sex, time since diagnosis, total resource use time and other patient characteristics that the costs of
care were higher for both DLB and PDD groups than their respective controls.
WORK PACKAGE 1: BASELINE STUDY
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Work package 2: development of
management toolkits for Lewy body
dementia
Objectives
The objectives of WP2 were to (1) complete a systematic review of evidence about the management of
LBD and (2) use this to develop a clinical guideline, using a Delphi process incorporating the views of a
multidisciplinary panel of independent experts combined with two facilitated PPI workshops.
Systematic reviews
At the time that these reviews were undertaken and to the best of our knowledge, no evidence-based
reviews of the comprehensive management of LBD existed. As a consequence, little formal management
guidance for LBD was offered in the NICE dementia guideline used at that time,18 despite the fact that
this group of patients has multiple symptoms requiring treatment. Clinical guidance at the time appeared
solely in the form of pharmacological reviews and expert consensus opinion statements.14,19,20 This was
an unsatisfactory situation for prescribers, health-care providers and recipients of care.We therefore
conducted systematic reviews on pharmacological and non-pharmacological management of DLB.
Methods
The first of our two systematic reviews21 examined research on treatment effects and costs, and
patient and carer views of pharmacological management strategies for LBD. Studies were identified
through bibliographic databases, trials registers, grey literature, reference lists and experts. The review
protocol is provided in Appendix 2.22 In brief, we used the keywords ‘Lewy or parkinson’ and ‘dementia’,
conducting searches until March 2015, without restrictions on publication date or language. Titles and
abstracts were screened, with non-English-language papers screened by native speakers, and criteria
used were (1) participants who had a diagnosis of DLB, PDD or LBD, (2) studies examined pharmacological
strategies and (3) outcome measures and scores were specified. No restrictions were placed on study
design, but opinion papers were excluded. Data were extracted in relation to participant demographic
characteristics, selection criteria, study design, management strategies, outcome measures and scores,
adverse events and withdrawals. Studies were grouped and analysed according to pharmacological
strategy. Methodological quality was assessed using the Quality Assessment Tool for Quantitative Studies
(QATQS) [URL: www.ephpp.ca/tools.html (accessed April 2021)]. The QATQS examines selection bias,
study design, confounders, blinding, data collection methods, withdrawals and drop-outs. Domains are
rated as being of weak, moderate or strong quality, which feeds into an overall rating of study quality.
Meta-analyses were conducted and, when studies could not be combined, summaries were provided.
The level of evidence and grade of recommendations for each management strategy were assessed
using the Oxford Centre for Evidence-Based Medicine criteria.23
Forty-four studies examining 22 strategies were included in the review. Meta-analysis indicated beneficial
effects of donepezil and rivastigmine for cognitive and psychiatric symptoms. Rivastigmine, but not
donepezil, was associated with greater risk of adverse events. Meta-analysis of memantine suggested
that it is well tolerated, but with few benefits. Descriptive summaries provided some evidence of benefits
for galantamine, modafinil, levodopa, rotigotine, clozapine, duloxetine, clonazepam, ramelteon, gabapentin,
zonisamide and yokukansan. Piracetam, amantadine, selegiline, olanzapine, quetiapine, risperidone and
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citalopram did not appear to be effective. Methodological quality was rated as weak for 41% of included
studies, moderate for 39% and strong for 20%. This review concluded that high-level evidence related to
pharmacological strategies for managing LBD is rare and that strategies for important areas of need in
LBD, such as autonomic symptoms and carer burden, had not been investigated, nor had the views of
patients and carers about pharmacological strategies.
This review21 of pharmacological management was published in the American Journal of Psychiatry
(impact factor= 13.6) and by the end of 2018 had been cited 92 times, with an Altmetric Attention Score
of 26 placing it in the top 5% of all research outputs scored. It formed the basis for the subsequent
development of the management guideline and the first round of statements for Delphi panel evaluation.
Our second systematic review in WP2 regarded the non-pharmacological management of LBD.24
Details of the search strategy are described in Appendix 3. As with pharmacological management,
the literature and guidance available about LBD management available to clinicians and families at
that time was virtually non-existent and mainly accessed through not-for-profit support organisations.
Bibliographic databases were searched using a wide range of search terms and no restrictions were
placed on study design, language or clinical setting. We used the search terms [(Lewy OR Park*) and
Dementia]. Interventions were any non-pharmacological treatment and identified using a wide range
of terms covering individual non-pharmacological therapies: activit*, acupuncture, alternative, animal,
aromatherapy, art therapy, assisted, balance, behav*, bicycle, calisthenics, carer intervention, caregiver
intervention, CBT, Chi gong, cognit*, cognitive behavioral therapy, cognitive behavioural therapy, counsel*,
creative arts, dance, dancing, diet, direct current stimulation, drama, ECT, educat*, electroconvulsive
therapy, enhanc*, environmental intervention, environmental modification, exercise, flexibility, humor
therapy, humour therapy, hydrotherapy, intervention*, leisure, light therapy, management, martial arts,
massage, meditation, Montessori, multisensory, music, non-pharm*, nonpharm*, nutrition, occupational
therapy, pet therapy, physical activity, physical therapy, physiotherapy, pilates, psychoeducation, psychol*,
psychosocial, psychotherapy, Qi gong, reality orientation, recreation*, reminiscence, resistance training,
run*, sensory, simulated presence, stimulation, Snoezelen, support*, support group*, swim*, tai chi, therap*,
therapeutic activity, TMS, training, training carers, training caregivers, transcranial magnetic stimulation,
treatment*, validation, weight training, yoga. Searches were conducted on 30 October 2016.
The search identified 21 studies [including two randomised controlled trials (RCTs) with available
subgroup data], seven case series and 12 case studies. Most studies reported beneficial effects of
the interventions used, although the only sizeable study was on dysphagia, showing a benefit of honey-
thickened liquids. Given the heterogeneity of interventions and poor quality of the studies overall,
no quantitative synthesis (meta-analysis) was possible. Overall, identified studies suggested possible
benefits of non-pharmacological interventions in LBD, but the small sample sizes and low quality of
studies meant that no definite recommendations could be offered. This work underscored the clear
and urgent need for future research on this topic.
The review of non-pharmacological management was published in Psychological Medicine24 (impact
factor = 5.4) and was also subsequently incorporated into the development of the management toolkit.
Public–patient workshops
Two public–patient workshops were held, with the participation of 38 people with LBD and their
family/carers. The first event focused on identifying best practice in LBD clinical management, based
on their own experiences. The content of the workshops is shown in Figure 2. The emergent themes
were developed further in the second event and refined into a set of guiding principles.
Some of the key themes that were held to be important are listed in Table 3. The themes were
structured in such a way as to help the clinical team deliver the guideline recommendations in a
user-friendly format.
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From our work, a core element was the recognition that the carer is often the expert on the person
with dementia and they need to feel that this is recognised. Although people want to be told what the
clinician feels would be best for them, they also expressed concern about doctors treating what they
know best, rather than following patient and carer preferences, or seeking help from other types of
expert. Carer diaries were often mentioned as a useful way of dealing with these issues. Opinions were
divided as to whether or not the patient and carer should be seen together by the clinical team,
separately or offered both. Some issues, such as increased carer stress, which is high in LBD, probably
need to be explicitly discussed with the carer on their own.
PPI meeting 1
(March 2015)




• Ref ine emergent themes
Incorporation
• Development of principles to be integrated into the draft
     guideline circulated to the Delphi panel
Further
development
• Workshop content to be shaped by further qualitative
     analysis and possible publication
FIGURE 2 Workshops and content.
TABLE 3 Management principles arising from public–patient workshops
Management
principle Summary of discussion point
1 l Provide practical information at an early stage (e.g. power of attorney, attendance allowance,
council tax)
2 l Advantages and disadvantages to a problem list were identified:
¢ Risks that problem lists generate unwarranted concerns
¢ A long list of problems could be demoralising
¢ Reassuring as realise that these are expected symptoms not part of a new illness
3 l Recognise that the carer is often the expert on the patient
l Recognise the danger of doctors treating what they know best
4 l Main reliance on decision-making is guidance from the doctor; people want to be told what
the doctor feels would be best for them
5 l Carer diary can be useful to see the pattern of response to medication on good and bad days
(but may not be completed when things are OK or improving)
6 l Increased carer stress in DLB – need to explicitly discuss with carer on their own
7 l Peer support groups may be helpful (providing people have the same condition)
l Where geographical distance is a problem, telephone or e-mail contact may still be helpful
l Carer groups are very valuable for support and practical help
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Although the advantages of developing and working through a problem list were recognised, it was
also said that a long list of problems could be demoralising, something that is particularly relevant for
LBD where there are often many symptoms, not all of which may need to be formulated as problems.
It was noted as helpful that an expert experienced in LBD is often able to offer reassurance that these
symptoms can be expected as part of the disorder and not part of another illness.
Carer and peer support groups are very valuable for support and practical help, providing people
have similar conditions. Support groups are one source of practical information at an early stage
on important general matters, including power of attorney, attendance allowance and council tax.
Where geographical distance is a problem, telephone or e-mail contact may still be helpful.
A clear message throughout the PPI consultations was that although they appreciated the levels of
care and concern that clinical teams offered, they often had difficulty in obtaining and understanding
information about LBD. A lack of post-diagnostic support, advice and counselling was frequently
mentioned, as was a shortage of easily accessible materials. As a result, the guideline that we produced
contained links to what were judged to be the best-quality information sources at the time of writing,
and it is hoped that these will be made freely available to those attending our NHS services and that
they will, in turn, be replaced by improved versions and adapted for local use.
Guideline development
Using the systematic reviews and public–patient feedback, an initial draft of the guidelines was developed
by two authors (J-PT and IMcK). Statements relating to symptom domains were created and, using an
anonymised online platform, reviewed by the Delphi panel. The panel comprised experts in the field
(n = 26), including psychology, geriatrics, psychiatry, neurology, primary care, physiotherapy, nursing and
academic experts and some key international opinion leaders (see Appendix 4 for list of contributors),
who were identified through consultation with relevant stakeholder groups and supported by an extensive
publication search and/or their role as keynote speakers on management of LBD at conferences. The Delphi
process was undertaken over three rounds. A high level of agreement was sought across the three rounds
(85% for rounds 1 and 2, and 75% for round 3). Controversial statements were modified on the basis of
feedback and rerun in the subsequent round or removed. Of 252 original statements, 161 were kept, with
78 of these (48.4%) gaining full consensus panel agreement for inclusion, 52 (32.3%) with 90–99%
consensus agreement and 31 (19.3%) agreed by 75–89% of the panel. After this process, the guideline
statements were re-collated and formulated into one document. More controversial statements (but still
meeting majority consensus opinion of > 50%) were included as clarifying footnotes, where appropriate,
in the guideline document.
The guideline statements were then supplemented by summary management sheets (one overall
summary figure and separate summary figures for each key symptom domain, produced by J-PT and
IMcK, with input from the DIAMOND-Lewy team) that accompanied the written guideline, with the
whole package being called the management toolkit. This toolkit was then subjected to further
evaluation and feedback in WP3 and typological corrections or clarification of guideline statements
(although no change to content or meaning) were made based on the feedback from clinicians.
The management toolkit was finalised at this point and put forward for evaluation in WP4 (see Report
Supplementary Material 1). The toolkit comprised an overview (see Appendix 5), brief summaries for each
symptom area and the management guideline.
Dissemination of the toolkit
Our major output has been the acceptance of an authoritative management review,25 which contains
reference to the Delphi statements and the evidence base used to produce the management toolkit,
in Lancet Neurology (impact factor = 27.14). This has made the findings from our guidelines accessible
for adaption and implementation in clinical services internationally.
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Specific to the UK and NHS context, we have a dissemination plan, including:
l making the management toolkit freely available via our website
l embedding the use of the management toolkit in significant national educational fora (e.g. the
British Association of Psychopharmacology)
l developing an online learning resource with video discussing management approaches in LBD.
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Work package 3: development of
assessment toolkits for the diagnosis of
Lewy body dementia
Introduction
Work package 3 was developed because the accurate recognition of LBD is crucial to ensuring
appropriate management and, therefore, central to improving patient care in dementia.26–28
Prior to this programme, there was no single simple-to-administer toolkit that incorporated assessment
of all the symptoms needed to make a diagnosis of DLB and PDD. Therefore, WP3 aimed to develop
such assessment toolkits to improve the recognition and diagnosis of both DLB and PDD.
Methods
We developed the final LBD assessment toolkits in three stages: (1) identifying validated assessments
for different symptoms and signs needed for a LBD diagnosis to make a pilot instrument, (2) obtaining
feedback on the acceptability and feasibility of the toolkit through interviews with clinicians and the
programme PPI group, and (3) piloting the toolkits in memory and movement disorder services prior to
producing a final version to be used in WP4.
Stage 1: development of pilot assessment toolkits
Following funding, the DIAMOND-Lewy PMG first discussed the basic approach to the problem and,
in particular, whether one overall assessment and assessment toolkit should be developed or two separate
ones, one for DLB (aimed at memory services) and one for PDD (aimed at movement disorder services or
neurology and geriatric medicine services that also see people with movement disorders). It was concluded
that two different instruments would be needed that matched the international diagnostic criteria for
DLB14 and PDD.29 The clinical experts in the DIAMOND-Lewy programme (AT, J-PT, IMcK, LA, DB and JOB)
then reviewed the published literature and supplemented this with their expert knowledge to identify
available validated assessment instruments26–28,30 that would form the contents of the toolkits. The PMG
identified appropriate components for each toolkit from the identified assessment instruments.
For the DLB toolkit, the aim was to improve identification of the core and suggestive diagnostic symptoms,
as diagnosis of cognitive impairment and dementia in specialist memory services is not a concern. At the
time of toolkit development, there were six core and suggestive symptoms for diagnosing DLB. One was
dopaminergic imaging, which would not form part of a clinical assessment tool, and another was neuroleptic
sensitivity, which can only be identified following exposure to antipsychotic drugs, which is now a rare
event.31,32 Therefore, the focus was on assessment of the four remaining symptoms: (1) persistent complex
visual hallucinations, (2) spontaneous cognitive fluctuations, (3) spontaneous parkinsonism and (4) rapid eye
movement (REM) sleep behaviour disorder. The following components of the instrument were identified:
l cognitive fluctuation – four questions to carers from the Dementia Cognitive Fluctuation Scale28
l REM sleep behaviour disorder – a single screening question to carers from the Mayo
Sleep Questionnaire27
l visual hallucinations – two core questions for patients and two for carers from the North East
Visual Hallucinations Inventory30
l motor features of parkinsonism – five items from the Unified Parkinson’s Disease Rating Scale.26
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For the PDD toolkit, the aim was to improve identification of cognitive impairment and to facilitate
matching of symptoms to the PDD diagnostic criteria.29 The Montreal Cognitive Assessment (MoCA)
was identified as most appropriate for brief cognitive assessment in this context.33
Stage 2: feedback and modification of toolkits
During 2014, as WP3 lead, Alan Thomas put together the two instruments and there followed a period
of iteration with the rest of the PMG. This led to the formulation of draft versions of the toolkits,
which were then sent to the PPI panel for feedback in early 2015. PPI panel feedback was incorporated
into a revised version, which was again commented on by the PMG and PPI members until final agreed
versions of the toolkits and text were agreed for the pilot study. These iterative rounds led to changes
in the wording of questions to try to improve clarity. In addition, a major change suggested was to
separate the PDD toolkit into one version for use with carers and one for use with patients, based on
how patients present to PD services where they may or may not have a carer present. After final
iterations between PMG and PPI groups, three final assessment toolkits were produced for the pilot
and feasibility study.
Stage 3: pilot and feasibility of assessment toolkits
During early 2015, as the final versions of the toolkits were developed and by mid-2015, the necessary
research ethics approval was obtained from Yorkshire and The Humber – Bradford Leeds Research
Ethics Committee (reference 15/NE/0028). Trust research and development approval was also obtained
prior to the start of the study.
In the autumn of 2015, we conducted the pilot study of the feasibility of the assessment toolkits
in memory and PD services at Gateshead Health NHS Foundation Trust. Details are published in
Thomas et al.34 Briefly, we obtained engagement from medical and nursing staff in these services who
administered the toolkits to > 20 patients, with individual clinicians using the toolkits between zero
and seven times in patients with and without LBD. Feedback on acceptability and thoughts on
improvement were obtained by direct comments to the WP lead (AT) and the research nurse by
comments written on the toolkits and from qualitative interviews with patients, carers and clinicians.
Clinicians found the toolkits straightforward to use, although in the PD service they found attempting
the cognitive assessment to be a problem because of time constraints. These clinicians were also keen
to have the questions about core symptoms of DLB included in the toolkit for PD services. Patients
and carers had no concerns about their use or how the questions were phrased. Therefore, following
the pilot, a revision of the toolkits was produced that took these comments into account. Specifically,
we produced a single assessment toolkit (the LBD toolkit) for PD services, which included the questions
from the DLB toolkit for identifying core DLB features. Finally, by this time, the revised DLB consensus
diagnostic criteria were being published,11 which led to a few final minor changes to these toolkits to ensure
that they were aligned with the revised criteria. Details of these changes were published.35
Use of the toolkits in work package 4
These final published versions of the DIAMOND-Lewy toolkits (see Report Supplementary Material 2)
were utilised in WP4 of the programme, with all services, whether randomised to intervention or
usual care, being supported in using the toolkits. The toolkits were published online in 2016 and in
print in 2017,34 and this contributed to making these toolkits publicly available through open access.
In parallel, the toolkits have also been made available through the DIAMOND-Lewy study website
[URL: https://research.ncl.ac.uk/diamondlewy/ (accessed April 2021)].
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Work package 4: a pilot cluster randomised
trial of the management toolkit
This WP involved the introduction of the assessment toolkits (developed in WP3) to memory/oldage psychiatry and PD/movement disorder services, with the aim of facilitating diagnosis of DLB
and PDD, and the introduction through a cluster randomised trial (randomised at the individual service
level) of the management toolkit (developed in WP2) into half of the services taking part, with the
other half continuing with standard care. The objectives of the pilot RCT were to (1) see if such a study
was feasible [i.e. that we could recruit subjects with DLB and PDD (target n = 120) and retain them for
6 months] and (2) obtain data to inform power calculations for future studies.
Methods
We included 11 services in four NHS trusts in the North East and 12 services in four NHS trusts
in East Anglia. The trial was supported by the Newcastle Clinical Trials Unit, which undertook the
randomisation via a statistician blinded to other aspects of the study. One service in the North East
was subsequently unable to recruit any patients and withdrew part-way through the study. This study
was approved by the West Midlands – Coventry and Warwickshire Research Ethics Committee
(reference 16/WM/0025).
Assessment toolkits and, for services randomised to the intervention arm, the management toolkit
were introduced during an in-person site initiation visit undertaken by the research team. The site
initiation visits comprised standardised presentations and handouts followed by a question and answer
session. The site initiation visits included as many clinical team members as were able to attend and
all those involved in the diagnosis and management of those with DLB and PDD were encouraged to
use the diagnostic and management toolkits. Follow-up support and further sessions were provided
as required, and the study team maintained regular contact with all services during the course of the
recruitment and follow-up period.
Assessment and management toolkits were provided as paper copies, with laminated copies of the
overview and symptom summary sheets for the management toolkit. Some sites requested electronic
[Portable Document Format (PDF)] versions and, where these were requested, they were supplied.
If services had questions regarding the assessment or management toolkits, they were free to ask
members of the research team. Regular trial newsletters that contained a ‘frequently asked questions’
section were sent to services to facilitate engagement with the study. Questionnaires regarding the
value and use of the management toolkit were sent to services in the intervention arm halfway
through the study and at the study end. Qualitative interviews (see Work package 5: qualitative studies
throughout the DIAMOND-Lewy programme) were conducted to ascertain barriers to and facilitators of
the implementation of both the diagnostic and management toolkits.
In all services, patients with DLB and PDD were recruited for data collection at baseline, 3 months
and 6 months. A carer/informant was recruited for all but two patients. The full study protocol, which
includes all the assessments undertaken, is available on the DIAMOND-Lewy website.36 In brief,
assessments included those of cognition (MMSE and MoCA), neuropsychiatric symptoms (Neuropsychiatric
Inventory and Geriatric Depression Scale), fluctuations (Cognitive Fluctuation Scale), activities of daily living
(Bristol Activities of Daily Living Scale), motor symptoms [Unified Parkinson’s Disease Rating Scale Part 3
(UPDRS)] and quality of life [DEMQOL (Dementia Quality of Life) and EuroQol-5 Dimensions, five-level
version (EQ-5D-5L)]. Current management and use of health care and personal/social care services were
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collected on a bespoke questionnaire. Global outcome scales were completed by the visiting researcher
and the carer/informant. Informant assessments included quality of life of the carer (EQ-5D-5L), carer
burden (Zarit Burden Interview) and the Hospital Anxiety and Depression Scale.
All baseline and 3- and 6-month assessments were undertaken by members of the Clinical Research
Network DeNDRoN teams in the North East and East Anglia, who were unaware of the service
allocation (to management toolkit or standard care).
Data entry was completed by those undertaking the assessments, and central checking and quality
assurance followed double-entry at local sites with an error rate of < 0.1% (all errors noticed were, of
course, corrected). Database integrity was therefore felt to be very good. Identical shell databases were
completed in the North East and East Anglia and then merged and sent to the study statistical team.
Results
One hundred and thirty-one participants consented to take part in the study. A CONSORT (Consolidated
Standards of Reporting Trials) flow diagram, indicating patient progression through the study, is shown
in Figure 3. One hundred and twenty-seven participants underwent a baseline assessment, and 6-month
data were available for 109 participants (86% of those who completed baseline, 83% of all participants
who consented). Eighteen participants were lost to follow-up, seven of whom died (four in the intervention
arm, three in the control arm). Those lost to follow-up were similar in demographic characteristics to those
remaining in the study except for age, with those lost to follow-up being significantly older (median age of
83 vs. 77 years).
The recruitment target was more than achieved. We aimed to recruit 120 patients and actually
recruited 131. Patient characteristics at baseline are shown in Table 4. Participants randomised to
receive the intervention did not differ significantly from those randomised to the control group on
any of the baseline measures except for carer-reported DEMQOL and carer anxiety symptoms as
assessed on the Hospital Anxiety and Depression Scale.
Health economics
The main objective of the economic component of the pilot RCT was to rehearse the methods for a
future definitive economic evaluation of the new management toolkit compared with the usual care
provided for dementia. As is typical for pilot trials, the modest sample size meant that a full economic
evaluation was not appropriate because estimates would be both imprecise and unreliable. Therefore,
the focus of the economic component was restricted to provide a descriptive analysis of the costs
and outcomes. Data on costs and outcomes for each patient sample (DLB and PDD) were examined
separately, as it was expected that the different diagnoses would lead to a differential use of services
and outcomes.
Deviations from protocol
The protocol, and the analysis plan (see Report Supplementary Material 3), which was based on the
protocol, stated that a cost-effectiveness analysis would be conducted, reporting an incremental
cost-effectiveness ratio. A stochastic analysis, reporting results in the form of cost-effectiveness
acceptability curves and cost–quality-adjusted life-year (QALY) plots, was also planned. However,
because of the smaller number of data collected than expected, this analysis was not conducted to
avoid reporting imprecise and unreliable results.
A full report of the economic component can be found in Appendix 6. A summary of the key results is
presented below.
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Costs
Costs were examined from the perspectives of the UK NHS and Personal Social Services, which
includes costs of medications and health and social service use. Costs incurred by other sectors
(e.g. local authorities) were not included; however, private costs incurred by patients and carers for
attending health-care services were included. Data on costs using a service use questionnaire
administered to the carer were collected at baseline and at the 3- and 6-month follow-ups. Data on
private costs to patients were collected using a time and travel questionnaire at the 6-month follow-up.
Health care and social service resource use
In both patient samples, mean costs associated with health and social service use decreased in the
intervention arms between baseline and the 6-month follow-up. However, in the control groups, costs
increased. There is a substantial amount of imprecision around the service use cost data, however,
and median values are considerably smaller than the mean values, which suggests that there is a
substantial right skew to the data, with some participants incurring much higher costs than the
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FIGURE 3 DIAMOND-Lewy WP4 CONSORT flow diagram of participants’ completion rate (27 March 2019). CRF, case
report form.
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TABLE 4 Baseline characteristics of the randomised participants
Characteristic Control (N= 52) Intervention (N= 75) p-valuea
Number of sites 11 12
Age (years)
Mean (SD) 77.0 (7.59) 79.3 (6.97) 0.086
Median 77.0 79.0 0.094
Interquartile range 72.0–83.0 75.0–84.0
Diagnosis, n (%) 0.846
DLB 31 (59.6) 46 (61.3)
PDD 21 (40.4) 29 (38.7)
Sex, n (%) 0.642
Female 10 (19.2) 17 (22.7)
Male 42 (80.8) 58 (77.3)
DEMQOL
Mean (SD) 0.76 (0.13) 0.78 (0.12) 0.229
Median 0.78 0.80 0.215
Interquartile range 0.70–0.82 0.70–0.88
Carer DEMQOL-proxy
Mean (SD) 0.70 (0.14) 0.76 (0.12) 0.021
Median 0.67 0.79 0.026
Interquartile range 0.55–0.82 0.67–0.85
Neuropsychiatric Inventory
Mean (SD) 25.0 (17.5) 20.0 (18.0) 0.125
Median 22.0 15.0 0.038
Interquartile range 12.0–31.0 9.0–24.0
UPDRS
Mean (SD) 43.7 (19.1) 38.2 (18.6) 0.112
Median 41.0 35.5 0.137
Interquartile range 28.0–55.0 26.0–51.0
Cornell Scale for Depression in Dementia
Mean (SD) 9.31 (6.10) 7.41 (4.85) 0.056
Median 9.0 7.0 0.104
Interquartile range 4.0–13.0 4.0–11.0
Geriatric Depression Scale
Mean (SD) 5.7 (3.5) 5.6 (3.3) 0.899
Median 5.0 5.0 0.952
Interquartile range 3.0–7.0 3.0–7.0
MMSE
Mean (SD) 20.8 (6.1) 21.4 (6.1) 0.581
Median 22.0 22.0 0.503
Interquartile range 17.0–25.0 19.0–26.0
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Medication costs
There was little variation in mean medication costs between baseline and the 6-month follow-up in both
patient samples.There was a trend towards increasing costs for both arms over the follow-up period. A
greater increase in mean medication costs can be observed in the intervention arms of both patient samples
than in the control arms. However, the increase is larger for the PDD patients (see Appendix 6, Table 13).
Intervention delivery costs
The cost of the intervention included the production of the management toolkits and training staff
to use them. The total delivery cost was divided by the number of participants in the intervention arm
in both patient groups combined (n = 75) to estimate a mean delivery cost per participant receiving the
intervention. The mean intervention delivery cost was estimated at £76.32 per participant in the intervention
arms and £0 for those not receiving the intervention (i.e. control arms) (see Appendix 6, Table 14).
TABLE 4 Baseline characteristics of the randomised participants (continued )
Characteristic Control (N= 52) Intervention (N= 75) p-valuea
MoCA
Mean (SD) 15.1 (4.9) 15.6 (6.0) 0.644
Median 15.5 16.0 0.690
Interquartile range 12.0–19.0 12.0–19.0
EQ-5D-5L
Mean (SD) 0.67 (0.27) 0.67 (0.21) 0.998
Median 0.74 0.73 0.516
Interquartile range 0.55–0.85 0.57–0.80
EQ-5D-5L (proxy)
Mean (SD) 0.55 (0.27) 0.56 (0.27) 0.769
Median 0.62 0.62 0.929
Interquartile range 0.37–0.73 0.40–0.77
Hospital Anxiety and Depression Scale: anxiety
Mean (SD) 6.7 (4.2) 5.2 (4.1) 0.052
Median 6.0 4.0 0.037
Interquartile range 3.0–9.0 2.0–8.0
Hospital Anxiety and Depression Scale: depression
Mean (SD) 4.6 (3.8) 4.2 (3.5) 0.553
Median 3.0 3.5 0.610
Interquartile range 1.0–7.0 1.0–7.0
Zarit Burden Interview
Mean (SD) 27.5 (15.6) 22.6 (15.3) 0.082
Median 26.0 18.0 0.070
Interquartile range 14.5–38.5 10.0–33.0
Carer EQ-5D-5L
Mean (SD) 0.80 (0.20) 0.81 (0.19) 0.822
Median 0.84 0.82 0.902
Interquartile range 0.72–1.0 0.69–1.0
SD, standard deviation.
a p-value from a t-test, Mann–Whitney U-test or chi-squared test.
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Total costs
Total costs included health and social service use, medication costs and intervention delivery costs (to
illustrate cumulative costs at that time point they were added to the cumulative costs, estimated at the
3- and 6-month follow-ups only). The health and social care use costs made up the largest proportion
of the total cost. In both patient samples, there was an overall increase in total costs between baseline
and the 6-month follow-up in the control arms, whereas total costs at the 6-month follow-up were
lower than baseline in both sample intervention arms (see Appendix 6, Table 15). There remains
substantial imprecision in the total cost values because of the small sample size and, therefore, the
total costs are, at best, illustrative.
Private costs
Private costs included the cost of travelling to inpatient services, outpatient appointments, general
practitioner (GP) visits and community dementia service visits for both patients and carers who may have
accompanied patients. The cost of time spent travelling to each appointment and the cost of time spent at
each appointment were also estimated. Costs were attributed to time based on activity rates for various
activities, using estimates published by the Office for National Statistics (ONS)37 (see Appendix 6 for
further details). For both patients and carers, mean travel costs decreased between baseline and
the 6-month follow-up in both trial arms and patient samples. An exception to this was the control
group of the PDD sample, which incurred higher mean costs at the 6-month follow-up than at baseline.
With reference to the cost of patients’ time spent attending health-care services, the intervention
groups of both patient samples incurred lower mean costs over the 3-month period between the
3- and 6-month follow-ups than during the 3-month period prior to baseline data collection, whereas
the control groups had a higher mean cost for the same 3-month period prior to the 6-month follow-up
than at baseline (see Appendix 6, Table 16). A similar pattern was observed for costs to carers, with
the exception that carers in the control group of the DLB sample incurred lower mean costs at the
6-month follow-up than at baseline (see Appendix 6, Table 17).
Quality of life
Patients’ generic quality of life was derived from the responses to the EQ-5D-5L questionnaire,38
completed at baseline and at the 3- and 6-month follow-ups (missing EQ-5D-5L data at each time point
are recorded in Appendix 6, Table 18). Responses to the EQ-5D-5L questionnaire were transformed into
health state utilities, using tariffs derived from the UK population.39 Using the change from baseline
approach, the health state utilities were used to estimate generic QALYs for each participant so that
the change in QALYs between baseline and the 6-month follow-up was estimated.
Overall, changes in QALYs in each trial arm for each sample were small to modest, but with consistent
decreases in mean and median scores for those with DLB, indicating a benefit for those in the intervention
arm. An extremely small decrease in QALYs was observed in the intervention arm of the PDD sample,
compared with a small increase in mean QALYs for the control arm (see Appendix 6, Table 19).
Discussion
This study demonstrated the feasibility of successfully recruiting a large number of participants with
DLB and PDD over an 18-month period from 23 sites, and we more than achieved the recruitment
target (target, n = 120; recruited, n = 131). Follow-up rates were good (85%), given the condition under
study, as LBD is known to be associated with more rapid functional decline and increased mortality
than other dementias.11,40 Completion rates of assessments for both patients and carers were high.
Using results from this study to inform a power calculation (80% power, alpha 0.05) gives a required
sample size of 726 for outcome based on the Neuropsychiatric Inventory {18.8 [standard deviation
(SD) 19.3] in the intervention and 22.6 [SD 16.3] in the control group}. Assuming 80% completion rates,
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the recruitment sample would need to be 908 for the Neuropsychiatric Inventory. However, given that
the toolkits are already evidence based and associated with some positive outcomes, even in this pilot
study, it is not clear that a larger trial based around demonstrating efficacy of the toolkits is needed.
Instead, an approach focused more on their routine implementation, through service improvement or
other approaches, may be preferable.
Taking account of the cost of implementing the management toolkits, the health economic analysis
indicated that the total costs for both DLB and PDD increased over the course of the study in the
control arms and decreased in the intervention arms, despite a slight increase in medication costs in
intervention groups. With such a modest sample size, data were insufficient to draw conclusions,
although there is no indication that the intervention increased costs. Data indicated that further study
on health economic consequences in a larger sample is needed.
The qualitative studies (see Work package 5: qualitative studies throughout the DIAMOND-Lewy programme)
indicate that implementation and use of the management toolkit varied considerably between individual
clinicians and between services. Limitations of the study are that we were not able to standardise or
measure this, nor – because this was randomised at a cluster level – could we directly associate the
impact of the management toolkit on patient outcomes at the individual patient level. Further study
should investigate these issues, but our results strongly support the need for a large, definitive trial of
the management toolkit and indicate that its introduction is not associated with increased costs.
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Work package 5: qualitative studies
throughout theDIAMOND-Lewy programme
The reasons for underdiagnosis and suboptimal management of LBD have not previously beenempirically investigated using qualitative methods. Research has focused on clarifying diagnostic
criteria, identifying biomarkers or screening tools to facilitate diagnosis, with little attention to
potential barriers to diagnosis. The emphasis has therefore been on identifying technical solutions,
rather than considering the full range of factors that might contribute to the underdiagnosis of LBD.
There is growing recognition of the contribution qualitative research can make to feasibility studies,
pilot trials and RCTs,41,42 for example by understanding the context into which interventions are to be
introduced, optimising interventions, understanding factors influencing the implementation of the
intervention and facilitating the interpretation of findings.41,43,44 In the DIAMOND-Lewy programme,
the objectives of the qualitative work were to:
l understand current practice in diagnosing and managing LBD (WP5.1)
l explore stakeholder views on the acceptability of the toolkits (WP5.2)
l explore the implementation of the assessment and management toolkits in routine NHS
practice (WP5.3).
A range of theories are available to assess the likelihood of a new intervention being successfully
embedded into routine practice.45 Normalisation process theory (NPT) is a well-established theory
of implementation, which has been used extensively in studies of health-care interventions.46 NPT considers
factors that affect implementation in relation to four key areas: (1) how people make sense of a new
practice (coherence), (2) the willingness of people to sign-up and commit to the new practice (cognitive
participation), (3) their ability to take on the work required of the practice (collective action) and (4) activity
undertaken to monitor and review the practice (reflexive monitoring) [URL: www.normalizationprocess.org
(accessed April 2021)].47
The qualitative work aimed to generate practical knowledge to inform subsequent stages of the
programme (e.g. by providing feedback that could be used in revising toolkits, proposing an implementation
strategy to address key barriers and proposing change mechanisms for the study findings). Ethics and
research governance approvals were sought in two phases. Favourable ethics opinion for phase 1 was
obtained from the Newcastle and North Tyneside 1 Research Ethics Committee (reference 13/NE/0322).
Subsequent research and development and Caldicott approvals were granted from each participating site.
Favourable ethics opinion for phase 2 was obtained from Wales Research Ethics Committee 5 (reference
16/WA/0098). Health Research Authority approval for phase 2 was obtained on 29 June 2016.
Methods
We used ethnographic methods, including semistructured interviews, focus groups and observations
of clinical practice, throughout WP5. Structured questionnaires were used to collect information on
current practice, confidence in diagnosing and managing LBD, and (in WP5.3) views on the assessment
and management toolkits (Table 5).
Participants
Participants included clinicians working in memory and movement disorder services (including
geriatricians and/or neurologists) and patients attending participating services together with any
companions (hereafter ‘carers’). We aimed to recruit maximum variation samples throughout (with the
exception of WP5.2 where we recruited all available participants). Relevant clinician characteristics
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were professional background (doctors, nurses, allied health professionals), specialty (e.g. geriatrics,
neurology, old age psychiatry), geographical location (East Anglia, North East) and, in WP5.3, study arm
(control, intervention). Only 22 services took part in WP5.3. The remaining service involved in WP4
dropped out prior to the start of WP5.3.
All clinicians in participating services were eligible for all components ofWP5, althoughWP5.3 questionnaires
were targeted primarily at those who had been exposed to the toolkits. All patients and carers seen by
participating clinicians on the dates of observation were eligible. Patients and carers for interview in
WP5.2 were identified by participating clinicians and the local research nurse. Recruitment continued
until no new themes or issues emerged from further interviews or observation. In WP5.3 interviews with
patients and carers were only planned in the event of any indication of the toolkits having had an impact
on consultations.
Data collection and analysis
Data collection and analysis were iterative to ensure that insights from observation informed the
interviews and vice versa. Clinician interviews and focus groups explored current practice, the
perceived relevance of the assessment and management toolkits, and facilitators of and barriers to




Clinician questionnaire (T0) 146/336 completed
questionnaires
Clinician interviews 20
Clinician focus groups Two (16 participants)
Observation of routine practice 17 clinical sessions (44 patients
and 36 carers)
Three clinical discussions
(eight patients and eight carers)
Twomultidisciplinary teammeetings




Clinician interviews 60 (across whole study)
Observation of acceptability of
toolkits in feasibility study
0
Interviews with patients and carers







Clinician questionnaires (T1 towards






Clinician interviews 40 (including nine from the
feasibility study)
Clinician focus groups Five (32 participants)
Observation of routine practice 25 clinical sessions
Interviews with patients and carers
were only planned in the event of
any indication of the toolkits having
had an impact on consultations
None
T0, initial data collection; T1, follow-up 1 (towards the start of WP5); T2, follow-up 2 (after the pilot trial).
WORK PACKAGE 5: QUALITATIVE STUDIES THROUGHOUT THE DIAMOND-LEWY PROGRAMME
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
their implementation (see Report Supplementary Material 4 for topic guides). The guides were informed
by NPT, but allowed additional issues to be raised. Interviews and focus groups were audio-recorded,
transcribed, checked and anonymised prior to analysis. Interviews with patients and carers explored
their perceptions of the assessment toolkit and also used cognitive interviewing techniques to obtain
feedback on question wording.48 Observation provided insight into clinic organisation, content of
consultations, team roles and the use of standardised tests. In the pilot trial, observation focused
primarily on if and how the toolkits were used. Anonymised field notes were written as soon as
possible after observation.
Questionnaires explored the views of clinicians on diagnosis and management of LBD and on
implementation in the pilot trial. Postal (WP5.1) and electronic questionnaires (WP5.3) were used,
with one reminder to non-responders. For full details of analysis, response rates and respondent
characteristics see Appendix 7, Tables 20–24.
Qualitative data were analysed thematically,49 with themes from WP5.3 subsequently mapped to the
core constructs of NPT. Questionnaire data were analysed using simple descriptive statistics using
SPSSX version 22 (IBM SPSS Statistics, Armonk, NY, USA).
The final data set for the qualitative work comprised 60 interviews with clinicians, seven focus groups
(with 48 clinicians), observation of 42 clinical sessions, four clinical discussions, two multidisciplinary
team meetings and interviews with six patients and four carers (see Table 5).
Results
Understanding current practice in the diagnosis and management of Lewy body dementia
(work package 5.1)
Factors influencing the diagnosis and management of LBD were grouped into four overarching themes:
(1) complexity of LBD, (2) service organisation, (3) skills, training and knowledge, and (4) clinician
attitudes and values (Table 6). Each comprised a number of subthemes (those identified as particularly
relevant to LBD are listed first and those relevant to dementia in general are shown in italics in Table 6).
The complexity of LBD and service organisation were relevant to both diagnosis and management,
whereas training and attitudes primarily related to diagnosis. The relative importance of each theme
and subtheme in movement disorder and memory services is explored below. For further illustrative
quotations and details of ID numbers see Appendix 8, Tables 25 and 26.
Complexity of Lewy body dementia
Variability in presentation within and between patients with LBD, together with a trend towards
earlier presentation to memory services, meant that diagnosing LBD was not straightforward. Several
old age psychiatrists (OAPs) commented on the subtleties of presentation, which were easy to miss
unless explicitly explored during assessments:
. . . this is a very special kind of dementia, which is very difficult to diagnose in the first stages of the illness.
Because the cognitive function is not that prominent, it’s mostly a sleep problem and falls, unsteadiness.
Sometimes, they are almost the same as the Alzheimer’s type [. . .] In the early stages, it’s not easy to diagnose.
0501, trainee OAP
Fluctuating cognition, a characteristic of LBD, meant that key symptoms were not necessarily present
during a single assessment or short follow-up appointment. Several clinicians in movement disorder
services commented on the difficulties in distinguishing dementia and delirium and identifying dementia
subtypes, as symptoms were not exclusively associated with a particular diagnosis. Although scans could
assist with diagnosis, access to some types of scans varied. The lack of a specific, definitive test for LBD
made it difficult for clinicians to develop confidence in their diagnostic skills.
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Complexity also influenced the management of LBD. Sensitivity to medication required a cautious approach
to introducing new treatments to minimise side effects. Eliciting patient priorities for treatment was crucial
to ensure that symptoms of most relevance to the patient (or carer) were addressed. Understanding how
patients had responded to new treatments in the context of fluctuation posed a further challenge and made
the availability of an informant particularly important.
Service organisation
The increasing demand on services, in a context of stable or diminishing resources, had a significant
impact on the diagnosis and management of LBD. In some memory services, new referrals were
triaged, with ‘straightforward’ patients being allocated for assessment by a nurse or memory assessor.
This could lead to DLB being missed, particularly when such staff had not received adequate training.
The limited time for follow-up appointments in movement disorder services influenced the extent
to which clinicians proactively explored memory problems. Although cognitive function was routinely
assessed (usually annually) in some services, this was not feasible in less well-resourced services: a
further difficulty related to disclosing a diagnosis of PDD in a short follow-up appointment.
Strategies adopted to support the diagnosis of PDD included using nursing staff to conduct annual
cognitive tests and developing a separate cognitive clinic with longer appointment times for patients
with suspected PDD. Some clinicians approached the possible diagnosis of dementia over a number
of visits to prepare patients and their families for disclosure gradually. Others emphasised the need to
educate patients at an early stage about the potential cognitive impairment associated with PD.
TABLE 6 Factors influencing the diagnosis and management of LBD
Theme Subtheme
Complexity of LBD Variability in presentation
Lack of a definitive test
Balancing treatments
Shift to earlier presentation
Availability of an informant
Service organisation Shift to nurse-led memory services
Follow-up arrangements
Fragmented care
Training, knowledge and experience Awareness of LBD and cognitive biases
If and how core symptoms were covered in consultations
Interpreting cognitive tests
Knowledge of dementia subtypes
Attitudes and values Perceived prevalence and status of LBD
Perceived value of diagnosing LBD
Perceived responsibility for LBD
Perceived value of diagnosing dementia subtypes
Note
Those identified as particularly relevant to LBD are listed first and those relevant to dementia in general are shown
in italics.
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Current service organisation emerged as a key barrier to the effective management of LBD, with
considerable inequity of provision. Where patients developed cognitive symptoms first and were
diagnosed with DLB by memory services, most were discharged back to GP care following diagnosis
and treatment initiation. Referrals were then made as and when needed, resulting in episodic care with
limited proactive management. PD patients who developed cognitive problems were typically managed
in line with the NICE PD guideline, with reviews every 6–12 months.50 Many PDD patients had access
to a specialist nurse and few were discharged. Clinicians in movement disorder services nevertheless
identified time as a barrier to holistic management of PDD patients:
The most frustrating thing is seeing a patient you may have known for a long time or who has been under
follow-up for a long time and then you have a 10-minute slot to deal with them when they have got
advanced Parkinson’s with dementia. It is ridiculous really but that is what happens [. . .] And so the most
needy patients actually get the least attention and time which is very frustrating.
2101, consultant neurologist
Although some experienced geriatricians preferred to manage all symptoms to ensure continuity of
care or expedite treatment, the complexity of LBD meant that most patients were referred between
old age psychiatry, older people’s medicine and neurology departments. In the UK NHS, joint working
or shared care by different specialties was difficult to achieve in practice because of funding arrangements,
lack of shared geographical boundaries, incompatible information technology systems and limited direct
consultant–consultant communication (with communication typically routed via the GP).
Although clinicians described a number of strategies to improve shared care of people with LBD, few
had proved sustainable. These included joint meetings between services about complex patients, and
adapting the care pathway to provide rapid access to interventions offered by memory services for
patients already diagnosed with PDD by a movement disorder specialist without further diagnostic
assessment. Although informal approaches, where clinicians in different specialties were co-located
and had worked together for a number of years, appeared most successful, such arrangements were rare.
Training, knowledge and experience
Training, knowledge and experience were identified as key barriers to the diagnosis of LBD, but were
less often discussed in relation to management. The questionnaires indicated that clinicians in memory
assessment services were less confident in diagnosing DLB and PDD than other types of dementia
(with the exception of frontotemporal dementia, see Appendix 7, Figure 7). Similarly, few clinicians were
confident in managing both cognitive and physical symptoms (see Appendix 7, Figures 8 and 9), reflecting
the need for shared care by different specialists.
Cognitive biases (where clinicians anticipated a default diagnosis of Alzheimer’s disease and framed
questions in ways that would confirm their expectation) were thought to contribute to underdiagnosis
of DLB:
I suppose I used to get told in medical school, that what the mind does not know, the eye will not see.
So, unless you actually have this as a probable differential in the back of your mind, you’re not going to
consider it, or then check to make sure that you aren’t missing something.
0601, consultant OAP, author’s emphasis in bold
In addition to awareness of LBD, clinicians needed to ask the right questions to elicit relevant
symptoms. Observation of memory services indicated that although symptoms such as hallucinations,
sleep and fluctuation were often explored, questions tended to be non-specific and/or leading. The lack
of formal neurological examination was also confirmed, although participants often described assessing
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parkinsonism informally, for example by observing or asking about gait, blink rate and facial expression,
and looking for tremor. Even when clinicians were aware of the need to explore core symptoms, such
as fluctuation, they were sometimes unsure how to do so. In movement disorder services, observation
confirmed the variable assessment of cognitive function. In addition, interviews suggested that, even
when cognitive tests were completed, declining scores were sometimes simply documented without
formally making a diagnosis of PDD.
The main facilitator to developing skills and confidence in diagnosing DLB was working alongside
experienced clinicians and exposure to DLB patients:
I think experience is the biggest thing and working with somebody who is experienced who can point
things out. [. . .] I think it’s quite nuanced. I think it is pattern recognition. The more you see, the more
comfortable you are with ‘this is . . .’ or ‘this isn’t . . .’ You just have a bit of a hunch with things.
2307, trainee, older people’s medicine
Staff attitudes and values
There was little evidence that staff attitudes or values influenced management beyond personal
preferences for managing certain symptoms themselves or referring patients to other specialties.
Staff attitudes, however, had an impact on the diagnosis of LBD, particularly in movement disorder
services.Where clinical experience of the number of patients with DLB contradicted published prevalence
rates, some clinicians acknowledged that they might be missing cases or wondered whether or not DLB
patients were being referred to other services. Others questioned the prevalence figures, for example
referring to DLB as ‘the Newcastle disease’.
Although clinicians in movement disorder services did not dispute the prevalence of PDD, some expressed
reservations over the value of making a formal diagnosis. Clinicians’ own views and attitudes clearly
influenced if and how they explored cognition in PD patients, and how they labelled and explained any
problems to patients. A range of benefits and disadvantages of formal diagnosis of PDD were identified.
Potential benefits were increased patient and carer understanding of symptoms, opportunities for
planning for the future and ensuring that potentially dangerous treatments were avoided. Formal diagnosis
was sometimes avoided because of the difficulties of disclosing dementia in the context of an ongoing
relationship, concerns over the potential negative impacts for patients and the stigma associated with
dementia. Clinicians in movement disorder services also expressed varied views concerning the
responsibility for diagnosis and management of LBD. Although some staff were confident to make the
diagnosis themselves, others thought confirmation of a diagnosis of dementia in PD by a specialist
memory service was essential. Views over responsibility for management similarly varied.
Although some clinicians questioned the value of diagnosing dementia subtypes, others argued that a
clear diagnosis was important in terms of understanding and access to support:
I think it [diagnosis] matters to carers if they are going to get a diagnosis because they can put the
symptoms into a context. They can obviously get frustrated and stressed seeing all these different
symptoms and not understanding, and if you can say ‘that’s because of their diagnosis of Lewy bodies,
that’s completely normal and you can expect this kind of prognosis’ then that is helpful for them to know
what to expect in the future. So we can support the carers better if they’ve got a proper diagnosis.
0904, community nurse, memory service
Stakeholder perspectives on the acceptability of the toolkits (work package 5.2)
Clinician views
Clinicians generally held positive views towards the concept of the toolkits. Potential benefits of the
assessment toolkits included increased awareness of core and suggestive features of LBD and a more
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consistent and systematic approach to assessment. The management toolkit successfully translated
academic papers to a format and style suitable for practice:
I think the good thing about it is it’s all in one place, and it’s really clear. The instructions and the advice
are really clear, which certainly, when I was training, Parkinson’s and Lewy body dementia always seemed
quite complicated illnesses to look after. You felt like you might not know quite what the current guidance
was. Whereas, at least with that, it’s a one-stop shop, which tells you everything that you need to know.
0701, consultant OAP
Feedback on the assessment and management toolkits covered a range of areas (for illustrative quotations
see Appendix 9, Tables 27 and 28). The majority of the feedback on the management toolkit related to the
version used in the pilot trial, as the format changed substantially after the feasibility study. Issues relating
to the assessment toolkits (already covered in Work package 3: development of assessment toolkits for the
diagnosis of Lewy body dementia) are not reiterated here, with the exception of question wording where
additional comments were made during the pilot trial.
Views on layout and presentation
The assessment toolkit for movement disorder services began with questions about relevant symptoms
and ended with diagnostic criteria. In contrast, the toolkit for memory services began with the
diagnostic criteria, followed by specific questions. Although few comments were made about the order
of the PDD toolkit, some participants thought that the order of the DLB toolkit was counterintuitive.
Furthermore, non-medical staff who did not make the diagnosis could find the first page off-putting.
Although few participants explicitly commented on signposting in the assessment toolkits, several did
not realise that the diagnostic criteria in the DLB toolkit were followed by specific questions to explore
core and suggestive features, or that instructions on how to perform and score the five-item UPDRS
were provided. The structure of the PDD assessment toolkit was widely misunderstood, with many
participants thinking that they were required to perform a formal cognitive test with all patients,
whereas this was relevant only if responses to the initial questions indicated potential problems.
The management toolkit was organised in three levels (Figure 4). A one-page overview provided a brief,
accessible summary of the symptom areas covered and the general principles for managing LBD.
The colour coding of the overview then carried through to the next level, which comprised one-page
summaries of recommendations for each of the five symptom areas. The final level comprised the full
reference guidelines.
Clinicians valued the colour coding, which facilitated navigation to different levels of detail. The majority
of clinicians found the symptom summaries most useful, although some relied primarily on the overview.
Format
Participants suggested a number of alternative formats to facilitate use of the toolkits, most commonly
integration with existing information technology systems or paperwork. Using the local intranet to
display the toolkits automatically for patients with relevant diagnostic codes was also suggested.
Applications were identified as an alternative way to ensure that the toolkits were easily accessible.
For the assessment toolkit, participants suggested portable summary ‘prompts’ for each section
(similar to the symptom summaries).
Several clinicians requested an A5 version of the overview and/or symptom summaries from the
management toolkit to make it more portable. Others recommended displaying a poster of the overview
to maintain awareness of the management toolkit. Another suggestion was to embed the management
toolkit within an e-learning module for trainee doctors.
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Some clinicians in movement disorder services suggested that the initial questions on memory and
executive function from the assessment toolkit could form a separate document to be completed by
patients and carers before their consultation. Other clinicians, however, thought that this would be
too burdensome for patients and carers.
The common perception that the toolkits were more relevant to doctors led to suggestions that separate
versions be produced for non-medical staff. This would enable non-medical staff to focus on those aspects
of the toolkits most relevant to their work and skills (e.g. questions on core and suggestive criteria in
the DLB toolkit and non-pharmacological interventions in the management toolkit). Although some
consultants saw the assessment toolkits as more valuable to nurses or trainees than themselves, others
thought that it was a useful reminder even for experienced staff. Some participants thought that the
management toolkit would be useful in other settings, notably primary care or inpatient wards.
Content
Feedback on the content of the toolkits related to five themes, some of which were more relevant to
specific toolkits.
Perceived relevance of content The inclusion of the diagnostic criteria was typically seen as a useful
reminder and prompt by medical staff. A number of clinicians, however, asked why key features they
associated with LBD (e.g. falls) were not included in the assessment toolkits. Some clinicians in
movement disorder services queried the absence of questions on hallucinations and fluctuations, as they
saw these as essential for differentiating between LBD and other dementias in PD. Although the toolkit
for movement disorder services was modified after the feasibility study, questions on hallucinations,
REM sleep behaviour disorder and fluctuations were not integrated into the toolkit for patients with
established PD.
Some clinicians queried the omission of key areas, such as carer support, psychosocial interventions
and information for patients and carers, from the management toolkit. These comments suggest that
the rationale for focusing on selected areas should be included in the toolkits.
Terminology and question wording Comments on terminology and question wording related mainly to
the assessment toolkits, particularly the DLB version. Unfamiliar terminology (such as ‘kinetic tremor’,
‘spontaneous parkinsonism’ and specific types of scans) was alienating, particularly for non-medical staff.
Although some clinicians emphasised the need for standardised questions, some questions were
thought to be inappropriate for patients and carers, or to lack sensitivity. Less experienced clinicians
valued the questions on REM sleep behaviour disorder, as they were sometimes unsure how to explore
this symptom. Few comments were made about wording in the management toolkit, although greater
clarity about incontinence (i.e. whether faecal or urinary) was suggested.
Details of drug dosages Several clinicians valued being able to use the symptom summaries to check
drug dosages. For drug treatments used infrequently, some clinicians suggested providing more
detailed protocols:
Clozapine is such a complicated drug. People like psychiatrists are afraid to touch it. You put it in one line
saying clozapine. There is some evidence for clozapine and I think clozapine should be written out in like
almost a protocol how to use it [. . .] Nobody really knows how often you are supposed to do the blood
test. When do you start and what is the best maximum dose. So, unless you de-mystify it and put it in
there [. . .] I think people will be worried to [use it].
1901, consultant geriatrician
The recommendations regarding melatonin were inconsistent with the clinical experience of some
participants, and several reported that GPs were reluctant to prescribe melatonin. To address this
issue, one clinician suggested including an information leaflet to support prescribing in primary care.
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Feasibility of the five-item UPDRS in memory services Although few comments were made about
the five-item UPDRS during the feasibility study, this was the most contentious aspect of the DLB
assessment toolkit in the pilot trial. Three main issues with the five-item UPDRS were highlighted:
(1) the rationale for focusing on these five items, (2) uncertainty over the value of scoring each item
and (3) the challenges of introducing the scale in services where non-medical staff were responsible
for assessments.
The toolkits used in the feasibility study and pilot trial gave no explanation for using the five-item
UPDRS. Understanding that the items in the scale had been demonstrated to be useful in distinguishing
between DLB and AD26 could have increased staff buy-in to the scale. Although the current version of
the toolkits (v3) includes a brief statement, it is unclear whether or not this is enough to counterbalance
the negative attitudes to this scale.
Clinicians frequently questioned the need to score each item on the UPDRS on a five-point scale,
preferring to record simply the presence or absence of symptoms. Common arguments against scoring
related to the difficulties in scoring accurately without extensive training, the additional time needed
and the perception that scoring was more relevant to research than to clinical practice.
Although non-medical staff in memory services were often confident in informally assessing for
parkinsonism, most saw physical examination as outside their area of expertise and role:
Because you haven’t got a full caseload of clients with Lewy body dementia you’re doing it occasionally.
So, for me, I need to be doing something all the time for it to click. I’m fine with asking the questions,
speaking to the carers and speaking to the patients, but when it comes to the actual of doing some of the
assessment here I lack confidence.
0904, community nurse, memory service
Consultants had varied views on whether or not it was feasible and/or appropriate to train non-
medical staff to perform the five-item UPDRS. Some were keen to train their colleagues, whereas
others felt that physical examination was a medical responsibility.
Feasibility of formal cognitive assessment in movement disorder services Some clinicians thought that
their ongoing contact with patients facilitated identification of emerging cognitive problems, but others
argued that symptoms could easily be missed without a formal assessment. Several clinicians in movement
disorder services described (or were observed) using selected items from formal cognitive tests to explore
cognitive impairment. Most clinicians in movement disorder services showed little interest in changing
their existing approach often because of time constraints:
I just think as a concept it is really frightening to try and commit to doing it [the assessment toolkit] in
a standard clinic. I think if you are going to do it, you would have to set up a stand-alone clinic [. . .] but
that’s the problem isn’t it? The sort of balancing the desirable against the practical.
2402, consultant geriatrician
Patient and carer views of the assessment toolkits
A number of patients and carers invited to take part in an interview declined because they felt unable
to comment on the assessment toolkit because they had been unable to distinguish it from the rest of
the consultation.
Interviews with six patients and four carers confirmed that the assessment toolkit was ‘invisible’ to
them. None of the questions from the assessment toolkit stood out as being inappropriate, unclear
or in any way different from the rest of the consultation. In view of the consistency of these findings,
data collection ceased before achieving the target sample size. Cognitive interviews with patients and
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carers highlighted some issues with question wording, typically with the same questions identified as
problematic by clinicians.
Implementation of the toolkits (work package 5.3)
The implementation of the toolkits is summarised in Table 7, using the framework of NPT (for illustrative
quotations see Appendix 10, Tables 29 and 30). Comments relating to all of the main NPT constructs
were made about both the assessment and management toolkits and by staff working in memory and
movement disorder services. Lack of investment in the assessment toolkits in many movement disorder
services meant that few of these clinicians had experience relating to collective action or reflexive
monitoring. They were able to comment, however, on both of these areas when discussing the
management toolkit.
Making sense of the toolkits (coherence)
The concept of the toolkits was relatively straightforward to grasp and clinicians valued the translation of
technical knowledge into practical tools. Key potential benefits of the assessment toolkits were improving
the consistency of assessment (both within and between clinicians) and increasing diagnostic accuracy.
Although many clinicians reported that their current practice was similar to the assessment and
management toolkits, this did not necessarily detract from their value. Most consultant and trainee
doctors were confident in the recommendations in the management toolkit because of the expertise
of the study team. Non-medics, however, were not necessarily familiar with the authors and some
TABLE 7 Implementation of the assessment and management toolkits
Making sense of the toolkits (coherence) All toolkits Translation of technical information into more
practical formats
Similarity to existing practice
Assessment toolkit Improve consistency
Management toolkit Confidence in robustness of toolkit
Investing in the toolkits (cognitive
participation)
All toolkits Perceived as more appropriate for ‘others’:
l Medical staff
l Less experienced/trained staff
l Other services
Lack of investment as a team
Adopting the toolkits (collective action) All toolkits Lack of integration with existing paperwork or
information technology system
Assessment toolkits Selective use when LBD suspected (memory
services)
Lack of resource for implementation
Management toolkit Insufficient alone to change practice
Assessing impacts of the toolkits
(reflexive monitoring)
All toolkits Increased awareness of LBD
Assessment toolkits Increased confidence in diagnosing LBD
Increased exploration and documentation of core
and suggestive features (memory services)
Management toolkit More holistic practice (memory services)
Increased confidence
Use to offer suggestions to GP for drug treatment
or referrals
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would have valued more detail on the background and references to source papers. The need to update
the toolkits was emphasised by several participants, in part prompted by changes to the diagnostic
criteria for DLB11 and to the NICE guidelines for management of PD50 during the pilot trial.
Investing in the toolkits (cognitive participation)
The generally positive views towards the toolkits did not, however, necessarily translate into a commitment
to implementation. Consistent with earlier findings on the acceptability of the toolkits, they were often
seen as more relevant to ‘other’ clinicians, typically junior doctors and non-medical staff. In addition, some
clinicians queried whether or not the toolkits were relevant to their specialty, service or geographical
location. Some movement disorder clinicians viewed diagnosis and management of LBD (particularly DLB) as
more appropriate for memory services. Participants in some memory services argued that the management
toolkit was of limited relevance, as their focus was primarily on diagnosis.
In three memory services, the lead clinician successfully made concerted and ongoing efforts to engage
staff with the toolkits. In movement disorder services, such efforts were less evident, with only two
services making efforts to engage some of the staff team. The majority of services, therefore, were
characterised by a striking lack of collaborative work regarding the implementation of both toolkits.
In these services, it was largely up to individual members of staff to decide if and how to use the toolkits:
For me, it was because we weren’t all invested as a team together. If you are trying to work with a team it
is really important to know, ‘This is what we are all going to sign up to. This is what we are all going to do.
This is how we are going to work together. This is how it will or won’t work’. You just feel as a team we never
had those conversations about, ‘How can this be used in practice? How are we going to implement it?’
2602, specialist PD nurse
For some non-medical staff, the lack of perceived relevance of the toolkits limited their willingness to
engage with the pilot trial.
Putting the toolkits into practice (collective action)
Implementation of both toolkits varied within and between services. Although the lack of integration with
existing electronic or paper documentation was identified as a significant barrier to implementation, several
clinicians reported incorporating some questions from the assessment toolkits into their routine practice:
What I’ve done is, actually, I’ve taken some of those criteria that are easy and then I have prepared my
own clinic pro forma. So that when I see someone I have a piece of paper and the kind of things I need to
ask. And part of my standard assessment question is to cover those criteria. That’s how I use them.
0102, trainee OAP
Although views varied on the additional time required to use the assessment toolkits, most participants
in memory services used the toolkits only when LBD was suspected, and often did so after a consultation
or during supervision, rather than embedding the questions into routine practice. The training on the
five-item UPDRS provided by the clinical research associates to staff in some services in the pilot trial
was well received, but insufficient to change practice on its own. The questionnaire explored the extent
to which respondents explored core and suggestive features of DLB in consultations with new patients.
Although over three-quarters of respondents from memory services reported that they always conducted
a cognitive test and explored fluctuation and hallucinations, fewer than half explored REM sleep behaviour
disorder, parkinsonism or used diagnostic criteria (see Appendix 7, Figure 10). Use of the assessment toolkits
was limited in movement disorder services, with most services continuing with their usual approach
to exploring cognition, although several individuals reported incorporating the initial questions on
executive function into their consultations.
The management toolkit was similarly typically used after consultations, partly because of the logistics
of accessing the documents but also because of concerns over patient reactions. Some clinicians
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appeared reluctant to change their practice purely on the basis of the management toolkit, preferring
to continue with tried and tested prescriptions (even if the evidence for these was less robust):
We had that discussion this morning about clozapine being the most helpful but we don’t tend to use
that, we tend to go for quetiapine.
Unidentified female participant, memory service 07
The questionnaires also explored views on the likelihood of embedding the toolkits into routine practice.
Similar views were expressed about integration and sustainability of the assessment and management
toolkits, although respondents had slightly more positive views about the management toolkit becoming
part of their normal practice (see Appendix 7, Figure 11). Data also indicated that more positive views
towards integration of the assessment toolkit were associated with having access to the management
toolkit (see Appendix 7, Figure 12) and working in memory services (see Appendix 7, Figure 13).
Assessing impacts of the toolkits (reflexive monitoring)
For many clinicians, a key outcome of both toolkits was increased awareness of LBD. Where lead
consultants in memory services had encouraged implementation of the DLB assessment toolkit, they
reported improved documentation of core and suggestive features by non-medical staff. Other changes
resulting from use of the assessment toolkit identified by staff in memory services included more
consistent documentation of negative findings and a more holistic approach to assessment. Even when
non-medical staff did not perform the five-item UPDRS, the assessment toolkit was thought to have
increased awareness of the range of possible signs of parkinsonism.
We tried to identify possible mechanisms through which the management toolkit could lead to improved
outcomes. Qualitative data from clinicians suggested that only a small number had adopted new treatments
and there was little evidence of increased management of new symptom areas.We included questions on
confidence in managing common LBD symptoms in all three WP5 questionnaires administered during the
programme (see Appendix 7). Comparison over time indicated that confidence in managing three symptom
areas (autonomic symptoms, parkinsonism and REM sleep behaviour disorder) increased significantly in
control practices during the programme (Figure 5). Clinicians who received the management toolkit
showed small, but (statistically) significant, changes in confidence in managing all but two symptom
areas (Figure 6). This suggests that a possible mechanism of change may be the accumulation of marginal
gains in confidence over a wide range of areas. However, the results should be interpreted with caution,
























FIGURE 5 Mean confidence ratings for symptom management for respondents in control services. *p < 0.05, **p < 0.01,
***p < 0.001. T0, initial data; T1, follow-up data 1; T2, follow-up 2.
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An alternative mechanism may be that change is achieved via indirect routes. For example, some clinicians
reported that they were now more willing to suggest possible changes of medication or referral to other
specialties to the patient’s GP. This more holistic approach to management is potentially a mechanism
through which change could be achieved:
It gives guidelines for things that I wouldn’t consider treating in a memory service [. . .] So, I’m not really
starting medications for constipation and even things like hypotension, but they might trigger me to ask
the falls clinic or somebody else to see people.
1601, consultant OAP
Views on implementation
The insights from the qualitative work in WP5.1 and WP5.2 were used to develop an implementation
strategy for the pilot trial (see Appendix 11, Tables 31–34). The extent to which this was implemented
during the pilot trial was limited because of the restricted time and resources available, concerns over
the risk of challenging and potentially alienating professionals, availability of credible professionals to
address some issues (particularly for movement disorder services) and lack of skills within the research
team to develop local implementation strategies.
During interviews and focus groups, we explored participant views on implementation in the pilot trial
and alternative ways to support toolkit use. The interviews and focus groups were often the first
opportunity for clinicians to reflect on if and how they were using the toolkits. Participants thought
that implementation had been influenced by local leadership and tailored education sessions. In a small
number of sites, a lead professional adopted the role of a local champion, typically acting as a focal
point for the intervention, engaging the wider team and maintaining momentum (e.g. by adding the
toolkits to the agenda of regular meetings). Some participants suggested that the lack of a lead
clinician had been a factor contributing to poor implementation:
What I would say in retrospect, is I’m not sure that we’ve maximised the value of this within the service.
But to do that, we would have actually needed a more sustained input, I think, from the team. And
somebody, one or two of us, actually, really taking a role in terms of getting hold of this and running with
it. You, actually, need somebody in the team who is going to take a real lead to try and sort of keep it on
people’s minds. Find out what people’s experience was, address any issues, advocate for its value, which,

























FIGURE 6 Mean confidence ratings for symptom management for respondents in intervention services. *p < 0.05,
**p < 0.01, ***p < 0.001. T0, initial data; T1, follow-up data 1; T2, follow-up 2.
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The above quotation also mentions the need for sustained input from the research team. Tailored
educational sessions were delivered by the study team to some sites (usually at their request).
Feedback on the sessions indicated that they were valued by practitioners and often provided new
insights into the assessment or management of LBD:
We had your colleague who came along and did the training on a Wednesday morning – which was
excellent, I learned loads from that [. . .] [He] was much better at assessing for increased tone and did a
far greater range of movement than I would have been routinely doing.
1101, consultant OAP
Although the site initiation visit provided an overview of the study and toolkits, several participants
would have preferred a more interactive approach in which they could have reviewed the toolkits in
detail with a knowledgeable clinician from the study team. This would have allowed queries to be
raised and discussed and could explicitly have addressed the misperception among many movement
disorder clinicians that the assessment toolkit required them to perform a cognitive assessment on all
patients. A final strategy suggested by several participants was to use team meetings or peer learning
groups to identify divergences between their current practice and the assessment or management
toolkits as a way of highlighting scope for change.
Discussion
The detailed qualitative work provided new insights into the complex and inter-related factors influencing
the diagnosis and management of LBD. The inherent complexities of the disease itself required input from
different specialties, leading to potential fragmentation of services. Other important factors identified
were a workforce with variable levels of training and confidence in LBD, and persisting negative attitudes
among some clinicians towards diagnosis and disclosure of dementia in patients with pre-existing PD.
Observation confirmed the lack of routine assessment of core and suggestive features of LBD in
memory services. In movement disorder services, resources were a key factor in determining whether
or not cognitive function was formally assessed. The assessment toolkits potentially address these
issues by including standardised questions for memory services and brief screening questions for
movement disorder services to determine whether or not formal cognitive assessment is required.
The management toolkit could potentially facilitate management of the complex and multiple symptoms
in LBD. Other barriers to diagnosis and management were not amenable to change through the toolkits
and some acted as barriers to their implementation.
Most clinicians welcomed the concept of the toolkits to facilitate the diagnosis and management of
LBD. Key potential benefits were increased awareness of LBD, more consistent and comprehensive
assessment and evidence-based management. The assessment toolkits were thought to be particularly
beneficial to junior doctors and non-medical staff.
Qualitative data highlighted aspects of the assessment toolkits requiring further revision. It is now
clear that training non-medical staff to administer the five-item UPDRS26 is neither feasible nor acceptable.
However, with nurse-led models of memory assessment services becoming more common, alternative
ways to conduct a simple neurological screen for non-medical staff are needed. Other issues related
to question wording, signposting and the rationale underpinning the diagnostic criteria and choice
of symptoms.
The positive feedback on the presentation of the management toolkit suggests that applying the same
design principles to the assessment toolkits may make them more appealing and easier to use in
practice. Ideally, the toolkits would be available in a variety of formats to suit personal preferences.
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Implementation of the assessment toolkits in the pilot trial varied within and between sites. In many
movement disorder services, key barriers related to cognitive participation or willingness to invest
in the assessment toolkits. This resulted in limited use of the assessment toolkits (which is likely to
explain the unchanged diagnostic rates of PDD observed in WP1R, see Work package 1 repeated:
re-assessment of diagnostic rates for Lewy body dementia after introduction of the assessment toolkits for
diagnosis). In three memory services in the North East, the lead clinician successfully encouraged
widespread adoption throughout the team. Although this was attempted in two further memory
services (both in East Anglia), uptake in these teams remained patchy. In other memory services,
there was little collective work to support implementation and it seemed largely up to individual
members of staff to decide if and how to implement the toolkits.
Uptake of the management toolkit varied, with some participants reporting that their practice was
already consistent with the toolkit. Barriers to implementation were that few LBD patients were seen
and that (memory) services focused on diagnosis with little involvement in management. Identifying
possible mechanisms through which the management toolkit could lead to improved outcomes was
challenging. Few participants reported changing their prescribing habits or managing additional
symptom areas. However, the use of the toolkit appeared to raise awareness of the range of symptom
areas affected in LBD and to increase confidence in managing common symptoms, and this may have
facilitated a more holistic approach to care. In any future implementation study, we recommend the
collection of data on prescriptions and referrals, and content analysis of letters to GPs, as it is possible
that some benefits accrue from changes made by GPs, rather than directly by the specialist clinicians
using the management toolkit.
Limitations
The increase in the number of services in WP4 (from 8 to 22), and the inclusion of East Anglia as a
second geographical region, meant that resources for the qualitative component were stretched.
One consequence was that a follow-up interview was conducted with only a single clinician in WP4 and,
therefore, we have limited data on how the implementation and views of the toolkits changed over time.
It proved impossible to engage four services in the qualitative work in WP4. The response rates to the
questionnaires were acceptable, although disappointing. The views of less engaged clinicians are likely
to be under-represented in our data set and consequently we may not have identified all barriers to
implementing the toolkits.
Although only a small number of patients and carers provided feedback on the toolkits, the consistency
of their comments means that we do not consider this a significant limitation. We achieved data saturation
with a small number of interviews and there was no indication in the pilot trial that further data collection
from patients and carers was merited.
We developed an implementation strategy for the pilot trial based on the initial qualitative data;
however, because of limited resources, many suggestions were not adopted. Participants in the pilot
trial identified additional strategies to inform future implementation.
Some services reported limited opportunities to use the management toolkit, as they focused on
diagnosis and discharged patients shortly afterwards. This suggests that additional criteria may be
required to identify potential services for a future trial.
There were occasionally some tensions between research paradigms, in particular in relation to managing
qualitative feedback on question wording in the assessment toolkits, with the value given to ‘validated’
questions derived from clinical research.
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Work package 1 repeated: re-assessment
of diagnostic rates for Lewy body
dementia after introduction of the
assessment toolkits for diagnosis
One of the aims of the programme was to seek to improve the diagnosis of DLB and PDD byfacilitating diagnosis so that more cases receive a correct diagnosis. To this end, approximately
2.5 years after WP1 was undertaken, and following the development and piloting of the assessment
toolkits in WP3 (see Work package 3: development of assessment toolkits for the diagnosis of Lewy body
dementia), they were introduced to 23 services as part of the pilot cluster randomised trial of the
management toolkit undertaken in WP4.
Some of the same services that took part in WP4, where the assessment toolkits were introduced,
also participated in WP1, which established the baseline diagnostic rates for DLB and PDD (see Work
package 1: baseline study of the diagnosis and management of Lewy body dementia). The aim of WP1R
was therefore to undertake, using exactly the same methodology as baseline, a revised study over an
18-month period, following the introduction of the assessment toolkits to examine diagnostic rates
for DLB and PDD. Our hypothesis was that the introduction of the assessment and diagnostic toolkits
would result in significantly increased diagnostic rates for DLB and PDD. This study was approved by
the North East – Newcastle & North Tyneside 1 Research Ethics Committee (reference 17/NE/0362)
and the Confidentiality and Advisory Group (reference 17/CAG/0188).
Methods
We used exactly the same methods as in WP1 (see Work package 1: baseline study of the diagnosis
and management of Lewy body dementia) to ensure comparability of findings. For DLB, case notes of
patients in four of the same memory services in three different NHS trusts from the two regions were
examined. For PDD, case notes were reviewed from three movement disorder services in three NHS
trusts in the two regions.
Results
Of 2058 referrals to the memory services over an 18-month period, 1279 received a diagnosis of
dementia, of whom 6.2% received a diagnosis of DLB.
This rate, found after introduction of the assessment toolkits, was significantly higher than the 4.6%
found at baseline before the introduction of the toolkits (χ2 = 5.3; p = 0.021). On further examination,
diagnostic practice in East Anglia was unchanged, whereas rates had significantly increased in the
North East (9.7% vs. 5.6% at baseline, χ2 = 14; p = 0.000019).
A total of 3405 referrals to movement disorder services were identified, of whom 1968 received a diagnosis
of PD. Of these, 8.2% received a diagnosis of PDD.This diagnostic rate, after introduction of the assessment
and diagnostic toolkits, was not significantly different from the 9.7% found at baseline (χ2 = 2.8; p= 0.09).
For PDD, there was a difference between regions, with the North East showing a significant decrease in PDD
rates (7.8% vs. 10.5%; p= 0.006); however, East Anglia showed a significant increase (13.3% vs. 8.3% at
baseline; p = 0.046).
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Discussion
The introduction of assessment and diagnostic toolkits for DLB and PDD was associated with a significant
increase in diagnostic rates for DLB, but not PDD. However, there were significant differences between
services and regions, with some services increasing their diagnostic rates and others not. Differences
between regions were also noted for WP1 in terms of baseline rates for DLB diagnosis, although it is not
entirely clear what factors drive these differences. There was diversity both within and between North
East and East Anglia in terms of service organisation. Both sites included memory services where initial
assessments of ‘straightforward’ patients were conducted by non-medical staff. Access to scans in the
North East appeared to be better. In East Anglia, issues with scans reflected both the significant travelling
required by some patients in rural areas and the informal limits described by some participants on the
‘appropriate’ number of scans. The North East has a long track record of research in DLB and many
clinicians working in the North East have been exposed to DLB, either during training and/or through
their involvement in research studies. This was reflected in a number of comments made by participants
in the qualitative work on the North East being particularly sensitised to DLB. There were, however,
clinicians in East Anglia with a long-standing interest in DLB who had similarly been involved in training
medical staff over a period of years. Interest in DLB was therefore by no means limited to the North East.
The strengths of this study include the inclusion of the same services for which we ascertained
baseline diagnostic rates in WP1, and use of exactly the same methodology for determining cases and
diagnosis. Limitations include that, as this was not a controlled study, we cannot definitely conclude
that the introduction of the assessment toolkits was causally related to the change in diagnostic rates.
Other factors may have been involved, including generally heighted awareness of DLB over time
and/or service or other changes. Finally, unlike WP1, in WP1R we did not undertake a repeat of the
more detailed case note study and so we could not determine whether or not the factors associated
with the diagnosis of DLB and PDD found at baseline had been moderated in any way. We did not collect
data on the additional time taken to administer the toolkits and so cost-effectiveness of the toolkits for
increasing diagnostic rates cannot be determined.
The qualitative studies (WP5) provide some insights as to why diagnostic rates for PDD (and DLB in
East Anglia) were unchanged, but further research is required to better understand whether the
unchanged diagnostic rates were linked to variation in implementation or whether additional factors
were involved. Further exploration of ways to tackle the barriers to diagnosis identified in WP5 and
to improve implementation of the assessment toolkit, especially in sites with low diagnostic rates at
baseline, is required.
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Overall programme discussion
The DIAMOND-Lewy programme achieved all its core aims. We demonstrated in WP1 thatdiagnostic rates for DLB and PDD were below, less than half, of those expected. For DLB, we found
significant variation between regions and services. There appeared to be several contributing factors
to this, including variations in availability of diagnostic tests, differences in service organisation and
a great awareness of some clinical staff to DLB and PDD as a diagnostic possibility. We could not
examine all these factors in detail within this programme. WP1 was retrospective in nature and used
case records. Although this was a strength in terms of examining an unselected group of referrals to
secondary care, there was some selection bias, as we could include people in the more detailed case
note study only if they were alive.
In WP2, we developed evidence-based management toolkits. One major limitation was that the evidence
base was thin, with most pharmacological studies focusing on a few agents, largely cholinesterase
inhibitors and memantine, and there were very few non-pharmacological studies. To address these gaps,
we used a Delphi approach with an expert clinical panel to develop a final management toolkit. Assessment
toolkits were assembled within WP3 and, together with the management toolkit, trialled in a busy NHS
trust that provided both memory assessment and movement disorder services. The toolkits were well
received, but the extra time needed to undertake cognitive assessments in movement disorder services
(where they are not standard) was a limitation. The toolkits had been designed to be as brief as possible,
while also being consistent with the evidence base informing their development. This will always be a
tension, and a limitation of WP3, as well as the pilot cluster randomised trial, is that we did not formally
gather information on the time taken to administer the toolkits. In WP4, we successfully undertook a pilot
cluster randomised trial of their implementation, demonstrating that such a study was possible, and we
achieved the recruitment target of 120 participants (n= 131 recruited) within 23 services. Our qualitative
studies (WP5) showed that implementation was variable, and one key lesson learned was that a clear
implementation plan is needed for future studies or introduction of the toolkits.
Power calculations showed that a main trial would need to be of around 900 people, allowing for attrition
and using an outcome measure such as the Neuropsychiatric Inventory. This would require a substantial
investment and would be a complex trial to undertake. There are alternative models to implementing the
assessment and management toolkits, including through service quality improvement initiatives and
working with services using principles from implementation science to tailor implementation to the local
context. In WP1R we used the same methodology as in WP1 to reassess diagnostic rates for DLB and
PDD after introduction of the assessment toolkits in services where we had baseline data from WP1.
We found a significant increase in diagnostic rates for DLB but not PDD; however, rates did not increase
in every service. One limitation is that we were not able to examine, in detail, factors associated with a
change in diagnostic rates. It appeared, contrary to expectation, that services that already had higher
baseline rates of DLB diagnosis showed the greatest increase in diagnostic rates. This may be because the
toolkits were introduced on the background of a high level of knowledge and interest in DLB diagnosis.
It also suggests that in areas of low diagnostic activity for DLB, the introduction of the assessment toolkits
themselves will not be sufficient to increase rates. Diagnostic rates for PDD did not change following
introduction of the assessment toolkits. Qualitative work indicated that this may be because of a
combination of insufficient time to always use these, as well as continued negative attitudes to making the
diagnosis of dementia in PDD. Further work needs to examine how to improve diagnostic rates for PDD.
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The DIAMOND-Lewy programme has provided considerable new knowledge about diagnosticand management practice of DLB and PDD in the NHS, has produced evidence-based assessment
and management toolkits, and has shown, through a pilot cluster randomised trial, the feasibility of
undertaking a study following their introduction into NHS services. In addition, introduction of the
assessment toolkits was associated with an increase in diagnostic rates for DLB, although we cannot
definitely conclude a causal link.
Implications for practice and any lessons learned
The findings of the programme have a number of important implications for clinical practice:
l In the regions we studied, DLB and PDD appeared to be underdiagnosed compared with expected
rates, with variability in diagnostic rates between services. This suggests that improvements may be
needed in the way in which clinicians assess people for symptoms and make diagnoses.
l We found that the reluctance of some clinicians to make a formal diagnosis of dementia could be a
significant factor contributing to the underdiagnosis of LBD (particularly PDD). This implies that
negative attitudes to disclosure may need to be challenged, possibly through supervision, appraisal
or local audits to examine the diagnostic rate of PDD.
l In eliciting symptoms, observation suggested that leading questions were not uncommon and that
some symptom areas (e.g. sleep) were often explored only superficially during memory assessments.
Existing clinical practices, such as supervision, may provide an opportunity to address both of these
areas. An iterative process of discussing and sharing ways of asking questions may enable staff to
critically evaluate their existing approach and develop more consistent ways of approaching certain
symptoms or issues. The concerns expressed over whether or not non-medical staff had received
adequate training for their role in assessment imply that additional on-the-job training on dementia
subtypes may improve diagnostic accuracy.
l There may be benefits for more training to enhance awareness in secondary care clinical teams
of how to make a diagnosis, and of why, including raising awareness of the opportunities for
evidence-based management.
l Using a structured method, like the assessment toolkit, for diagnosis may help increase diagnostic rates.
l The complexities of managing LBD may require input from a range of specialties, which has the
potential to lead to fragmentation of care pathways. Successful strategies for joint working included
telephone multidisciplinary team meetings for complex patients, informal consultation arrangements
across specialties where clinicians were co-located and adapting a memory service pathway to enable
patients diagnosed with LBD by a geriatrician or neurologist to access support without further
assessment. These initiatives highlight the potential value of developing tailored, local strategies to
address barriers to cross-specialty working.
Recommendations for research
Findings from the programme highlight a number of areas for future research:
l Further study to ascertain whether or not unchanged diagnostic rates, despite access to the toolkits,
reflect poor implementation of the assessment toolkits or additional factors.
l Research into how best to co-ordinate multispecialty input to patients with LBD is needed to
streamline management and facilitate a holistic approach.
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l Further work is needed to better understand how assessment toolkits for PDD can be integrated
into practice to improve diagnostic rates. Qualitative studies indicate that there remain important
barriers and negative attitudes to diagnosis and management, and further work is needed to see
how these are best addressed.
l The evidence base informing the management of LBD is limited, especially for non-pharmacological
interventions. More therapeutic studies are needed, especially well-designed RCTs for both
cognitive and non-cognitive symptoms.
l Future research should investigate the specific domains contained within the management toolkit
and the extent to which global improvements are due to specific symptom improvement, as opposed
to a number of marginal gains in several areas.
l Our successful pilot demonstrates that a larger, more comprehensive trial of introducing
the management toolkit could be undertaken, but it would need to include a minimum of 410
(and up to 908) people, depending on the primary outcome.
CONCLUSIONS AND RECOMMENDATIONS FOR RESEARCH
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Appendix 1 Health economic analysis for
work package 1
Comparison of health-care service utilisation and costs between Lewy body
and non-Lewy body dementia patients: the DIAMOND-Lewy study
Introduction
This appendix describes the methods and results of the economics component of WP1. The aim of
this component was to compare the cost of the pathway to final diagnosis and costs of care for those
with DLB with non-DLB dementia (WP1A), and those with PDD with those with PD without dementia
(WP1B). For both comparisons, the main objective of the study was to explore differences in the cost
of assessments, appointments and diagnostic investigations undertaken, as well as hospital inpatient/
day hospital resources and treatment.
Methods
Study sample and recruitment
Patients for the study were recruited into a DLB cohort and a PDD cohort. All participants were recruited
from four UK NHS trusts in two different geographical regions of England (North East and East Anglia).
DLB patients were recruited from nine psychiatry of old age/memory services from January 2013 to
December 2014. PDD patients were recruited between August 2015 and February 2016 across eight
movement disorder clinics (four neurology services and four geriatric medicine services). For each of
the DLB and the PDD patient groups, control groups were also recruited (non-DLB dementia and PD
without dementia, respectively), identified as the next control patient seen that could be matched. These
controls were matched for sex, age (± 5 years) and MMSE score (in three bands 0–10, 11–20 and 21–30)
to match for dementia severity.51
At the point of recruitment, all participants had had their cognitive function assessed and had been
diagnosed with dementia and/or PD 12 months prior to the start date of the study. This reflects the fact
that the determination of diagnosis can take several months, especially for DLB. Diagnoses were confirmed
by an independent expert panel of three clinicians (a method previously validated as an acceptable
approach to discriminating incorrect diagnoses, compared with autopsy and imaging measures).52
Data
For the DLB cohort, the research team screened the clinical notes of 9449 consecutive people seen
within old age psychiatry/memory assessment services. Of these 9449 people, 4504 (47.7%) had a
dementia diagnosis. Of these, 207 (4.6%) received a clinical diagnosis of DLB during this period
and 105 were approached to participate in the study. Seventy-four people consented and granted
researchers further access to their clinical records. Seventy-two non-DLB dementia control participants
were also recruited into the study.
For the PDD cohort, consecutive clinical notes of 2263 patients in movement disorder neurology and
geriatric medicine services were screened. Of these 2263 patients, 151 (6.7%) received a clinical
diagnosis of PDD. Out of these 151 cases, 53 patients were approached for consent and 38 were
recruited into the study. A total of 1474 people received a diagnosis of PD. Forty-four people were
approached to take part in the study, with 35 providing consent.
Measures
The records of consenting participants in both the DLB and PDD cohorts were reviewed and extracted
into case report forms tailored to each patient cohort. For each participant, data were collected on the
DOI: 10.3310/pgfar09070 Programme Grants for Applied Research 2021 Vol. 9 No. 7
Copyright © 2021 O’Brien et al. This work was produced by O’Brien et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
61
use of services spanning several years of clinical records before and after final diagnosis. Data collected
included the number of appointments before and after diagnosis and the number and type of diagnostic
investigations undertaken before and after diagnosis.
To estimate the cost of service use and to compare differences between the pathway to diagnosis and
the post-diagnosis cost of care for LBD (DLB and PDD) participants compared with control participants,
the data on use of services were combined with unit cost data taken from routine sources, such as NHS
reference costs15 and Personal Social Services Research Unit costs.16 These data were then used to
estimate the total cost of diagnosis and management for each participant. All costs were reported in
Great British pounds (£) for the year 2017. Costs were categorised into components of total cost of
diagnosis and care as ‘medical history costs’, ‘medication costs’, ‘investigation costs’, ‘pathway to diagnosis
costs’ and ‘post-diagnosis costs’. ‘Investigation costs’ excluded neuropsychology and tests of cognition
and function (e.g. MMSE, Addenbrooke's Cognitive Examination Revised and Bristol Activities of Daily
Living Scale) because the costs of these were thought to be negligible. Investigation costs did include
blood tests, brain imaging and other imaging examinations (such as ultrasounds and computerised
tomography, radiographs, electrocardiograms, echocardiograms, etc.). ‘Pathway to diagnosis costs’
covered the cost of home visits by specialists (e.g. OAP, physiotherapist, social worker), clinic appointments
(e.g. specialist PD nurse, physiotherapist, geriatric physician) and appointments with secondary care specialists
(e.g. Community Mental Health Team, clinical psychologist, memory support service). ‘Medical history costs’
included operations, hospitalisations and attendances at accidents and emergency departments after the
date of final diagnosis. ‘Medication change costs’ were based on the only available complete list of
medications recorded for each patient in the case report form and refers to post-diagnosis medication
changes. Finally, ‘post-diagnosis costs’ included home visits by specialists and clinic appointments, but
excluded services associated with dementia management strategies, as these would have already been
captured in other cost categories.
Statistical analyses
Demographic and clinical characteristics of the sample were summarised using proportions and
measures of central tendency. Differences between DLB and non-DLB participants and PDD and PD
without dementia participants were explored using independent-samples t-tests with unequal variance
for normally distributed variables, Wilcoxon rank-sum tests for continuous non-normally distributed
variables and chi-squared tests to explore differences in proportions. Differences between cases and
controls in average costs of the different components of diagnosis and care costs and differences in
the proportion to the total of each cost category were also estimated. A third set of analyses explored
the contribution of patient characteristics to total costs.
The dispersion around the average was estimated using 95% CIs, with bias correction from 1000
bootstrap replications clustered by study site. The difference between patient groups was explored
using Wilcoxon rank-sum tests. Finally, the marginal effects from a generalised linear model, using a
gamma distribution with log-link function, adjusting by time of resource use and clustered standard
errors by study site, were used to explore the effect of participant demographic and clinical
characteristics on the total cost of diagnosis and care.
Results
Cohort characteristics
For the DLB comparison, the proportion of men in the sample was comparable between the DLB and
non-DLB dementia groups at around 60% of participants (Table 8). The average age of participants
across the two groups was 77 years and almost all participants reported a white British background.
DLB participants had received a larger number of previous diagnoses before achieving a final diagnosis,
and presented with more clinical features of LBD (e.g. fluctuating cognition, recurrent visual
hallucinations, features of parkinsonism) than non-DLB participants.
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TABLE 8 Characteristics of the participant cohort. Percentages across different characteristics unless otherwise stated









Male 59 58 73 74
Female 41 42 0.890 (χ2 = 0.019) 27 26 0.899 (χ2 = 0.016)
Ethnicity
White British 95 98 96 95
Other 5 2 0.370 (χ2 = 0.802) 4 5 0.947 (χ2 = 0.004)
Age (years),a mean (SD) 77.6 (8.4) 77.2 (8.0) 0.757 (t= 0.311) 66.3 (19.7) 68.1 (15.2) 0.661 (t= –0.441)
Number of previous diagnosesb
Mean (SD) 1.1 (1.0) 0.6 (0.8) 0.004 (z = 2.911) 1.4 (1.1) 0.5 (0.6) < 0.001 (z= 3.837)
None 31 51 24 51
One 39 36 24 43
Two to four 30 13 0.012 (χ2 = 8.856)
Two to five 53 6 < 0.001 (χ2 = 19.136)
Living arrangementsc
Home or family 56 68 49 100
Institution 44 32 0.145 (χ2 = 2.121) 51 0 < 0.001 (χ2 = 23.839)
Use of care supportc
No 0 3 75 45
Yes 82 75 6 52



































































































































































































































































































TABLE 8 Characteristics of the participant cohort. Percentages across different characteristics unless otherwise stated (continued )








Time of resource use
(years), mean (SD)
6.4 (4.7) 5.1 (4.6) 0.052 (t= 1.637) 9.2 (3.5) 7.8 (4.4) 0.129 (t= 1.537)
Time since diagnosis
(years), mean (SD)
1.8 (1.4) 1.7 (1.9) 0.290 (t= 0.554) 3.2 (4.3) 5.9 (3.9) 0.007 (t= –2.797)
Number of clinical features of DLB or PDDd
Mean (SD) 3.5 (2.1) 0.9 (1.3) < 0.001 (z = 7.848) 7.2 (3.4) 1.8 (2.0) < 0.001 (z= 5.732)
None 4e 46e 8f 20f
One or two 36 44
Three or more 59 10 < 0.001 (χ2 = 52.249) < 0.001 (χ2 = 41.043)
One to five 16 77
Six or more 16 77 < 0.001 (χ2 = 41.043)
a Age at referral.
b Number of previous diagnoses before final diagnosis. Previous diagnoses refers to other diagnoses the patient received before the final diagnosis of DLB or PDD dementia.
Previous diagnoses before final diagnoses included Lewy bodies dementia, PDD, vascular dementia, Alzheimer’s disease, frontotemporal dementia, mixed vascular dementia and
Alzheimer’s disease, MCI and ‘other’.
c Captured at the end of the study recruitment period. Carer involvement refers to both formal and informal carers. One visit per week was the minimum required for a ‘yes’
condition of carer involvement.
d Clinical features recorded before the date of final diagnosis. Institutions where patients resided included nursing homes, elderly mentally infirm care homes, NHS long stay and
sheltered accommodation.
e Three DLB cases with no recorded clinical features before final diagnosis and 33 non-DLB cases with no recorded clinical features before final diagnosis. Clinical features for DLB
includes fluctuating cognition, recurrent visual hallucinations, features of parkinsonism, REM sleep behaviour, severe neuroleptic sensitivity, repeated falls and syncope, transient
unexplained loss of consciousness, constipation, incontinence, orthostatic hypotension, depression, hallucinations in other modalities, delusions, abnormal sense of smell and
swallowing difficulties.
f Three PDD participants with no recorded clinical features before final diagnosis and seven non-PDD participants with no recorded clinical features before final diagnosis. Clinical
features for PDD includes parkinsonism, cognitive impairment, dementia impact on activities of daily living, cognitive deficits in two or more domains, anxiety, apathy, depression,
delusions, visual hallucinations, excessive daytime sleepiness, changes in personality, REM sleep behaviour disorder, fluctuation, swallowing difficulties, repeated falls, abnormal
sense of smell, orthostatic hypotension, constipation and bladder instability.
Notes
z-scores from Wilcoxson rank-sum test.
t-score from an independent-samples t-test with unequal variance.































For the PDD cohort (across the 38 PDD and 35 non-PDD participants) the proportion of men in the
sample was comparable between the two groups, with mean age across the two PDD cohort groups
of 67 years. Those with PDD had received a larger number of previous diagnoses before reaching
a final diagnosis than those with non-PDD dementia, and presented with more clinical features (e.g.
cognitive impairment, dementia impact on activities of daily living, cognitive deficits). The proportion of
participants who were receiving support from a formal or informal carer was higher for those in the
non-PDD group than for with those with PDD.
Cost of diagnosis and care
Dementia with Lewy bodies participants had higher costs arising from medication changes, investigations
and the use of primary and secondary care services associated with the pathway to diagnosis (Table 9).
Overall, the average cost of care for DLB participants was £6557, compared with £3425 for non-DLB
participants (mean difference £2868, 95% CI –£68 to £4013; p = 0.055).
Parkinson’s disease dementia participants also had higher average costs of investigations, at around
£250 per patient (95% CI £237 to £306; p = 0.001) and higher post-diagnosis management costs (average
difference of £570 per patient, 95% CI £281 to £808; p = 0.001). However, there was no evidence of a
difference in overall costs between those in the non-PDD group (£2024, 95% CI –£3598 to £5548;
p = 0.462) and those with PDD.
Table 10 shows the contribution to total cost of the different cost subcategories associated with pathway
to diagnosis, medical history post diagnosis and post-diagnosis treatment. For DLB participants, medical
history costs represented the largest contribution, with an average across patients of 40% of total
costs (27% for non-DLB participants) (p = 0.042). The share of investigation costs was lower for DLB
participants (20%) than for non-DLB participants (26%) (p = 0.042), although, on average, investigation
costs were higher for DLB patients (see Table 9), probably reflecting the effect of the higher medical
history costs on the share of total DLB costs.
No evidence of differences was observed between PDD and non-PDD participants, except for the share of
cost of pathway to diagnosis and the post-diagnosis costs. For pathway to diagnosis, these represented 19%
of total costs for PDD participants [a lower share than for those in the non-PDD group (36%; p= 0.004)].
For the post-diagnosis management costs, these were higher in the PDD group (see Table 9), which is also
reflected in the much higher proportion of total cost of post-diagnosis management in PDD participants
than in control participants (15% vs. 1%; p < 0.001).
Factors influencing costs of diagnosis and care
Table 11 shows the estimated difference in total costs of diagnosis and care between participants
with DLB and participants with non-DLB dementia (see Table 11, top rows, panels A and B), and between
participants with PDD and participants with PD but without dementia, after taking into account the
influence on costs of differences in sex, time since diagnosis, total resource use time and other patient
characteristics (see Table 11, bottom rows, panels A and B).
Results show that for DLB participants, having a DLB diagnosis represented higher total costs of
approximately £3683 (95% CI £1478 to £5507; p < 0.001) than for non-DLB participants (see Table 11, top
panel A). When disaggregating the DLB group according to the number of clinical features associated with
DLB (recorded before final diagnosis), participants with two or fewer clinical features before diagnosis
(n = 30) had costs at an average of £5763 higher than those of non-DLB participants (95% CI £2432 to
£9093; p = 0.001), and DLB participants with three or more clinical features had, on average, higher
costs than non-DLB participants (of around £2482, 95% CI £1664 to £2833; p < 0.001) (see Table 11,
top panel B).
Average costs across all patient types in the DLB cohort (i.e. participants with DLB and non-DLB
dementia) were influenced by the number of previous diagnoses and type of delivery of care.
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TABLE 9 Summary statistics for the costs (£) of DLB and non-DLB and of PDD and non-PDD dementia
Cost Mean
DLB (£) PDD (£)
SD Median Maximum Minimum Mean SD Median Maximum Minimum
Medical history costs
Case 4715 6901 1547 29,081 0 5303 8828 537 32,667 0
Control 2398 5327 1408 32,860 0 5054 9010 0 35,114 0
Difference (95% CI) 2202 (–2035 to 3164) 285 (–6876 to 4344)
Difference p-value 0.170 0.957
Medication changes costs
Case 208 348 97 2433 0 2244 3695 473 16,325 23
Control 86 170 52 1245 0 1439 3235 221 13,282 0
Difference (95% CI) 104 (28 to 137) 828 (–1235 to 1777)
Difference p-value 0.002 0.580
Investigation costs
Case 462 333 22 2313 28 473 448 311 2287 43
Control 278 174 0 997 18 212 229 186 994 0
Difference (95% CI) 153 (5 to 216) 257 (237 to 306)
Difference p-value 0.042 < 0.001
Pathway to diagnosis costs
Case 480 633 305 4351 0 889 778 674 2949 0
Control 206 248 126 1515 42 869 494 863 1988 0
Difference (95% CI) 250 (160 to 311) 33 (–323 to 350)
































DLB (£) PDD (£)
SD Median Maximum Minimum Mean SD Median Maximum Minimum
Post-diagnosis costs
Case 693 750 517 3449 0 656 734 594 3555 0
Control 458 598 309 4027 0 39 174 0 995 0
Difference (95% CI) 176 (–2 to 281) 574 (281 to 808)
Difference p-value 0.062 < 0.001
Total of all costs
Case 6557 7303 3745 30,954 274 9567 9738 6556 43,437 744
Control 3425 5514 1186 33,977 60 7614 9769 2886 38,646 330
Difference (95% CI) 2868 (–62 to 4013) 2024 (–3598 to 5548)
Difference p-value 0.055 0.462
Notes
For DLB a case equals a dementia with Lewy bodies (DLB) participant, and a control equals a non-DLB participant. For PDD a case is someone with Parkinson’s Diesease Dementia
(PDD) and control is a participant with Parkinson's disease but without PDD.
p-values of the difference in mean costs between A and B from generalised linear model with gamma distribution and log-link function, with an indicator variable for patient type and
adjusting for differences in total resource use time. p-values reported in bold are statistically significant at the 5% level. Standard errors clustered by study site. CIs of the difference


































































































































































































































































































TABLE 10 Average share (%) of total costs by cost subcategories: DLB and non-DLB dementia participants (WP1A) and
PDD and non-PDD participants (WP1B)
Cost subcategory Mean DLB 95% CI Mean non-DLB 95% CI
Difference
z-value p-value
Total cost of care 100.0 100.0
Medical history 40.0 38.1 to 41.9 26.7 11.8 to 41.5 2.034 0.042
Medications 6.0 5.6 to 6.4 4.6 4.3 to 4.9 0.861 0.389
Investigations 19.5 16.9 to 22 25.9 17.1 to 34.7 –2.035 0.042
Pathway to diagnosis 15.5 15 to 16.1 17.6 14.9 to 20.3 –0.799 0.425
Post diagnosis 19.0 18.6 to 19.5 25.2 22.1 to 28.2 –1.675 0.094
Mean PDD Mean non-PDD
Total cost of care 100.0 100.0
Medical history 33.3 15.5 to 51.2 33.1 4.4 to 61.9 0.667 0.505
Medications 22.8 17.4 to 28.3 19.0 11.4 to 26.6 1.204 0.229
Investigations 10.3 9.9 to 10.7 11.0 5.7 to 16.3 1.027 0.304
Pathway to diagnosis 18.8 15.1 to 22.5 35.9 22.3 to 49.5 –2.866 0.004
Post diagnosis 14.8 6.7 to 22.9 0.9 0.0 to 2.03 6.826 < 0.001
Notes
CIs are based on 1000 replications, with clustering over project site.
p-value from a Wilcoxon rank-sum test of the difference across the two groups.
TABLE 11 Regression estimates of factors influencing total cost of care for participants
Factor
A B





DLB dementia 3638 1028 < 0.001* 1478 to 5507
DLB with two or
less clinical
features
5763 1699 0.001* 2432 to 9093
DLB with three or
more clinical
features




2247 421 < 0.001* 1421 to 3072 2315 382 < 0.001* 1566 to 3064
Institution care 3373 1067 0.002* 1281 to 5465 3312 1079 0.002* 1198 to 5426
Sex –562 601 0.350 –1740 to 616 –456 700 0.515 –1827 to 916
Total resource
use time
–299 166 0.072 –623 to 27 –324 106 0.002* –532 to –116
Time since
diagnosis
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TABLE 11 Regression estimates of factors influencing total cost of care for participants (continued )
Factor
A B





PDD 7655 2030 < 0.001* 3676 to 11,634
PDD with five or
fewer clinical
features
6856 1600 < 0.001* 3721 to 9991
PDD with six or
more clinical
features




–625 3411 0.855 –7311 to 6061 –706 3461 0.838 –7489 to 6076
Institution care –3394 3753 0.366 –10,749 to 3961 –3809 3446 0.269 –10,563 to 2946
Sex –5235 1365 < 0.001* –7909 to –2561 –4391 2576 0.088 –9441 to 658
Total resource
use time
618 270 0.022* 90 to 1146 610 265 0.021* 90 to 1130
Time since
diagnosis
3177 3895 0.415 –4458 to 10,811 3319 3893 0.394 –4310 to 10,948
n 69b 69b
AIC 1367 1367
*Significant at p < 0.05.
AIC, Akaike information criterion; n, total sample size; SE, standard error.
a Sample size decreases from 146 to 136 because of one missing value in age at referral and nine missing values for
living arrangements.
b Sample size decreases from 73 to 69 because of one missing value in the sex variable, one missing value in time
since diagnosis and two missing values for living arrangements.
Notes
Values expressed in GBP (£).
Clinical features recorded before the date of final diagnosis.
Clinical features in DLB includes fluctuating cognition, recurrent visual hallucinations, features of parkinsonism, REM
sleep behaviour, severe neuroleptic sensitivity, repeated falls and syncope, transient unexplained loss of consciousness,
constipation, incontinence, orthostatic hypotension, depression, hallucinations in other modalities, delusions, abnormal
sense of smell and swallowing difficulties.
Clinical features for PDD includes parkinsonism, cognitive impairment, dementia impact on activities of daily living,
cognitive deficits in two or more domains, anxiety, apathy, depression, delusions, visual hallucinations, excessive
daytime sleepiness, changes in personality, REM sleep behaviour disorder, fluctuation, swallowing difficulties, repeated
falls, abnormal sense of smell, orthostatic hypotension, constipation and bladder instability.
Previous diagnoses before final diagnoses included LBD, PDD, vascular dementia, Alzheimer’s disease, frontotemporal
dementia, mixed vascular dementia and Alzheimer’s disease, MCI and ‘other’.
Institutions where patients resided included nursing homes, elderly mentally infirm care homes, NHS long stay and
sheltered accommodation.
Time of resource use (in years) included in the DLB model with a quadratic trend, and time since diagnosis included
in the model with a square root transformation. Time of resource use (in years) included in the PDD model with a
quadratic trend, and time since diagnosis included in the model with a linear function.
Average marginal effects from a generalised linear model with a gamma family and a log-link function.
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Total costs of diagnosis and care increased, on average, around £2250 for each time a participant
was diagnosed with a dementia-related condition before receiving a final diagnosis (p < 0.001). Those
participants who were residing in a care institution at the time of the study had, on average, £3300
higher total costs of care than those residing at home or with a family member (p = 0.002). As time
over which resource use data increased, total cost declined, although this effect was small and not
always significant. In contrast, there was strong evidence of a positive relationship between time since
diagnosis and total costs.
Participants with PDD had, on average, higher total costs of diagnosis and care of approximately
£7650 than non-PDD participants (95% CI £3676 to £11,634; p < 0.001) (see Table 11, bottom panel A).
When disaggregating the PDD group according to the number of clinical features recorded before final
diagnosis (five or fewer, or six or more), those participants with five or fewer clinical features before
diagnosis (n = 24) had, on average, £6800 higher costs than non-PDD patients (95% CI £3721 to £9919;
p < 0.001), and PDD participants with six or more clinical features had, on average, higher costs than
non-PDD cases (of around £8700, 95% CI £3571 to £13,810; p = 0.001) (see Table 11, bottom panel B).
In the PDD cohort, across all participant types, there was no evidence of an impact of the number of
previous diagnoses on total costs, on residing in a care institution at the time of recruitment to the
study or on time since diagnosis. Each additional year of recorded service use increased total costs by
an average of £610 (p = 0.021–0.022). Finally, there was some evidence of a difference in cost between
men and women, with women having lower costs (between £4400 and £5200) than men (p < 0.10).
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Appendix 2 Review protocol for
systematic reviews
Reproduced with permission, June 2021.53
PROSPERO: international prospective register of systematic reviews
A systematic review of management strategies for Lewy body dementia (dementia with
Lewy bodies and Parkinson’s disease dementia)
Chris Stinton, Claire Bamford, Victoria Cambridge, Louise Lafortune, Elijah Mak, James Mason,
Ian McKeith, John-Paul Taylor, Alan Thomas, John O’Brien.
Citation
Stinton C, Bamford C, Cambridge V, Lafortune L, Mak E, Mason J, et al. A Systematic Review of Management
Strategies for Lewy Body Dementia (Dementia with Lewy Bodies and Parkinson’s Disease Dementia). PROSPERO
2014:CRD42014007180. URL: www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=7180.
Review question(s)
What are the benefits, harms and costs of management strategies for Lewy body dementia delivered
to (1) patients and (2) carers?
How, when and where should management strategies for Lewy body dementia be implemented?
What views do patients and carers have of management strategies for Lewy body dementia?
Searches
We will search the following electronic bibliographic databases: AgeInfo, Allied and Complementary
Medicine, Applied Social Sciences Index and Abstracts (ASSIA), BiblioMap, British Nursing Index (BNI),
Campbell Collaboration, CenterWatch, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials
(CENTRAL), Cochrane Database of Abstracts of Reviews of Effects (DARE), Database of Systematic
Reviews, Cochrane Dementia and Cognitive Improvement Group Specialised Register, Cumulative
Index to Nursing and Allied Health Literature (CINAHL), Database of Promoting Health Effectiveness
Reviews (DoPHER), EMBASE, Educational Resources Information Centre (ERIC), Health Services
Research Projects in Progress, Health Technology Assessment database, IFPMA Clinical Trials Portal,
Lilacs: Latin American and Caribbean Health Sciences database, MEDLINE, metaRegister of Controlled
Trials, NHS Economic Evaluation Database (NHS EED), NHS Evidence, PROSPERO, PsycInfo, Scopus,
Social Care Online, Trials Register of Promoting Health Interventions, UK Clinical Research Network
Portfolio database, UMIN Clinical Trials Registry, WHO International Clinical Trials Registry Platform.
The search strategy will include terms relating to Lewy body dementia.
We will also search the grey literature (i.e. data reported outside peer-reviewed publications), reference
lists of studies included in the review and seek expert input from within the extended review team.
There will be no restrictions on language or publication period.
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Where the function is available, we will set up auto-alerts in databases to capture any new data arising
after we have conducted our searches.
Types of study to be included
There are no restrictions on the types of study designs for this review, but opinion papers will
be excluded.
Condition or domain being studied
Lewy body dementia (LBD) is the second most common cause of neurodegenerative dementia
after Alzheimer’s, accounting for around 15% of cases. It is characterised by psychiatric symptoms
(e.g. hallucinations), impairments and fluctuations in cognition, and parkinsonism. LBD comprises
two related disorders: dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD).
DLB and PDD are distinguished on the basis of the temporal sequence of the onset of motor
symptoms; a diagnosis of PDD is applied when motor symptoms occur at least one year before
dementia and a diagnosis of DLB when dementia precedes motor symptoms or they arise within
one year of one another.
Participants/population
Patients: We will include study participants who have received a formal diagnosis of LBD on the basis
of operationalised criteria or clinical judgement.
Carers: We will include participants who provide care (formal or informal) to people who have received
a diagnosis of LBD.
Intervention(s), exposure(s)
Any management strategy, or combination of strategies, that are intended to address the needs
(medical, social, economic, etc.) of people who have LBD or their carers. These will include, but not be
limited to, pharmacotherapy, psychotherapy, physiotherapy, education, speech and language therapy,
support services.
Comparator(s)/control
We will include studies with and without comparison/control groups.
Context
We will place no restriction on the settings in which managements strategies are delivered.
Outcome(s)
Primary outcomes
The primary outcome variables of interest are cognition and psychiatric and motor symptoms.
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Secondary outcomes
The secondary outcome variables of interest will include carer burden, costs, sleep disorder, autonomic
symptoms, falls, activities of daily living, quality of life, hospitalisation, institutionalisation, mortality,
acceptability of management strategies, and harms/side-effects (e.g. physical, psychological, financial).
Data extraction, (selection and coding)
Selection of studies
Titles and abstracts will be screened independently by two reviewers. Studies that are considered by
either reviewer to be relevant (or potentially relevant) will be obtained in full. Full-text articles will be
assessed by each of the reviewers for inclusion in the review. Any discrepancies between the studies
selected for inclusion by the reviewers will be resolved through discussion, with the involvement of a
third reviewer if necessary.
Data extraction
Data from studies will be extracted into forms designed by the reviewers. We will collect information
relating to eligibility, quality, participant details, study methods, management strategies employed,
outcomes, results and author conclusions.
Risk of bias (quality) assessment
The assessment of quality of studies will be conducted independently by two reviewers using the
Quality Assessment Tool for Quantitative Studies (Effective Public Health Practice Project, 1998),
the NICE Methodology Checklist: Qualitative Studies (NICE, 2009), and the Drummond Checklist for
Economic Evaluations (Drummond & Jefferson, 1996). Any disagreement between the reviewers will
be resolved through discussion and, if necessary, by consulting a third reviewer. Where reviewers
identify significant lack of quality, these studies will be excluded.
Strategy for data synthesis
Quantitative and qualitative data will be treated as separate streams in the initial phase of the review.
Qualitative evidence will subsequently be used to aid in the interpretation of quantitative evidence.
We will distinguish between published and unpublished literature and assess the impact that
publication status has on the results of the review using sensitivity analysis and/or descriptively.
Quantitative data
Where studies of management strategies employ quantitative methods we will select appropriate data
against a hierarchy of evidence (i.e. giving preference to RCTs over studies with cohort designs) and
synthesise the results using meta-analysis. Where we identify significant heterogeneity, we will employ
random-effect models. If there is no significant heterogeneity we will used fixed-effect models. Where we
are not able to combine data from different studies, we will provide a descriptive summary of the results.
Qualitative data
We anticipate that qualitative data will be synthesised thematically. Descriptive analysis will be
conducted if this is not possible.
Ongoing studies
Data from ongoing studies will not be available for quantitative or thematic analyses but we will
provide a list of ongoing research to inform on the gaps in the evidence.
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Analysis of subgroups or subsets
If sufficient data are available, we will consider data for participants who have DLB and those who
have PDD separately.
If sufficient data are available, we will conduct subgroup analyses based on dementia severity.
Dissemination plans
The findings will be disseminated to NHS professionals, NHS commissioners, Social Care, and patient/public
organisations. Scientific findings will be published in academic journals and presented at conferences.
Contact details for further information
Chris Stinton
Organisational affiliation of the review
University of Cambridge, University of Newcastle, University of Durham.
Review team
Dr Chris Stinton, University of Cambridge.
Ms Claire Bamford, University of Newcastle.
Dr Victoria Cambridge, University of Cambridge.
Dr Louise Lafortune, University of Cambridge.
Mr Elijah Mak, University of Cambridge.
Professor James Mason, University of Durham.
Professor Ian McKeith, University of Newcastle.
Dr John-Paul Taylor, University of Newcastle.
Professor Alan Thomas, University of Newcastle.
Professor John O’Brien, University of Cambridge.
Anticipated or actual start date
16 September 2013.
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NIHR Programme Grants for Applied Research (Project ref. DTC-RP-PG0311-12001) – Improving








Subject index terms status
Subject indexing assigned by CRD.
Subject index terms
Humans; Lewy Body Disease.
Any other information
This review is being conducted as part of a programme of research to improve the care of people who
have LBD within routine NHS secondary care.
Date of registration in PROSPERO: 16 January 2014
Date of publication of this revision: 16 January 2014
Stage of review at time of this submission Started Completed
Preliminary searches Yes Yes
Piloting of the study selection process Yes Yes
Formal screening of search results against eligibility criteria Yes No
Data extraction No No
Risk of bias (quality) assessment No No
Data analysis No No
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Appendix 3 Search strategies for
systematic reviews
Work package 2 was underpinned by two major systematic reviews conducted by the Diamond-Lewy study group. The reviews focused on pharmacological21 and non-pharmacological24




We searched the following electronic bibliographic databases: AgeInfo, Allied and Complementary
Medicine Database (AMED), Applied Social Sciences Index and Abstracts (ASSIA), BiblioMap, British
Nursing Index (BNI), The Campbell Collaboration Social, Psychological, Educational, and Criminological
Trials Register, CenterWatch, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials (CENTRAL),
Database of Abstracts of Reviews of Effects (DARE), Database of Systematic Reviews, Cochrane Dementia
and Cognitive Improvement Group Specialised Register, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Database of Promoting Health Effectiveness Reviews (DoPHER), EMBASE™ (Elsevier,
Amsterdam, the Netherlands) Educational Resources Information Center (ERIC), Health Services Research
Projects in Progress, Health TechnologyAssessment database, International Federation of Pharmaceutical
Manufacturers & Associations (IFPMA) Clinical Trials Portal, Latin American and Caribbean Health Sciences
Literature (LILACS), MEDLINE,metaRegister of Current Controlled Trials, NHS Economic Evaluation Database
(NHS EED), NHS Evidence, PROSPERO, PsycInfo® (American Psychological Association,Washington, DC,
USA), Scopus® (Elsevier), Social Care Online,Trials Register of Promoting Health Interventions, UK Clinical
Research Network Portfolio database, University hospital Medical Information Network (UMIN) Clinical
Trials Registry and theWorld Health Organization’s International Clinical Trials Registry Platform.The
search strategy included terms relating to LBD.We also searched grey literature (i.e. data reported
outside peer-reviewed publications), reference lists of studies included in the review, and sought expert
input from within the extended review team.There were no restrictions on language or publication period.
Where the function was available, we set up auto-alerts in databases to capture any new data arising after
we conducted our searches.
Study selection
Titles and abstracts were screened independently by four of the authors, with non-English-language
papers screened by native speakers. Discrepancies were resolved through discussion between
screeners. Potentially relevant studies were obtained in full and examined in detail by the first author
against the following criteria: (1) participants had a diagnosis of DLB, PDD or LBD (or were the carers
of patients with these diagnoses), (2) studies examined pharmacological strategies and (3) outcome
measures and scores were specified. No restrictions were placed on study design, but opinion papers
were excluded.
Data extraction
Data were extracted by two reviewers and recorded in an a Microsoft Excel® spreadsheet (Microsoft
Corporation, Redmond, WA, USA). We collected information relating to participant demographic
characteristics, selection criteria, study design, management strategies, outcome measures and scores,
adverse events and withdrawals.
Data synthesis
Studies were grouped and analysed according to pharmacological strategy. For each strategy, studies
of the highest level of evidence were included in the review. Classification of level of evidence was
determined using guidelines from the Oxford Centre for Evidence-Based Medicine.23
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Methodological quality
Methodological quality was assessed by three of the authors using the QATQS,54 which was developed
to assess quality across study designs, aiding consistency and clarity of reporting. The QATQS examines
selection bias, study design, confounders, blinding, data collection methods, withdrawals and drop-outs.
Domains are rated as being of weak, moderate or strong quality, which feed into an overall rating of
study quality. The reliability and validity of the QATQS have been demonstrated.6
Statistical analysis
Meta-analysis was conducted using RevMan version 5.3 (The Cochrane Collaboration, The Nordic
Cochrane Centre, Copenhagen, Denmark), employing the inverse variance method. Heterogeneity was
assessed using the chi-squared and I2-statistics and considered significant with p-values < 0.10 for
chi-squared and > 40% for I2. We employed random-effects models when there was significant study
heterogeneity and fixed-effect models when heterogeneity was not significant. Missing data were
sought from study authors. For data that were not obtainable, values were estimated using methods
outlined in the Cochrane Handbook for Systematic Reviews of Interventions.55 We estimated risk ratio with
95% CIs for dichotomous outcomes and weighted mean difference or standardised mean difference




The search identified studies through bibliographic databases, trial registers and the grey literature.
Bibliographic databases and trial registers included the following: MEDLINE (1946–present), PreMEDLINE,
PubMed, EMBASE (1974–present), Scopus, the Web of Science™ (Clarivate Analytics, Philadelphia, PA,
USA) (1900–current), PsycInfo (1806–present), CINAHL (1981–present), Cochrane libraries [Cochrane
Database of Systematic Reviews (2005–October 2016), CENTRAL (August 2016) and the Cochrane
Methodology Register (third quarter of 2012), other evidence-based medicine databases [American
College of Physicians® (ACP)] Journal Club (1991–September 2016), DARE (first quarter of 2015), Health
Technology Assessment database (third quarter of 2016) and NHS EED (first quarter of 2015)]; AgeLine
(1978–present); ALOIS (ALzheimer’s and cOgnitive Improvement Studies register); AMED (1985–present);
Physiotherapy Evidence Database (PEDro) (1929–present); Social Work Abstracts (1968–present) and the
National Association of Social Workers (NASW) clinical register (14th edition). The grey literature was
searched using such resources as the System for Information on Grey Literature in Europe (SIGLE),
National Technical Information Service (NTIS) database and PsycExtra® (American Psychological
Association) (1908–present).
The search strategy used only population and intervention terms to maximise the likelihood of identifying
relevant studies. Comparator and outcome terms were not used. The population was people with LBD
or their carers and this was identified using the search terms: [(Lewy OR Park*) and Dementia].
Interventions were any non-pharmacological treatment and identified using a wide range of terms:
(activit*, acupuncture, alternative, animal, aromatherapy, art therapy, assisted, balance, behav*, bicycle,
calisthenics, carer intervention, caregiver intervention, CBT, Chi gong, cognit*, cognitive behavioral therapy,
cognitive behavioural therapy, counsel*, creative arts, dance, dancing, diet, direct current stimulation,
drama, ECT, educat*, electroconvulsive therapy, enhanc*, environmental intervention, environmental
modification, exercise, flexibility, humor therapy, humour therapy, hydrotherapy, intervention*, leisure,
light therapy, management, martial arts, massage, meditation, Montessori, multisensory, music, non-
pharm*, nonpharm*, nutrition, occupational therapy, pet therapy, physical activity, physical therapy,
physiotherapy, pilates, psychoeducation, psychol*, psychosocial, psychotherapy, Qi gong, reality orientation,
recreation*, reminiscence, resistance training, run*, sensory, simulated presence, stimulation, Snoezelen,
support*, support group*, swim*, tai chi, therap*, therapeutic activity, TMS, training, training carers, training
caregivers, transcranial magnetic stimulation, treatment*, validation, weight training, yoga). Searches were
conducted on 30 October 2016.
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In addition to bibliographic database searches, the reference lists of papers included in the review and
previous systematic reviews on both LBD and non-pharmacological interventions were checked for
relevant papers. Advice was also sought from experts in the field.
Study selection
Two reviewers independently assessed search results for inclusion by title and abstract. All articles
deemed relevant by either reviewer were obtained in full. Both reviewers then independently
evaluated full-text articles for inclusion. Any disagreements were resolved through discussion or,
if necessary, with a third reviewer.
Data extraction
Two reviewers independently extracted relevant data from publications using a standardised form.
This included participant details (e.g. demographics, number, recruitment, clinical context, dementia
severity), intervention type, study design, measures and results. Qualitative data were also collated.
The primary outcomes were measures of cognition, function, neuropsychiatric symptoms and motor
symptoms. The secondary outcomes were measures of any other clinically relevant outcomes, such as
quality of life, carer burden, financial costs, other symptoms (e.g. sleep or autonomic disturbances) and
objective end points (e.g. falls, hospitalisation, institutionalisation, mortality). Secondary outcomes also
included the perceived acceptability of treatments, reported side effects and drop-out rates (a measure
of treatment acceptability).
Quality assessment
Two reviewers independently assessed study quality and risk of bias using standardised tools. These
included the Effective Public Health Practice Project QATQS54 and the NICE methodology checklist for
qualitative studies.56 Any disagreements were resolved through discussion.
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Appendix 4 List of Delphi panel contributors
Contributor Location
Dag Aarsland King’s College London, London, UK
Neil Archibald South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK
Louise Allan University of Exeter Medical School, Exeter, UK
Clive Ballard University of Exeter Medical School, Exeter, UK
Bob Barber Newcastle University, Newcastle upon Tyne, UK
Roger Barker University of Cambridge, Cambridge, UK
Brad Boeve Mayo Clinic, Rochester, MN, USA
Daniel Collerton Newcastle University, Newcastle upon Tyne, UK
Tom Dening University of Nottingham, Nottingham, UK
Murat Emre Istanbul University, Istanbul, Turkey
Duncan Forsyth Cambridge University Hospitals Foundation Trust, Cambridge, UK
John Hindle Bangor University, Bangor, UK
Clive Holmes University of Southampton, Southampton, UK
Clare Lawton Cambridgeshire and Peterborough NHS Foundation Trust (retired), Cambridge, UK
Ian Maidment Aston University, Birmingham, UK
Eneida Mioshi University of Cambridge, Cambridge, UK
Sean Page Bangor University, Bangor, UK
Jill Rasmussen The Lewy Body Society, London, UK
Sharon Reading Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Louise Robinson Newcastle University, Newcastle upon Tyne, UK
Lynn Rochester Newcastle University, Newcastle upon Tyne, UK
Ben Underwood Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK
DOI: 10.3310/pgfar09070 Programme Grants for Applied Research 2021 Vol. 9 No. 7
Copyright © 2021 O’Brien et al. This work was produced by O’Brien et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
81

Appendix 5 Overview of management
guideline
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Appendix 6 Health economic analysis for
work package 4
Introduction
The main objective of the economic component of the pilot cluster RCT was to rehearse the methods
for a definitive economic evaluation of the new management toolkit for DLB and PDD compared with
usual care. For a definitive study, a within-trial economic evaluation is anticipated. Such a study would
seek to estimate costs and outcomes for each trial participant over the duration of the trial follow-up.
These data would then be used to estimate cost-effectiveness. As is typical for pilot trials, because of the
modest sample size available for each randomised patient group, a full economic evaluation was not
conducted. The small sample size would not provide reliable conclusions on the cost-effectiveness of the
management toolkit. Therefore, the focus of the economic component deviated slightly from protocol
and the analysis aimed rather to provide a descriptive analysis of the costs and outcomes. Data on costs
and outcomes for each patient sample (DLB and PDD) were examined separately, as it was expected
that different diagnoses would lead to a differential use of services and outcomes. Suggestions for reducing
the number of missing data will be made and methods that would be employed in a full evaluation of a
definitive trial will also be discussed.
Methods
Costs
Costs were examined from the perspectives of the NHS and Personal Social Services, which includes
costs of medications and health and social care use. Costs incurred by other sectors (e.g. local authorities)
were not included. Data on use of health and social care were captured by using a bespoke service
utilisation questionnaire that was developed based on questions included in the Client Service Receipt
Inventory (CSRI).57 Data were collected at baseline and at the 3- and 6-month follow-ups. The participants
were asked about their use of a broad range of services, including inpatient services, outpatient services,
day activity services and community care services, over the preceding 3 months. All costs are reported
in GBP (£) for the financial year 2017/18. As the study follow-up was < 12 months, no discounting
was performed.
Health care and social service resource use
Unit costs were estimated using the National Schedule of Reference Costs 2017/1815 and Unit Costs
of Health and Social Care 2018.58 Resources from the voluntary sector (e.g. dementia cafes) and
local authority-run services (e.g. local authority day activity services) were not included in the NHS
and Personal Social Services perspective; however, these services would be included in a broader
societal perspective.
Resource use costs per patient at each time point (baseline and at the 3- and 6-month follow-ups)
were estimated by multiplying total reported use of each service by each relevant unit cost. A total
resource use cost for each participant was calculated by summing all individual service use costs for the
individual. Mean and median resource use costs were then estimated by trial arm for each patient group.
Medication costs
Data were collected at each visit (baseline and at the 3- and 6-month follow-ups) on all medications
taken by participants for the previous 3 months. Data on dose, frequency and duration taken were
collected for each medication. Unit costs for medications were obtained from the British National
Formulary (BNF).59
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Over-the-counter supplements (e.g. cod liver oil) were excluded from the analysis, as these were
not assumed to be provided as part of NHS care and the costs would be considered ‘out-of-pocket’
costs for the participant. Medications that were insufficiently specific to obtain costs for (e.g. general
antibiotics or steroids) were also excluded, as costs vary depending on the precise medication prescribed.
Where data were missing on either dosage or frequency, recommended dosage was taken from the BNF
where possible. Where this was not possible, the use of that medication was excluded, as no assumptions
could be made on the average use of those medications. Therefore, where data were missing on dose,
frequency or duration, and data could not be estimated using the BNF, costs could not be calculated.
Intervention delivery costs
The delivery of the intervention incurred costs from the production of the management toolkit and
training staff to use it. The cost of producing the toolkit included materials and staff time. Unit costs
for each element of production were obtained from invoices provided by the trial support team and
service costs listed on the Newcastle University print services website.60 The service costs stated by
print services were assumed to include labour time.
The cost of training staff to use the toolkit was estimated from data collected on staff attending
training sessions and approximate duration of the sessions, in addition to staff time required to
develop training sessions. Unit costs for staff were obtained from publicly available pay scales for
university staff and the Unit Costs of Health and Social Care 2018.58
Total costs
Costs from each area of resource use (medications and health and social care) were combined at each time
point. For the cumulative totals at the 3- and 6-month follow-ups, intervention delivery costs are also
added to reflect the additional cost of receiving the intervention. In a definitive trial, cost differences
between trial arms would be estimated using regression analysis, which would estimate total follow-up
costs at 6 months, adjusting for baseline costs (which may differ between trial arms despite randomisation).
To avoid double counting in the regression analysis, delivery costs would be included only once in the total
follow-up costs, which would combine cost data collected at both the 3- and 6-month time points.
Patient and carer private costs
Costs incurred by patients and by carers who accompanied patients to appointments were also measured
using data collected from a time and travel questionnaire combined with data on use of resources. The
time and travel questionnaire was administered at the 6-month follow-up and elicited information on
patients’ and carers’ most recent inpatient attendance, outpatient appointment, GP appointment and
community dementia specialist appointment (i.e. community neurologist, OAP or geriatrician). Information on
the mode of transport used to travel to the appointment, the time taken to travel and the time spent at the
appointment (or days spend in inpatient care) was elicited.Where public transport or taxis were used to travel
to an appointment, the cost of travel one-way was recorded.Where a private car was used, the cost of travel
was estimated from the distance travelled using a cost of £0.45 per mile taken from the 2018 TAG Data Book61
and any additional parking charges. If both patient and carer travelled by taxi or private car, it was assumed
that this journey was taken together and, therefore, the cost of travel was calculated for only the patient to
avoid double counting.
The cost of time spent attending an appointment for both the patient and carer was calculated based
on activity rates for various activities published by the ONS, according to the activity that either
the patient or carer reported they would have been doing at the time of attending the appointment.
Paid work, child care, caring for a relative or friend and voluntary work was valued as £13.88, which
is the average hourly wage, according to the ONS.37 Housework and leisure activities were valued at
£10.10 an hour. Time spent in unemployment, retirement or in education was valued as £6.04 an hour.
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The mean unit costs of time and travel for both patients and carers were calculated and multiplied by
the number of attendances or appointments reported at each time period.
Quality of life
Patients’ generic quality of life was derived from the responses to the EQ-5D-5L questionnaire, completed
at baseline and at the 3- and 6-month follow-ups. The EQ-5D-5L asks about a patient’s general quality of
life over five dimensions (i.e. mobility, pain, usual activities, anxiety and depression, and self-care) and five
levels. Responses to the EQ-5D-5L questionnaire were transformed into health state utilities using tariffs
derived from the UK population. Values for the EQ-5D-5L were recently derived by Devlin et al.;62 however,
there is some debate over the accuracy of values in this new value set. Therefore, NICE63 recommends
applying index values from a ‘crosswalk’ between the original EuroQol-5 Dimensions, the three-level
version and the new five-level version, until the concerns over the new value set have been addressed.
Therefore, the ‘crosswalk’ value set was used in this study to derive utility values for each participant.
The crosswalk index value calculator, developed by EuroQoL Foundation39 and based on the index values
estimated by van Hout et al.,64 was used to estimate the health state utilities for each participant.
The health state utilities were then used to estimate generic QALYs for each participant using the
change from baseline approach.65 This approach was chosen because the difference in baseline utilities
was very small between trial arms.66 In a full evaluation, QALYs would be calculated using the area
under the curve approach67 and QALYs at the 6-month follow-up would be adjusted using regression
analysis, including baseline utilities as a covariate. As unadjusted values are being reported here, the
change from baseline approach was used because it accounts for differences at baseline, which the




For the data from the service utilisation questionnaire, substantially more participants for the PDD
sample were missing all service use data in the intervention arm than in the control arm at the
6-month follow-up (Table 12). It is possible that participants were missing because they were unable
to complete follow-up visits because of deterioration in their health, which would imply that the
intervention arm costs are lower than they should be. Conversely, there are more participants missing
all service use data in the control arm in the DLB patient sample. Therefore, higher costs would be
expected in the control arm than are observed.
A similar pattern of missing data was observed when examining data collected for each individual
component of service utilisation across all visits. In the PDD patient sample, 11% of data across all
areas of service use was missing in the intervention arm compared with 6% in the control arm. For the
DLB patient sample, 7% of data across all areas of service use was missing in the intervention arm
compared with 16% in the control arm. The majority of these missing data can be attributed to
participants missing at each visit.
The pattern of missing data on all medication use is almost identical to that identified for health and
social care resource use (Table 13). Data missing on dose, frequency or duration (therefore preventing
the calculation of a cost for the medication reported) were also examined. For participants with a
diagnosis of DLB, 7% of data were missing in the intervention group and 9% of data in the control
group. For the PDD sample, the corresponding proportions were 3% and 4%, respectively.
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Health and social care resource use
Table 12 suggests a difference in mean health and social care resource use costs between the
trial arms at baseline in both patient groups, although the small sample size cautions against any
conclusions being drawn. The mean costs in the intervention arm for the DLB sample decreased at each
follow-up visit, compared with costs calculated at baseline, whereas costs increased for the control arm.
For the PDD sample, intervention arm costs also decreased at the 6-month follow-up compared with
costs incurred between baseline and 3 months, whereas control group costs increased at each follow-up
visit. The SDs for both randomised arms, both groups and at all time periods are larger than the mean
values, suggesting substantial imprecision. The median values are considerably smaller than the mean
values, which suggests that there is a substantial right skew to the data, with some participants incurring
very much higher costs.

















Control 33 0 (0) 1454 (2118) 561 (790) 18 1 (5) 685 (812) 410 (385)
Intervention 44 0 (0) 2369 (5007) 648 (1055) 31 0 (0) 1312 (2697) 359 (631)
3 months
Control 25 8 (24) 2852 (5759) 535 (1134) 18 1 (5) 905 (1378) 345 (1026)
Intervention 40 4 (9) 1393 (2745) 411 (845) 28 3 (10) 2148 (3917) 502 (1080)
6 months
Control 26 7 (21) 2091 (4738) 520 (1585) 18 1 (5) 1089 (1637) 322 (499)
Intervention 40 4 (9) 1070 (1472) 519 (951) 24 7 (23) 783 (1119) 369 (603)
IQR, interquartile range.
a Participants with data related to all services missing at visit.

















Control 33 0 (0) 225 (268) 141 (230) 19 0 (0) 195 (182) 126 (190)
Intervention 43 1 (2) 218 (220) 156 (197) 31 0 (0) 231 (182) 180 (269)
3 months
Control 26 7 (21) 222 (200) 161 (239) 18 1 (5) 210 (193) 153 (167)
Intervention 39 5 (11) 264 (247) 225 (276) 28 3 (10) 269 (195) 248 (282)
6 months
Control 27 6 (18) 245 (216) 166 (253) 18 1 (5) 206 (192) 156 (171)
Intervention 40 4 (9) 272 (258) 223 (263) 24 7 (23) 331 (331) 264 (329)
IQR, interquartile range.
a Participants with all medication data missing at visit.
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Medication costs
Table 13 shows little variation in both mean and median medication costs between baseline and
the 6-month follow-up for both patient samples. There is a trend towards increasing medication costs
for both arms over the 6-month follow-up period. Given the degenerative nature of both dementia
and PD, this is unsurprising.
A greater increase in mean medication costs is observed for the intervention arms of both patient
samples than in the control arms. However, the increase is greater for the PDD sample than for the
DLB sample (see Table 13). Alternative rationales for this could be advanced. For example, the data
may indicate that the management toolkit encouraged increased medication prescribing. An alternative
explanation is that the larger proportion of missing observations in the intervention arm of PDD
patients was a result of these participants being less well and, therefore, less able to complete follow-up
visits. However, the small sample size prevents any robust conclusions being drawn.
Intervention delivery costs
Table 14 shows the breakdown of the resource costs associated with the intervention delivery. The
total delivery cost was divided by the number of participants in the intervention arm in both patient
groups combined (n = 75) to estimate a mean delivery cost per participant receiving the intervention.
Mean intervention delivery cost was estimated at £76.32 per participant in the intervention arms.
Participants in the control arms did not receive the intervention and, therefore, delivery costs are
£0 for the control groups.
Total costs
Table 15 shows the total costs for each trial arm at all time points. Total costs include health and social
service use, medication costs and intervention delivery costs (for the intervention arms at the 3- and
6-month follow-ups). The health and social care use costs make up the largest proportion of the total
cost. In both patient samples, there is an overall increase in total costs between baseline and the 6-month
follow-up in the control arms, whereas there is an overall decrease in total costs in the DLB sample
intervention arm. In the PDD sample, an increase in costs occurs between baseline and 3 months; however,
a decrease in costs occurs between the 3- and 6-month follow-ups, and the mean 6-month cost is lower
than the baseline cost for the control arm.
The median costs imply a right skew to the total cost data, indicating that a small number of participants
incurred much higher costs than the remainder of the sample. The SDs are larger than the mean values
for each reported cost, which demonstrates imprecision. The imprecision is probably caused by the small
sample size. For this reason, these total costs should be considered only illustrative.
TABLE 14 Breakdown of intervention delivery costs
Resource Cost (£)
Total staff preparation time 133
Total staff training time 2338
Total materials 3252
Total 5724
Total per person with dementia 76.32
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Private costs
Table 16 shows the mean combined travel costs incurred by patients from travelling to all inpatient,
outpatient, GP and community dementia specialist appointments for each time point. Table 16 also
shows the mean combined time costs for the time spent in attendance at each of the four aforementioned
areas of health-care services. There is an overall decrease in mean travel costs between baseline and
the 6-month follow-up for both intervention and control groups, with the exception of the control group
of the PDD sample whose mean travel costs increased at the 6-month follow-up. For both patient
samples, there is an observed increase in mean time costs between baseline and the 6-month follow-up
for the control group, yet a decrease in mean time costs for the intervention group. However, the
median time costs imply a strong right-skew, which indicates that a small number of patients incurred
much higher costs than the remainder of the sample.
Table 17 shows the mean and median travel and time costs incurred by carers for attending appointments
with patients, including the time cost of visiting patients who were hospital inpatients. The mean travel
costs are lower for carers (see Table 17) than for patients (see Table 16), largely because of the assumption
that patients incur the cost of travel if a carer has accompanied a patient in a taxi or private car.
There is a slight decrease in mean travel costs for the carers of both patient samples in both trial arms
between baseline and the 6-month follow-up, with the exception of carers of PDD patients in the control
arm whose mean travel costs increased between baseline and the 6-month follow-up. The same pattern
is observed for the mean time costs, which decrease between baseline and the 6-month follow-up for
carers of patients in both trial arms and patient samples, except for the control group of PDD patients.
The mean travel and time costs for carers of DLB patients are typically slightly higher for carers of
patients in the intervention group than for carers of patients in control group. The opposite is observed
for carers of PDD patients, as both mean time and travel costs are typically higher for carers of patients
in the control group than for carers of patients in the intervention group.
TABLE 15 Mean and median total costs, including health service use, medications and delivery cost (intervention arm

















Control 33 0 (0) 1679 (2154) 797 (1237) 19 0 (0) 844 (793) 593 (677)
Intervention 44 0 (0) 2582 (5076) 806 (1214) 31 0 (0) 1543 (2769) 572 (913)
3 months
Control 26 7 (21) 2964 (5681) 797 (1203) 18 1 (5) 1114 (1385) 591 (928)
Intervention 40 4 (9) 1726 (2807) 783 (1040) 28 3 (10) 2493 (3961) 770 (1314)
6 months
Control 27 6 (18) 2259 (4763) 574 (1645) 18 1 (5) 1295 (1607) 600 (653)
Intervention 40 4 (9) 1419 (1506) 947 (1207) 24 7 (23) 1191 (1196) 730 (917)
IQR, interquartile range.
a Participants with all cost data missing at visit.
Notes
Participants assumed missing at follow-up if cost data missing. Intervention delivery costs not included for participants
who are considered missing in intervention arm.
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TABLE 16 Mean and median total travel and time costs for patients attending inpatient services, outpatient
appointments, GP appointments and dementia specialist appointments, combined, based on data from a time and travel
questionnaire combined with data on resource use
Time point
DLB PDD


















Control 33 (42) 27 (43) 255 (671 22 (30) 36 (58) 25 (29) 26 (40) 18 (20)
Intervention 44 (40) 33 (40) 378 (729) 33 (73) 32 (39) 17 (38) 121 (383) 16 (30)
3 months
Control 21 (16) 20 (20) 260 (573) 16 (24) 18 (21) 12 (16) 13 (17) 8 (11)
Intervention 29 (35) 17 (39) 174 (468) 12 (38) 19 (19) 16 (25) 342 (764) 14 (35)
6 months
Control 27 (36) 17 (16) 314 (757) 14 (25) 53 (138) 19 (28) 121 (370) 14 (19)
Intervention 30 (33) 19 (33) 213 (516) 15 (38) 21 (25) 16 (23) 79 (313) 12 (17)
IQR, interquartile range.
a Travel cost includes the cost of travel from either the fare of travel (if public transport or taxi) or cost of mileage
and parking if in a private car, in addition to the time cost from the length of time spent travelling.
b Time cost refers to the cost of the length of time spent attending each appointment based on the ONS activity rates
for the activity patients reported that they would have been engaged in at the time of each appointment.
TABLE 17 Mean and median total travel and time costs for carers accompanying patients to inpatient services,
outpatient appointments, GP appointments and dementia specialist appointments, combined, based on data from a time
and travel questionnaire combined with data on resource use
Time point
Carers of DLB patients Carers of PDD patients


















Control 9 (13) 6 (13) 21 (24) 15 (26) 10 (18) 5 (8) 17 (31) 8 (15)
Intervention 13 (12) 9 (12) 28 (26) 23 (37) 9 (11) 4 (11) 16 (22) 9 (19)
3 months
Control 6 (5) 5 (7) 15 (15) 9 (16) 5 (8) 2 (5) 9 (13) 3 (9)
Intervention 9 (11) 4 (11) 18 (21) 7 (27) 5 (6) 3 (7) 16 (20) 5 (25)
6 months
Control 8 (11) 4 (7) 20 (28) 9 (18) 15 (40) 6 (6) 28 (71) 9 (11)
Intervention 9 (11) 5 (9) 20 (22) 9 (26) 6 (8) 4 (6) 11 (15) 7 (12)
IQR, interquartile range.
a Travel cost includes the cost of travel from the fare of public transport in addition to the time cost from the length
of time spent travelling.
b Time cost refers to the cost of the length of time spent accompanying a patient at each appointment (including time
spent visiting patients during inpatient stays) based on the ONS activity rates for the activity carers reported that
they would have been engaged in at the time of each appointment.
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The DLB group had a larger proportion of missing observations for the EQ-5D-5L utilities at the
6-month follow-up than the PDD group, although the difference was not large (4 percentage points).
Both groups had between 30% and 35% data missing at the final follow-up (Table 18).
Health state utilities and quality-adjusted life-years
Using the change from baseline method, the difference in QALYs between baseline and the 6-month
follow-up was calculated for each arm. Table 19 shows the mean and median utility score at each time
point and the QALY change from baseline at the 6-month follow-up for each patient group. As the sample
size was small, these values should be considered only illustrative. Overall, changes in QALYs in each trial
arm for each sample were small to modest, but with consistent decreases in mean and median scores for
those in the DLB sample. A similar pattern was not evident for the PDD sample. However, with such small
samples, data are insufficient to draw conclusions.
TABLE 18 Proportion of sample missing self-reported EQ-5D-5L utility at each time point
Sample
Baseline 3-month follow-up 6-month follow-up
DLB PDD DLB PDD DLB PDD
n % n % n % n % n % n %
Control 3 9 2 11 11 33 4 21 12 36 4 21
Intervention 3 7 4 13 8 18 5 16 11 25 9 29
Total 6 8 6 12 19 25 9 18 23 30 13 26
TABLE 19 Mean and median QALY change from baseline at the 6-month follow-up
Utility score
DLB PDD
n Mean (SD) Median (IQR) n Mean (SD) Median (IQR)
Health state utilities
Control: baseline 30 0.681 (0.267) 0.763 (0.295) 17 0.640 (0.283) 0.739 (0.298)
Intervention: baseline 41 0.658 (0.214) 0.707 (0.211) 27 0.678 (0.219) 0.746 (0.217)
Control: 3 months 22 0.658 (0.190) 0.699 (0.195) 15 0.743 (0.184) 0.742 (0.19)
Intervention: 3 months 36 0.612 (0.278) 0.657 (0.295) 26 0.694 (0.159) 0.735 (0.223)
Control: 6 months 21 0.592 (0.291) 0.619 (0.391) 15 0.696 (0.180) 0.720 (0.227)
Intervention: 6 months 33 0.683 (0.206) 0.714 (0.246) 22 0.613 (0.228) 0.663 (0.185)
QALYs
Control 18 –0.029 (0.068) –0.015 (0.065) 15 0.007 (0.060) 0.000 (0.037)
Intervention 30 –0.009 (0.039) –0.001 (0.040) 22 –0.001 (0.057) –0.001 (0.023)
IQR, interquartile range.
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Discussion
Robust conclusions cannot be drawn on the impact of the intervention on costs and quality of life,
given the small sample size of the trial. In a definitive trial, the impact on cost would be more reliably
assessed in conjunction with the impact on quality of life. The impact of the intervention on quality of
life, indicated by this pilot study, is small and appears to differ between patient samples. As with costs,
the impact of the intervention on QALYs cannot be reliably assessed from this sample.
Given the disease area being studied in this trial, a substantial number of missing data might be
expected because of difficulties in collecting data from people with dementia. Within a definitive trial,
precision of results could be improved through the use of statistical methods to replace missing data
with appropriate values where some data collection was unsuccessful. Numerous methods exist for
handling missing data. The choice between these methods depends on the nature and pattern of
missing data.
A substantial number of quality-of-life data were missing from responses to the EQ-5D-5L. If participants
are unable to complete the questionnaire themselves, as a sensitivity analysis, proxy utilities from EQ-5D-5L
responses completed by a carer on behalf of the patient participant could be used. Statistical tests for
correlation between proxy and self-reported EQ-5D-5L can be conducted to assess whether or not the
proxy values are sufficiently similar to the self-reported values (where both are available). If the tests
indicate that proxy and self-report EQ-5D-5L utilities are not strongly correlated, using proxy values
would introduce bias to the outcome. In a base-case analysis, imputation may be more reliable if there is
sufficient data for this to be a reliable option.
Lessons learned
During the analysis of this pilot study data, lessons have been learned on how to approach a full
economic evaluation of a definitive trial. These are briefly discussed below.
In a definitive trial, it would be important to include all costs associated with the health and social
service use, including voluntary and local authority sectors, as they have an opportunity cost that
could be relevant to NHS costs. For instance, if voluntary care services were discontinued, it would be
likely that NHS resource use may increase, as NHS-provided services absorb the voluntary service
users, or the burden would be placed on informal carers. This would have an impact on informal carers’
time available for work or leisure and may affect their own health, resulting in further NHS resource
use. However, costs associated with voluntary sector and some community resources (e.g. educational
classes) are not readily available. Therefore, these would have to be estimated via direct contact with
services for a definitive trial.
In addition, informal care from relatives and friends is common for people with dementia and,
therefore, it would be beneficial to assess the impact of the intervention on carers if a broader societal
perspective is to be considered for the definitive analysis. If the intervention reduces or increases the
need for informal care then this has a societal impact in terms of productivity (i.e. if the carer is still an
active member of the workforce) and an opportunity cost in terms of care being provided informally,
as opposed to via the formal care sector. Therefore, the costs (both time and financial) associated with
care responsibilities and carer quality of life would be analysed in a definitive analysis.
The difficulty in conducting reliable analysis imposed by a small initial sample and compounded by
missing data indicates that a much larger sample would be needed in a definitive trial. The number of
total missing data identified in this pilot analysis could be used to estimate a sample size that would allow
for a sufficiently large sample, given the expected numbers of participant drop-off across follow-up visits.
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Appendix 7 Analysis of clinician
questionnaires from work package 5
During the programme, three questionnaires were sent to professionals working in participatingservices to supplement the qualitative work. The aim of the first questionnaire (T0, distributed
during WP5.1) was to explore self-reported confidence in diagnosing and managing conditions typically
seen in memory and/or movement disorder services. The second questionnaire (T1, distributed towards
the start of the pilot trial) aimed to collect baseline data on assessment practices and views of the
assessment toolkits (and management toolkit in intervention services). The final questionnaire (T2,
distributed after the end of the pilot trial) aimed to explore views on the toolkits, assessment practices,
implementation and sustainability of the toolkits. A set of questions on confidence in managing common
LBD symptoms was repeated in all three questionnaires. Details of potential explanatory variables
(e.g. role, region and experience/training) were also collected. We hoped that using questionnaires
would enable us to achieve greater coverage of respondents than was possible through interviews
and observation.
Data collection
In January 2015, the first questionnaire was sent by post to staff working in most participating
services, along with a prepaid envelope. One reminder was sent, including a copy of the questionnaire
and a prepaid envelope, after approximately 3 weeks. As one NHS trust was unwilling to release staff
details, we had to rely on local contacts to distribute the questionnaires. Although some attempts
were made to send reminders within this trust, the process was hampered by a lack of information on
individual participants and limited local resources to support distribution of the questionnaires.
The intention was to distribute the second questionnaire (T1) shortly after completion of all site
initiation visits for the pilot trial. As there was insufficient capacity within the team to send out
questionnaires to each site as approvals were obtained, distribution was delayed until all approvals
were in place. Unfortunately, approvals for the qualitative work were not necessarily processed in
parallel with approval for the pilot trial and obtaining approval from one trust was a protracted
process. As a result, by the time T1 questionnaires were sent out (in January 2017), some sites had
been using the toolkits for some time. The final questionnaire (T2) was sent out after the end of the
pilot trial, as planned (in October 2018). The T1 and T2 questionnaires were administered using
SurveyMonkey® (Palo Alto, CA, USA), with one electronic and one paper reminder.
Questionnaires completed on paper were entered into SPSS version 16 (IBM, New York, NY, USA).
Questionnaires completed electronically were transferred to SPSS for analysis. All questionnaires were
identified by a unique identifier.
Analysis
The questionnaires were analysed using simple descriptive statistics. Analysis of variance was used to
explore the impact of potential explanatory variables. The reasons for selecting potential plausible
explanatory variables are summarised in Table 20. It is evident that these potential explanatory variables
are not independent, with region and role, in particular, being confounded.
There were difficulties in examining changes over time, as, although the respondents to the
three questionnaires overlapped, they were not identical and only seven individuals completed
questionnaires at all three time points. For the analysis of confidence in symptom management
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(for which information was available at all time points), we maximised the number of observations
for analysis by constructing a file containing people who responded to the T0 questionnaire and either
the T1 and/or T2 questionnaires (where respondents completed both questionnaires, the T2 response
took precedence).
Response rates
Response rates to each questionnaire are summarised in Table 21. Undelivered questionnaires are
excluded from calculation of the response rate. Overall response rates were similar for each of the
questionnaires (ranging from 37% to 48%). Data from SurveyMonkey indicated that, overall, nearly
two-thirds of questionnaires delivered electronically (62%) were unopened, highlighting the need to
provide copies of the questionnaire by post as well as e-mail.
Data were available to compare response rates to each questionnaire by region and specialty. There
was no evidence of differential response rates by region. Response rates were significantly higher
for movement disorder than for memory services at T0 (p < 0.01) and T2 (p < 0.001), but not at T1
(Table 22). Response rates were examined by study arm for T1 and T2 questionnaires. There was no
difference at baseline, but a trend for a better response rate from the control arm at T2 (54.5% vs.
31.8%; p < 0.05). This is likely to reflect the unequal distribution of larger teams between study arms.
TABLE 20 Rationale for identifying potential explanatory variables
Explanatory variable Rationale
Specialty The marked differences in organisation of movement disorder and memory services suggested
that staff views might systematically differ. Furthermore, the introduction of the assessment
toolkits had different implications for the services, which might influence views of their
acceptability and feasibility
Region Newcastle upon Tyne is a leading centre in LBD research and doctors who have trained in the
region are likely to have experienced greater exposure to LBD. There are also marked regional
differences in the organisation of memory services, with nurse-led models predominating
in East Anglia and a higher proportion of consultant-led services in the North East
Role Knowledge of and training in LBD are likely to differ systematically between doctors and
other allied health professionals
Study arm (relevant to
T1 and T2 only)
Access to the management toolkit may influence perceptions of the value and purpose of the
assessment toolkits, as respondents may feel that there are greater benefits in identifying and
diagnosing people with LBD if they have resources to support better management
Time Impacts on practice and perceptions of the toolkits may change over time, either as a result
of successful embedding into practice or because of growing realisation of the difficulties of
integrating the toolkits into routine practice
TABLE 21 Response rates to questionnaires
Response T0, n (%) T1, n (%) T2, n (%)
Distributed 346 127 145
Not delivered 0 3 5
No response/incomplete 193 (56) 64 (51.6) 88 (62.9)
Completed 153 (44) 60 (48.4) 52 (37.1)
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Characteristics of respondents
Respondent characteristics at each time point are shown in Table 23. Respondents had a range of roles,
although the majority were either consultants or nurses. To facilitate subsequent analyses, role was
recoded into doctors (including trainees) and allied health professionals (including nurses).
At T0, information was collected on experience of working with patients with dementia and/or PD.
This varied from < 1 to 40 years, with an average of 13 years’ experience with dementia (median
12 years) and just under 10 years’ experience of working with PD patients (median 9 years). The T1
and T2 questionnaires asked more specifically about the training in LBD received by respondents.
The response categories were chosen on the basis of comments made by interview participants that
TABLE 22 Response rates by specialty
Questionnaire returned T0, n (%) T1, n (%) T2, n (%)
Memory services
Yes 109 (40.5) 48 (45.7) 31 (28.7)
No 160 (59.5) 57 (54.3) 77 (71.3)
Total 269 105 108
Movement disorder services
Yes 44 (57.1) 12 (63.2) 21 (65.6)
No 33 (42.9) 7 (36.8) 11 (34.4)
Total 27 19 32
TABLE 23 Characteristics of questionnaire respondents
Characteristic T0 (N= 153), n (%) T1 (N= 60), n (%) T2 (N= 52), n (%)
Sex
Male 53 (34.6) 20 (33.3) 22 (42.3)
Female 100 (65.4) 40 (66.7) 30 (57.7)
Specialty
Memory service 110 (71.9) 48 (80) 31 (59.6)
Movement disorder service 43 (28.1) 12 (20) 21 (40.4)
Role
Consultants and trainees 72 (47.1) 29 (48.3) 31 (59.6)
Nurses 56 (36.6) 28 (46.7) 18 (34.6)
Others 25 (16.3) 3 (5.0) 3 (5.8)
Region
East Anglia 104 (68.0) 34 (56.7) 24 (46.2)
North East 49 (32.0) 26 (43.3) 28 (53.8)
Study arm
Intervention NA 44 (73.3) 34 (65.4)
Control 16 (26.7) 18 (34.6)
NA, not applicable.
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emphasised the value of exposure to LBD through working with experts in the field. Data were combined
to explore training received by each unique participant to T1 and/or T2 questionnaires (n = 80). A series
of binary variables was constructed and we explored whether or not training varied systematically
by professional background (doctors vs. others), specialty (movement disorder vs. memory services),
region (East Anglia vs. North East) or study arm (intervention vs. control). Overall, around one-third of
respondents (33.8%) had received only basic training, a similar proportion (32.5%) reported self-directed
study (through reading or attendance at conferences) and nearly half (45.0%) had worked with a team
with expertise in LBD (the totals do not sum to 100, as some respondents reported both self-directed
study and working with an expert team).
No differences in training were found by specialty or study arm. Respondents in East Anglia were more
likely to report only basic training than those in the North East (43.2% vs. 22.2%; p < 0.05). Although
working with an expert team was not associated with professional background, doctors were more likely
to report self-directed study and less likely to have received only basic training (Table 24). The findings
suggest that those completing and returning the questionnaires may have considerable knowledge of
and expertise in LBD, and highlight the need to provide additional training on LBD for non-medical staff.
Confidence in diagnosing selected conditions (T0 only)
A seven-point scale was used to assess confidence in diagnosing and managing a range of conditions
commonly seen in memory and/or movement disorder services. A not applicable column was included,
as some staff were not responsible for making diagnoses or for managing certain conditions (the number
of respondents therefore varies for different conditions). Figure 7 presents the mean level of confidence
(where 1 = low and 7 = high confidence).
TABLE 24 Training in LBD by professional background (T1 and T2 respondents)
Training in LBD Doctors, n (%) Non-medics, n (%)
Basic training only 7 (17.5) 20 (50)
Self-directed study, conferences and/or LBD research 23 (57.5) 3 (7.5)



















































FIGURE 7 Confidence in diagnosing selected conditions by specialty at T0 (n= 98–120). *p < 0.01, **p < 0.001.
AD, Alzheimer’s disease; FTD, frontotemporal dementia; HD, Huntingdon’s disease; MS, multiple sclerosis;
PSP, progressive supranuclear palsy; VaD, vascular dementia.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
With the exception of FTD, clinicians were, generally, less confident in diagnosing DLB and PDD
than other types of dementia. There were significant differences between specialties in confidence
in diagnosing six conditions (see Figure 7). Greater confidence in diagnosing predominantly physical
conditions would be anticipated for staff in movement disorder services (i.e. multiple sclerosis,
progressive supranuclear palsy, PD and stroke, all p < 0.001). Staff in these services also rated their
confidence higher in diagnosing both PDD and DLB than those in memory services (p < 0.001 and
p < 0.01, respectively).
Confidence in managing selected conditions (T0 only)
Parallel analyses were conducted for confidence in managing the same set of conditions (Figure 8).
Significant differences between specialties were generally as would be anticipated. Professionals in
movement disorder services were more confident in managing more physical conditions (multiple sclerosis,
p < 0.01; progressive supranuclear palsy, PD and stroke, all p < 0.001), whereas those in memory services
were more confident in managing some dementias, including frontotemporal dementia, mixed dementia,
Alzheimer’s disease and MCI (all p < 0.001). Staff in both specialties reported similar levels of confidence in
managing DLB and PDD. Examination of confidence in managing symptoms common in these conditions
suggests a possible explanation for this.
Confidence inmanaging symptoms common in Lewy body dementia
(all time points)
The questionnaire also included a section on confidence in managing common symptoms in LBD (again
rated on a seven-point scale). Figure 9 shows that both specialties have areas of expertise, but neither
are confident in managing the full range of symptoms associated with LBD. The pattern of responses
underpins the dual pathway experienced by many people with LBD.
As this set of questions was included in all three questionnaires, responses at T0 were compared
with those at either T1 or T2. Radar plots were used to illustrate changes in confidence in managing
common LBD symptoms between the beginning and end of the programme for respondents in the
control and intervention arms (see Figures 5 and 6). The plots indicated that confidence in symptom
management reported by staff in intervention services later in the programme was significantly higher





















































FIGURE 8 Confidence in managing selected conditions by specialty at T0 (n = 130–150). *p < 0.01, **p < 0.001.
AD, Alzheimer’s disease; FTD, frontotemporal dementia; HD, Huntingdon’s disease; MS, multiple sclerosis;
PSP, progressive supranuclear palsy; VaD, vascular dementia.
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included changes significant at a p-value < 0.05, as these suggest a trend towards greater confidence in
some areas. Although, as previously emphasised, interpretation is hindered by the lack of matched
samples, these findings suggest that including questionnaire data may help in understanding the
mechanisms through which changes occur, particularly if larger samples are available with more consistent
respondents at both time points. The findings lend some support to the hypothesis that the positive
outcomes achieved in the pilot trial may result from the accumulation of marginal gains.
Approach to new assessments (T1 and T2 only)
The questionnaires administered during the pilot trial asked respondents how frequently they explored
key LBD symptoms, completed formal cognitive assessments and used formal diagnostic criteria.
These items related to the content of the assessment toolkits. As the focus of the toolkits varied for
clinicians in movement disorder and memory services, the findings are presented by specialty. Analysis
of variance indicated no significant changes between responses to T1 and T2 questionnaires relating to
new assessments. Figure 10 therefore presents data from only T1, which indicated that staff working







































































































FIGURE 9 Confidence in managing common LBD symptoms by specialty at T0 (n = 136–150). *p < 0.01, **p < 0.001.























FIGURE 10 Percentage of T1 respondents reporting always covering specific areas in new consultations by specialty.
**p < 0.001.
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behaviour disorder, whereas those in memory services were more likely to report using formal cognitive
tests and applying diagnostic criteria.
These results suggest that, despite the availability of the assessment toolkits, staff working in memory
services were not routinely exploring all key features of DLB in new patient assessments. With respect
to diagnosing PDD, it would not be anticipated that formal cognitive testing would be conducted at
every new consultation, as clinicians often emphasised that there was insufficient time and that it was
not always appropriate to look at cognition in the first appointment. In the absence of data on practice
prior to the introduction of the assessment toolkits, it is difficult to interpret these results.
Integration of the toolkits into routine practice (T1 and T2 only)
Questions related to NPT explored the perceived value of the toolkits, whether or not participants
believed that the toolkits were a legitimate part of their role, ease of integrating the toolkits into their
work and whether or not they thought that the toolkits would become part of their normal practice.
Parallel questions were asked about the assessment and management toolkits, with responses on a
seven-point scale (where higher scores indicate greater agreement with each statement). Responses
from T1 have been coded into three groups (agree, neutral and disagree) in Figure 11. Views on the
assessment and management toolkits were generally similar, although respondents had slightly more
positive views about the management toolkit becoming part of their normal practice. Only one person
disagreed with any of the items, and this was on the item relating to whether or not the assessment
toolkit was likely to become part of their normal practice.
Further analyses explored whether or not views on integration of the assessment toolkits were
related to role, specialty and study arm or changed between T1 and T2.There were trends for views on
implementation to become less positive over time and for allied health professionals to express less positive
views on whether or not the assessment toolkit was a legitimate part of their role (both p< 0.05).The mean
values on the seven-point scale for each NPT item by study arm and specialty are shown in Figures 12 and 13.
Respondents in the intervention arm generally held more positive views towards implementation of the
assessment toolkits than those in the control arm. Although rarely explicitly mentioned during interviews,
the availability of the management toolkit may have created more positive views towards accurate
diagnosis of LBD and, therefore, towards the assessment toolkit. Respondents in memory services had












FIGURE 11 Views on integration of the management and assessment toolkits into routine practice at T1. AT, assessment;
MT, management.
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more positive views towards implementation of the assessment toolkits than their colleagues in movement
disorder services (see Figure 13). These findings are consistent with the views expressed in qualitative
interviews when professionals in movement disorder services often expressed concerns over the feasibility
of implementation of the assessment toolkits.
Parallel analyses were conducted for the NPT questions about the integration of the management
toolkit. There were no significant differences in views expressed according to region, role or specialty
(study arm was not relevant, as only those in the intervention arm received the management toolkit).
Overall views on toolkits (T2 only)
On the final questionnaire, we asked if and how the toolkits had an impact on the respondents’ work.
These questions were included in only the intervention questionnaire (n = 34). Six respondents had
not used the assessment toolkits (17.6%), half reported that it had changed their approach to new
or follow-up assessments (50.0%), five were unsure (14.7%) and the remaining six felt that it had not
changed their approach (17.6%).







FIGURE 12 Mean scores on NPT questions relating to the assessment toolkit by study arm (T1). *p < 0.01, **p < 0.001.








FIGURE 13 Mean scores on NPT questions relating to assessment toolkit by specialty. *p < 0.01, **p < 0.001.
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Three respondents did not answer the question relating to the impact of the management toolkit
and nine reported that they had not used it. The remaining respondents had most commonly used
the management toolkit for reference (19/22, 86.4%), with smaller numbers using it to explore new
treatment options (9/22, 40.9%) or with trainees (8/22, 36.4%). (As respondents could use the toolkit
in more than one way, the percentages do not sum to 100.)
Comments on open questions (T1 and T2 only)
Overall, just under half (45.5%) of respondents made at least one comment on either the T1 or the T2
questionnaire. Analysis of the comments indicated that they were consistent with the analysis of
qualitative interviews and focus groups. As some questionnaire respondents were based in services
where it had not been possible to conduct any observation or interviews, this provided useful
triangulation of the qualitative analysis from new perspectives.
Summary
Response rates to the questionnaires were acceptable and staff with a variety of roles took part.
The large number of questionnaire invitations left unopened when delivered electronically suggests
that both electronic and paper copies of questionnaires should be sent to maximise response rates.
The findings from the T0 questionnaire confirm that confidence in diagnosing and managing DLB and
PDD is lower than for most other subtypes of dementia. This supports the need for assessment and
management toolkits. Confidence in managing common LBD symptoms varied according to specialty
and underpinned the dual pathway, with referrals to both movement disorder and memory services,
experienced by many people with LBD. Consistent, small but (statistically) significant changes in
confidence in managing these common symptoms were found between the first questionnaire and
those administered during or after the pilot trial for respondents based in services that received the
management toolkit, lending support to the hypothesis that the potential mechanism for change is
through the accumulation of marginal gains. Caution is, however, needed in interpreting differences
over time, as the respondents at each time point are overlapping, but not identical.
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Appendix 8 Factors influencing the
diagnosis and management of Lewy body
dementia: illustrative quotations from
work package 5
Quotations from interviews and focus groups shown in italics and identified by a unique speakeridentifier. The first two digits indicate the service (memory services are represented by 01–16 and
movement disorder services by 17–26). Services 01–08 and 17–21 are in East Anglia, and services 09–16
and 22–26 are in the North East. The third and fourth digits indicate the individual within the service.
TABLE 25 Factors influencing the diagnosis of LBD with illustrative quotations
Theme Subtheme Illustrative quotation
Complexity of LBD Variability in presentation The fluctuating nature of Lewy Body, I think, meant that
when he [consultant] saw her – his ward rounds were in the
morning – [. . .] he found that she was pretty good and quite
plausible. Then, you’d see her later in the afternoon or
evening and she’d be struggling
2307, trainee geriatrician
Lack of a definitive test and
restricted access to scans
The only thing we can’t do DaTscans. I mean for DaTscans
we probably have to send it to [hospital 1]. I mean to be
honest, I don’t use DaTscan a lot. I’ve probably one done
one DaT for the last 3 years
2001, consultant geriatrician
Shift to earlier presentation . . . this is a very special kind of dementia, which is very
difficult to diagnose in the first stages of the illness.
Because the cognitive function is not that prominent, it’s
mostly a sleep problem and falls, unsteadiness. Sometimes,
they are almost the same as the Alzheimer’s type [. . .] In
the early stages, it’s not easy to diagnose
0501, trainee OAP
Availability of an informant Some people will say ‘yes, I can do everything’ and you’re
pretty sure they probably can’t but, again, it’s difficult to know
what they’re doing for themselves [. . .] it’s quite tricky with
that generation as well, with older people. The way their
relationships were set up, often women did do everything
around the house. Often, retired older men don’t do masses of
activities of daily living that you can easily assess
2307, trainee geriatrician
Service organisation Shift to nurse-led memory
services
For a start, who are we asking to make the diagnosis of our
patients? Is it people who are properly trained and who
have good clinical expertise, who’ve seen a range of
different dementias? Or is it people who are trained, who
have had exposure to, maybe, lots of Alzheimer’s disease?
And their clinical repertoire is very narrow
0901, consultant OAP
Follow-up arrangements Let’s say you have a follow-up review, you have 15 minutes,
roughly. All the other things you have to address and then
how do you in that time say ‘oh, by the way, I think you
have got dementia?’ It is a huge thing to be diagnosed with
dementia, a massive thing. So I think you don’t do people
justice just throwing it in on the way out ‘you have got
dementia’. So very rarely do people do that in that setting
2306, trainee neurologist
continued
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TABLE 25 Factors influencing the diagnosis of LBD with illustrative quotations (continued )
Theme Subtheme Illustrative quotation
Training, knowledge
and experience
Awareness of LBD and cognitive
biases
I think also one of the problems is that when we think
about dementia we would – you’re never surprised of a
symptom, we put everything down to dementia. So a lot of
the things that you see there you just say, ‘Well it’s their
dementia’. And you may not pick out some of those little
nuances of Lewy body
0208, community worker, memory service
If and how LBD symptoms were
covered in consultations
I’ve never really clearly understood what the nature of the
fluctuation is despite talking to various people and trying to
read up about it, because everybody’s cognitive fluctuation,
you know, everybody’s cognitive function fluctuates a bit,
[. . .] is it a kind of regular fluctuation pattern, but how
quickly as well? Are you talking days, or weeks, or hours?
1402, consultant OAP
I always ask ‘Have you noticed any shakiness or tremor?’
So that’s a question I always ask and I’m always observing
for that as well
0403, memory assessment nurse
Interpreting cognitive tests I also think that differentiating between MCI and dementia
is something that people find more difficult to do, so what
we may find in the notes is that a lot of people on their
problem list have Parkinson’s disease, cognitive impairment.
But those people who have cognitive impairment listed
could have an MMSE anywhere from 24 to 12
2201, consultant geriatrician
Knowledge of dementia subtypes Unfortunately is quite difficult to characterise, whether it’s
PD dementia or Lewy body dementia or it’s Alzheimer’s
dementia with Parkinson’s
1701, consultant geriatrician
Attitudes and values Perceived prevalence and status
of LBD
I don’t think we see that many people with Lewy body
dementia, which might suggest that it’s underdiagnosed
or else they’re just not coming through to our service.
And I wonder whether some of them might be going to
neurology instead
0209, community worker, memory service
Perceived value of diagnosing
LBD
I’m sure a psychiatrist will say ‘we must know what every
sort of dementia is’. You know, and perhaps we should.
They’re probably right, but I’ve never felt it makes a great
deal of difference to the patient really. [The patient] doesn’t
care whether she’s got Lewy body or Alzheimer’s or
whatever else really
2401, consultant geriatrician
I guess it [disclosing dementia] gives them a rough idea how
the disease might progress of how their mental function
might progress in the next few months so that they’re
aware of how things might go, as well as the carers and
their family, explain that there are possible drugs, if they
meet the criteria, to go on temporarily, may to halt
progression of the cognitive impairment for some time.
It may not improve things, but it might hold the decline of
it. Also, I guess once you label people with dementia they’re
more entitled to some of the support services and benefits
and allowances and things like that
1701, consultant geriatrician
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TABLE 25 Factors influencing the diagnosis of LBD with illustrative quotations (continued )
Theme Subtheme Illustrative quotation
Perceived responsibility for
diagnosing LBD
But you still want the most authoritative person [. . .] Being
in the medical paradigm everything goes to the diagnosis.
So what you want is the person who is going to give you a
diagnosis and then suggest what to do
2402, consultant geriatrician
. . . you have fantastic movement disorder people and then
just a few rooms further down are fantastic dementia
people, but the overlap is still not good there. There are not
many, if any at all, movement disorder people with an
interest in dementia and vice versa
2306, trainee neurologist
Perceived value of diagnosing
dementia subtypes
I suppose the other practical thing as well, what difference
does it make? And actually it doesn’t make that much
difference, if it’s either Lewy body disease or Alzheimer’s,
because you’ll be treating them pretty much the same
way anyway
1402, consultant OAP
There’s not that many common dementias, we should at




TABLE 26 Factors influencing the management of LBD with illustrative quotations
Theme Subtheme Illustrative quotation
Complexity of LBD Balancing treatments I think it’s getting the balance between the cognitive and
motor issues. So cutting back on the motor treatments
and the balance between that, hallucinations and the
cholinesterase inhibitors
2305, consultant geriatrician
Service organisation Follow-up arrangements The way things are at the moment, with the changes to
monitoring as well, people are being discharged much more
early to GPs than they used to be.We used to have 6-monthly
monitoring to go on indefinitely and now it’s that people are
discharged back to GP
0501, trainee OAP
Fragmented care pathways From a technical, diagnostic and pharmacological,
perspective, I am happy to diagnose and manage both
DLB and PDD. The difficulty that I have, or where I come
unstuck, is if I do that I then, quite often, can’t get patients
into community mental health services because they’ve
been furnished with a diagnosis and therefore, the piece of
work is done. It takes longer to get them into services if
there are crises, which clearly there quite often are, from a
psychological perspective. So I can’t, then, get access to
Community Mental Health Team, CPN [community
psychiatric nurse] support, medical support for those
individuals. If I make that diagnosis, and manage that
diagnosis initially, they don’t get the other softer stuff
around the dementia diagnosis that community mental
health teams are commissioned to provide
2703, consultant geriatrician
continued
DOI: 10.3310/pgfar09070 Programme Grants for Applied Research 2021 Vol. 9 No. 7
Copyright © 2021 O’Brien et al. This work was produced by O’Brien et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
107
TABLE 26 Factors influencing the management of LBD with illustrative quotations (continued )
Theme Subtheme Illustrative quotation
. . . it becomes a lot harder to coordinate care for really
complex people who need their care coordinated. What
happens then is a little bit of indecision, because nobody
wants to take the wrong step if they don’t know what




I haven’t got enough knowledge about sleep hygiene. I
mean, I can offer basic things about people trying to avoid
sleeping through the day and taking a regular pattern, but I
don’t think I have enough knowledge to advise people on a
sleep hygiene
0503, specialist PD nurse
Attitudes and values Perceived responsibility for
managing LBD
But obviously DLB – the thing is, a lot of people are on
things like anticholinergics for urinary dysfunction. It’s not
up to us to avoid centrally acting anticholinergics because
they’re always started by other people, by urologists. It’s
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Appendix 9 The acceptability of the
assessment and management toolkits:
illustrative quotations from work package 5
TABLE 27 Feedback on the acceptability of the assessment toolkits with illustrative quotations
Theme Comment Illustrative quotation
Layout and
presentation
General appearance I think it’s [assessment toolkit] quite nicely formatted and
visually it doesn’t look too crowded or too dense. So I think
that’s always important [. . .] it’s not one of those annoying
pieces of paper that you feel ‘oh, I can’t even read what is
written here’. It’s very clear and easy to go through. It sort
of flows naturally
0601, consultant OAP
Signposting and rationale I could be doing things that aren’t necessary, potentially
[. . .] I could literally trim it down to these [five-item UPDRS]
and these are the ones that are the most evidence based as
being the most discriminatory [. . .] That’s a helpful thing
to know
1213, GPSI, memory service
Format Integration with existing pro formas Then there’s a question of, for any toolkits, remembering
where they are because they’re not incorporated into our
computer system. If I complete a toolkit, I’ve got to have a
pen with me because I would have to do it as a paper
version. What do I then do about getting it into our
computer system? I’m completing the questions I want to
ask, which I want to be in the computer system
1801, consultant geriatrician
Local intranet . . . if the assessment toolkit was made available on, say, the
shared drive where people could access [it]
0601, consultant OAP
A self-completion version for patients
and carers (PDD toolkit only)
I guess that would be one option, just screen everyone,
hand them out while they wait. Give them those things so
you have got something when they walk in, you can check
already, ‘OK, you don’t have to worry about it’. Or I do have
to worry about it and dig in a bit further
2306, trainee neurologist
Brief laminated summaries of sections
for reference
We thought about making a smaller thing that we could
cover in our assessments and then that was always
something you could pull out
1104, community psychiatric nurse
Separate versions for medical and non-
medical staff
I’m just thinking that the therapists ask a lot of the
questions, and if we pull the nursing assessment to pieces
and put that in place
1708, specialist nurse, movement disorder service
Content Perceived relevance of content And I guess the other reason is that we might not always
recognise them. So, we might be seeing someone with a
different type of dementia but we wouldn’t know. So, I
thought it would be a really good tool for us to remind us
of the diagnostic criteria, what questions to ask
0101, consultant OAP
continued
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TABLE 27 Feedback on the acceptability of the assessment toolkits with illustrative quotations (continued )
Theme Comment Illustrative quotation
. . . there is nothing in here [toolkit for movement disorder
services] that mentions hallucinations, or the fluctuating
nature. And actually, I think we might, if we’d used this we
might have missed that
2403, specialist PD nurse
Terminology and question wording With the hallucinations at the moment, all you have to
those two questions to the information is ‘yes’ or ‘no’
answers. There’s a thing about the frequency, the duration,
the distress. There’s just something else which might give
you a feel for how significant this area is. Because my
understanding of Lewy Body disease is that [. . .] it’s not just
the presence or absence of hallucinations; it’s the duration
of them, it’s the frequency, it’s the intensity of those
1301, consultant OAP
We probably wouldn’t ask ‘Does the patient show moderate
changes in their level of functioning during the day?’ Not
with that sentence. People wouldn’t know what it was
on about
0901, consultant OAP
Inclusion of five-item UPDRS (memory
services)
I think that is useful in terms of awareness. Because a
lot of people, certainly in my team I think, could spot
parkinsonism from a tremor point of view, but might not
have necessarily from the bradykinesia and the facial
expression. As being as important as tremor. I think that’s
the message, isn’t it? Parkinson’s disease isn’t just about
tremor. So I think that there is an awful lot of value in this
0901, consultant OAP
If you think there’s Parkinsonism, it doesn’t matter whether
it’s mild or severe, does it, for DLB? Do you see what I
mean? Does it matter? Do you need to go into that amount
of detail? It’s just whether it’s there or not [. . .] Because
we’re not Parkinson specialists, we just need to know
whether there is enough to meet the diagnostic criteria for
DLB not Parkinson’s
1503, consultant OAP
Inclusion of formal cognitive
assessment (movement disorder
services)
I have yet to be convinced that a nurse with good instinct
won’t pick it up, as part of her general assessment. It’s
difficult to know what would be gained by routinely doing it
because most patients, although I dare say the Carslake
study and everything after it showed you get very high
cumulative instance of dementia in Parkinson’s, it’s not
everybody. I think they could pick it up instinctively first,
rather than screening
2501, consultant neurologist
So, briefly, I’ll probably do an AMTS [Abbreviated Mental
Test] and I do a clock drawing and an intersecting
pentagon, just to cover, get a bit of visuospatial things. So,
that’s why I do the clock drawing, clocks and a pentagon
thing. And with the AMTS, I know the AMTS is rubbish in
Parkinson’s. It’s not going to give us anything, but I don’t
have time to do a detailed thing
2001, consultant geriatrician
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
TABLE 28 Feedback on the acceptability of the management toolkits with illustrative quotations
Theme Comment Illustrative quotation
Layout and
presentation
Use of colour and ability to access
information at different levels
was valued
I think the fact that it’s broken down into three levels in
itself is a help, because if we’d gone straight to the tome
[reference guidelines] it would absolutely go over my head,
but this breaks it down quite well
1106, community psychiatric nurse, focus group
The colouring is terrible. People have problems with
eyesight. Sorry but the contrast is not so good
0501, trainee OAP
We need to look at everything. When you go out to see
someone in the community, they’re going to describe to you
something that they’ve noticed or they’re concerned about
and it could be anything. So we don’t necessarily have the
answers, but if you can look at this [one page summary]
and say ‘Oh actually, with Lewy body dementia, that’s quite
a common sort of symptom’. To me, then I’d find that
really useful
0710, social worker, memory service
Format Integration with existing electronic
records
In an ideal world, you’d be seeing somebody with Lewy
body in clinic, and there would be a link from their patient
records to say, ‘Your toolkit’, so that you can just click on it
0701, consultant OAP
Access via computer or application I guess if you put it on the computer, you can sort of look at
things while you are talking to someone without it being so
in your face, if it is easy to access
2302, trainee neurologist
Having availability of guidance on the management tool
I see would fit potentially quite nicely into the sort of
guidance that we have on our intranet and put into
bite-sized chunks
1801, consultant geriatrician
Small A5 versions for portability The only thing is perhaps the size of it. Maybe if you could
make it kind of pocket size, so we can carry it around
0702, consultant OAP
Tailored versions for medical
and non-medical staff
I think maybe splitting it and having one that was more
about the management role of CPNs [community
psychiatric nurses] and one that was more tailored to
the medics
1104, community psychiatric nurse
Version for patients would be useful I think it would be helpful to have something that you could
give to the patient as well, not just something we can use
for our own things to ask, but actually something you could
physically give to the person as well to go through and
explain it a bit more. So rather than it just being something
that we can be aware of, ask and talk about, but something
that we can actually give out as well
1103, community psychiatric nurse
Relevance to other settings Where I most commonly find mismanagement of Lewy body
disease is in primary care [. . .] I think the people for whom
computerisation would be especially important, would be in
GP surgeries, where, when they are seeing someone with
Parkinson’s disease, flagging up the things and the different
pages that they need to be mindful of
1101, consultant OAP
continued
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TABLE 28 Feedback on the acceptability of the management toolkits with illustrative quotations (continued )
Theme Comment Illustrative quotation
Content Perceived relevance of content But then they probably go out of date quite quickly, so
you’d need an online version to keep up to date with it.
That would be my only concern, because treatments change
1501, consultant OAP
There’s no point saying there’s no evidence for it because
if somebody’s got low mood, you’re going to give them
something. You can’t ignore it. I’m not going to say to the
patient, ‘There’s no evidence for use of antidepressants’,
because if it’s really impeding their function and causing
distress, I will treat [. . .] It’s about alleviating their distress
and their symptoms. I don’t know that it’s that helpful.
You might want to say, ‘If using antidepressants, just avoid
significant anticholinergic things’
1503, consultant OAP
They seem to push melatonin for poor sleep. Firstly, GPs are
not familiar with melatonin [. . .] A lot of people will start
feeling sick, elderly people feel sick on it and can’t tolerate
it. So you have to warn them that might happen. Because it
says, given the relatively benign side effect profile, but in
this high dose, it does make them nauseous [. . .] I can’t get
to grips with melatonin. I have tried it several times and
everybody seems to come back sick [. . .] But maybe
because we are working with people who are frail
1901, consultant geriatrician
Appropriate for other professionals I think they are something for a GP, for somebody that is
more involved in the long-term management, would be
helpful [. . .] I think that’s quite educational for GPs as
a whole, that it affects sleep, it affects hypotension,
constipation, urinary dysfunction, all these sorts of things
that you expect sometimes to happen in the elderly, but
you wouldn’t necessarily put together as being part of the
dementia syndrome
1213, GPSI, memory service
Dosage information I think it’s excellent and I think it’s really useful, especially
the more detailed ones actually. I like the fact that they
actually tell you doses to use as well, which I think most
guidelines don’t. Most guidelines shy away from actually
saying, ‘Use this specific dose’, or, ‘Between these doses’. [. . .]
Actually, people who use things want to be told what they
can use and have some support. The doses are very similar
to what I’d use. It gives you that additional confidence that
you’re using the right doses
1601, consultant OAP
I know we’ve got the BNF and everything but that’s really
just quite dry. I think you’d need something a little bit more
practical, for example, maybe an information sheet that you
could give to patients about melatonin so that both you
and they know what to expect from it. Also, just some
specific advice on dosage and when to review somebody,
how long do you wait for the therapeutic effect to kick in,
etc., etc. Yes, I think a well-designed information sheet for
using melatonin in DLB would help
1213, GPSI, memory service
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Appendix 10 Implementation of the
assessment and management toolkits:
illustrative quotations from work package 5
TABLE 29 Implementation of the assessment toolkits with illustrative quotations
NPT construct Illustrative quotation
Coherence For me, the toolkit is a really good idea that we’ve got some commonality that we all should
be asking the same questions.We should all be working towards the same guidelines [. . .]
2602, specialist PD nurse
I thought it was very useful because as part of our training we have a lot of exams, a lot
of basic knowledge and then a lot of practical knowledge, which we gain by experience or
seeing other people. But to gain this practical knowledge, there is no specific way of doing
it because it is different reading in books and its different doing the things. I think those
sorts of toolkits are in the middle. They bring the criteria to day-to-day practice, so I find
them very useful
0102, trainee OAP
Before I actually saw the paperwork of the toolkit, I thought it was a good idea, because
I think it’s something that people often make errors in diagnosis with. Either they can be
too keen and any patient who presents with confusion and hallucinations, people sort
of start thinking ‘oh, could this be Lewy body dementia?’ Or, sometimes, equally it gets
completely missed because people haven’t asked all the questions. So I did think it would
be quite useful, but then, I suppose when I actually looked at the toolkit for assessment,
I felt that it didn’t add anything to what I already knew. But it was useful in the sense of
there being a checklist and that you’re forced to go through all of the items and you’re
then sure that you don’t miss anything
0601, consultant OAP
Cognitive participation I think that the toolkits are potentially useful for people who don’t feel so confident [. . .]
as a guide for them as to sorts of questions they might need to be asking. As somebody
who feels confident, my view on the toolkits has been I can see how they can be useful for
others. They don’t necessarily help me that much because I think they cover all of the
questions that I think I’m asking but I don’t necessarily ask them in the way that they’re
written in the toolkit
1801, consultant geriatrician
I run the clinic with my registrar, it was easy to train him quite quickly [. . .] it was easy to get
my specialist nurse up to speed [. . .] We are kind of all united on this assessment tool, so we
don’t have to discuss and everybody has different opinions [. . .] it is ultimately uniting the
approach in making assessment more straightforward
1901, consultant geriatrician
I think it’s difficult when we’re not getting referrals for Lewy body dementia every week,
I think that makes it more difficult to keep your interest and momentum going
1106, community psychiatric nurse
What I would say in retrospect, is I’m not sure that we’ve maximised the value of this
within the service. But to do that, we would have actually needed a more sustained input,
I think, from the team. And somebody, one or two of us, actually, really taking a role in
terms of getting hold of this and running with it. You, actually, need somebody in the team
who is going to take a real lead to try and sort of keep it on people’s minds. Find out what
people’s experience was, address any issues, advocate for its value, which, to be fair, I don’t
think there was somebody who took on that role
1209, consultant OAP
continued
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TABLE 29 Implementation of the assessment toolkits with illustrative quotations (continued )
NPT construct Illustrative quotation
Collective action Unless it’s incorporated into our computer system it adds another level of complexity,
which is just another barrier for me
1801, consultant geriatrician
It is just a bit of extra work. I mean just asking a couple more questions and maybe
getting into the habit of doing a physical examination for all patients
1505, trainee OAP
I honestly wouldn’t have the time to go through all the questions. And to be honest with
you, most of them, we do ask anyway, like, ‘Do you have hallucinations? Do you have that?
Do you have a problem with planning? Do you forget familiar names?’ We kind of ask that
anyway, but as a quick screening thing, we just generally go, ‘Oh, yes, any problems with
memory?’ and I usually turn to the [patient’s] wife: ‘Have you noticed anything with the
memory?’ rather than go, formulaic, through the individual
2301, trainee geriatrician
Reflexive monitoring What I’ve been particularly impressed with . . . Because really this is about team work,
I very rarely would see the patients independently. Information is presented to me much
earlier in the pathway than it would have been before. I’m not having to ask these
symptoms, they’re already there. The team are already asking the relatives, ‘What is this
patient like when they’re asleep at night? Are they all over?’ They are following and picking
up, particularly, those kinds of symptoms
0901, consultant OAP
Personally, I think having had this, it’s probably made me document that there’s, like no
REM sleep behaviour disorder or no visual. Do you see what I mean? [. . .] And that’s
maybe me assuring myself that I’m asking, you know, at a later date, if somebody, you
know if they come across this person and wondered, I wonder whether – say they develop
DLB later on or something like that and you just think, well ‘How long have they had it?’,
then it’s a good account for the future
1503, consultant OAP
It improved my understanding of DLB, and maybe I’m thinking more about DLB now. Because
I think as a movement disorder service you always tend to focus on Parkinson’s dementia,
but now with DLB we’re doing more of DLB now, I would think, or diagnosing more, definitely
1701, consultant geriatrician
And maybe the heuristic that I use should be different. Because like, I said, I do this if
I have a suspicion they might have fluctuation, Parkinsonian symptoms, or visual
hallucinations. So, if they have none of these, I’m not going to do this form. So maybe –
well, I don’t know – I was thinking maybe I should do the form anyway, on everyone,
but we don’t. [Later in the interview]. But it’s just a niggling thought in my mind now.
Maybe we’re missing some
0101, consultant OAP
GPSI, general practitioner with a special interest.
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TABLE 30 Implementation of the management toolkit with illustrative quotations
NPT construct Illustrative quotation
Coherence I think it is, at a glance, by all means it is a very complicated condition with a lot of little
branches. Again, none of the textbooks will tell you exactly what medication to use on
which condition. Although we were doing very much what it says here, before this toolkit
came forward [. . .] this comes in a very supportive way, explaining that you are doing the
right thing, this is exactly what we use, so it was very, very helpful
1901, consultant geriatrician
Obviously, coming from a consensus from the best experts available, we trust the material.
So it’s definitely very useful [. . .] you regard this as the expert opinion, evidence-based
expert opinion. So, you consult it because you are even expecting to find things in it that
you wouldn’t find in the BNF, or you wouldn’t find in some of the other sources that you
look to usually
0101, consultant OAP
Cognitive participation We haven’t got round on our monthly mentoring sessions to specifically doing one where
I would have thought about bringing these in. Some of the mentoring sessions have been
about some aspects of the management of dementia, but the questions they’ve had have
been more about which drugs and why. There have been some questions within that about
behaviour, so I probably could have used some of it, now I think back
1801, consultant geriatrician
I think the first problem is, would we manage them at all? [. . .] because to me conceptually
it falls into the province of old age psychiatry
2402, consultant geriatrician
I think this would be quite useful for juniors. I think our SHOs [senior house officers]
would really find this very informative and practically very useful. I think that would be
the case, not just at SPR [specialist registrar] level but also the SHOs, VTS [vocational
training scheme] trainees that we have, they’d find it very useful. I think nursing staff,
community mental health nurses, memory clinics, they’d find it useful just to give a broad
awareness of the various symptoms and management. I think they’d find it useful as well
1504, consultant OAP
Collective action I think one thing is you know if you’re sort of flicking through sheets and things it looks a
bit rubbish and it also kind of looks like you don’t know what you are doing. So, and if
they don’t know what the diagnosis is and you’ve got like ‘neuropsychiatric’ symptoms and
stuff, then that’s a bit stressful
2302, trainee neurologist
Very occasionally, when I’ve had somebody, where they’ve had a problem and you’ve tried
one or two things, I might just refer to it and say ‘have I done what the toolkit would say?’
0701, consultant OAP
So when I’m supervising the trainees, I’m supervising memory clinic nurses and they come
to me with a specific problem, then we get this out of the cupboard and have a read and
make a decision. Sometimes, but very rarely, when the patient is in the room as well
0101, consultant OAP
Reflexive monitoring I suppose I feel like most people did when I first looked at it. You think, ‘Is that what I do?
Is that what I not do? Should I do be doing it differently?’
1101, consultant OAP
It adds more awareness of other things which might be worrying people, not just cognition
and neuropsychiatric and sleep. There are also other things. It sort of gives me an
indication of some of the other medical issues which can affect quality of life. I think it
also allows me to set the signposts better. [. . .] I could ask the GP to do things a bit more,
like constipation and sexual dysfunction, that sort of thing [. . .] I guess it’s raising
awareness of it and raising the profile of it
1502, consultant OAP
Like the melatonin thing, I certainly wouldn’t feel confident about that [. . .] I wouldn’t feel
that it is appropriate for me to prescribe it. It might prompt ‘I have heard melatonin might
be used sometimes in this situation’
2402, consultant geriatrician
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Appendix 11 Proposed implementation
strategy for work package 4
TABLE 31 Orientation and training on assessment toolkit (intervention and control groups)
Content Who Duration How
Introduction to the programme, study
team and WP4
WP1 team 5–10 minutes Presentation supported by
documentation (e.g. PIS)
Study background and summary WP1 team/CTU





What study participation involves: for
patients and for clinicians
WS1 team/CTU 5 minutes Presentation supported by flow chart(s)
Discussion of evidence base for the
assessment toolkits and potential
benefits of improved diagnosis of LBD
Credible
professional
10 minutes Brief presentation on process of
developing assessment tool and
provision of supplementary materials
(e.g. references for validated questions
included in the assessment toolkits;
rationale for recommending MoCA).
Case studies to highlight benefits of
improved diagnosis








Clarify when assessment toolkits could
be used and how clinicians can ensure
that the assessment toolkit is readily
available (e.g. how copies will get into
patients’ notes)
Facilitator 10 minutes Group discussion
Highlight variances from usual practice
and focus on planning how to integrate
new aspects into assessments
Facilitator 10 minutes Reflection, group discussion to first
identify barriers and then strategies to
overcome these. Identify additional
training needs to be met through
web-based materials and/or local
training sessions







with feedback, supplementary resources
(e.g. web-based materials, document
with FAQs)
cRCT, cluster randomised controlled trial; CTU, clinical trials unit; FAQ, frequently asked question; PIS, patient
information sheet.
Notes
Dark purple shading indicates activities supported by WP5 data that would ideally be included, but could be excluded if
insufficient time is available.
Light purple shading indicates additional sessions to be locally organised.
Facilitator indicates either team member or external person with appropriate skills to facilitate group discussion and
group work.
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TABLE 32 Additional training on management guidelines (intervention group only)
Content Who Duration How




5 minutes Brief presentation on process of
developing management guidelines;
provision of supplementary materials
(e.g. systematic review)
Highlight specific issues regarding management
of LBD (include feedback from patients/carers




5 minutes Summary of literature and case studies
Explore how the management guidelines could
be used in practice and consider ways of
ensuring that the guidelines are readily
available (e.g. is it feasible to include copy of
the overview diagram in paper notes of
patients with LBD?)
Facilitator 10 minutes Group discussion: sharing ideas (e.g. use
as reference document when writing
letters, have a copy of overview diagram
in notes of LBD patients to check key
aspects covered in consultation)
Identify variances from usual practice and
problem-solve to overcome potential barriers
to use of management guidelines
Facilitator 15 minutes Case studies, group discussion (requires
time to review the guidelines, identify
barriers and strategies to overcome these)
Note
Light purple shading indicates additional sessions to be locally organised.
TABLE 33 Reminders and troubleshooting (all in relation to assessment toolkits and intervention only in relation to
management guidelines)
Content Who How
Physical prompts: laminated management overview
diagram for office wall; DIAMOND-Lewy coasters,
pencils, Post-its® (3M, Cynthiana, KY, USA); inserts
for diaries with management overview diagram
Project team Send out at regular intervals
Agenda item at regular team meetings to review
use and identify problems
Local services Local team member to liaise with lead clinician to
obtain feedback and to attend occasional meetings
to problem-solve, address queries, etc.
Audit and feedback of use of assessment toolkits,
either through small-scale notes review or through
case discussions
Local services Local team member to liaise with lead clinician to
check progress, etc.
Case-based discussions to discuss use of
management guidelines and identify any
impacts on management and any queries
Local services Local team member to liaise with lead clinician to
check progress, etc.
Notes
Dark purple shading indicates activities supported by WP5 data that would ideally be included, but could be excluded if
insufficient time is available.
Light purple shading indicates additional sessions to be locally organised.
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TABLE 34 Proposed web-based resources to support implementation
Resource Aim Availability For
Copy of assessment toolkit Ensure clinicians are able to access copies as required ✓ C/I
Copy of management guidelines Ensure clinicians are able to access guidelines
To incorporate user-friendly navigation system to
facilitate use
✓ I
Clinician PIS for cRCT Easy access to a reminder about the design of the
study and what participation involves
✓ C/I
Clinician PIS for qualitative study Easy access to a reminder about the components of
the qualitative study
✓ C/I
Summary of key points from SIV This may cover the previous two points to identify
which resource would be most useful to clinicians
C/I
Videos of UPDRS To facilitate skill development and provide a reminder
if needed
✓ C/I
Videos of MoCA To facilitate skill development and provide a reminder
if needed
✓ C/I
FAQs for assessment toolkits To provide easily accessible information on common
questions about how to use the assessment toolkits
C/I
FAQs for management guidelinesa To provide easily accessible information on common
questions about how to use the assessment toolkits
I
Published literature review To enable keen clinicians to review source material
for guidelines
To demonstrate credibility of management guidelines
✓ I
Copies of training materials on
assessment toolkits (e.g. case studies)
To facilitate further discussion within teams if required
To enable clinicians who were unable to attend
the briefing/training session(s) to work through
the materials
C/I
Copies of training materials on
management guidelines (e.g. case studies)
I
C, control group; cRCT, cluster randomised controlled trial; FAQ, frequently asked question; I, intervention group;
PIS, patient information sheet; SIV, site initiation visit.
a These documents will be ‘live’ on the website and updated regularly with clinicians being able to submit new FAQs
as needed.
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